<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/receptors">
		<title>Receptors</title>
		<description>Latest open access articles published in Receptors at https://www.mdpi.com/journal/receptors</description>
		<link>https://www.mdpi.com/journal/receptors</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/receptors"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
		<image rdf:resource="https://pub.mdpi-res.com/img/design/mdpi-pub-logo.png?13cf3b5bd783e021?1777446772"/>
				<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/2/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/2/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/2/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/2/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/5/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/4/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/3/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/3/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/3/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/3/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/3/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/3/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/2/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/4/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/29" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/28" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/27" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/26" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/25" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/4/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/3/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/3/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/3/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/3/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/3/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/3/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/2/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/3/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/4/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/4/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/4/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/4/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/4/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/3/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/3/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/3/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/2/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/2/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/2/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/2/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/1/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/1/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/1/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/1/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/1/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2813-2564/1/1/1" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/2813-2564/5/2/15">

	<title>Receptors, Vol. 5, Pages 15: Analyzing the Molecular Effects of Endomorphin-2 Degradation on Stabilizing Interactions at the &amp;mu;-Opioid Receptor</title>
	<link>https://www.mdpi.com/2813-2564/5/2/15</link>
	<description>Background: Endogenous opioids, such as endomorphin-2, are key regulators of the body&amp;amp;rsquo;s pain pathways and mediate analgesia by engaging the &amp;amp;mu;-opioid receptor. This class of opioids are distinguished by their transient activation of the &amp;amp;mu;-opioid receptor, which is attributed to rapid enzymatic degradation. Methods: To understand how degradation of endomorphin-2 by the enzyme DPP IV affects its interaction with the &amp;amp;mu;-opioid receptor, we analyzed the ligand&amp;amp;ndash;receptor conformational dynamics and interaction patterns of molecular dynamics simulations data of morphine, fentanyl and endomorphin-2 and one degradation product Phe-Phe-NH2, using molecular fingerprints and the mathematical framework ISOKANN. Results: Our analyses revealed that both the clinically relevant opioids, morphine and fentanyl, as well as the endogenous opioid endomorphin-2, adopt a set of recurring binding conformations within the &amp;amp;mu;-opioid receptor binding pocket, maintaining overlapping interaction motifs throughout the simulations. In contrast, Phe-Phe-NH2 failed to maintain a persistent binding mode over the simulated timescale. This instability arises from the dipeptidyl peptidase IV mediated cleavage of endomorphin-2, which generates Phe-Phe-NH2 and removes critical proline and tyrosine residues, thereby leading to the loss of stabilizing hydrophobic contacts with receptor residues Tyr1503,33, Val2385,43 and Val3026,55. Conclusion: By mapping structural interaction motifs essential for stable &amp;amp;mu;-opioid receptor binding, this study provides mechanistic insights into how endogenous degradation reshapes ligand&amp;amp;ndash;receptor interactions.</description>
	<pubDate>2026-04-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 15: Analyzing the Molecular Effects of Endomorphin-2 Degradation on Stabilizing Interactions at the &amp;mu;-Opioid Receptor</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/2/15">doi: 10.3390/receptors5020015</a></p>
	<p>Authors:
		Celvic Coomber
		Jakob J. Kresse
		Surahit Chewle
		Marcus Weber
		Christof Schütte
		Vikram Sunkara
		</p>
	<p>Background: Endogenous opioids, such as endomorphin-2, are key regulators of the body&amp;amp;rsquo;s pain pathways and mediate analgesia by engaging the &amp;amp;mu;-opioid receptor. This class of opioids are distinguished by their transient activation of the &amp;amp;mu;-opioid receptor, which is attributed to rapid enzymatic degradation. Methods: To understand how degradation of endomorphin-2 by the enzyme DPP IV affects its interaction with the &amp;amp;mu;-opioid receptor, we analyzed the ligand&amp;amp;ndash;receptor conformational dynamics and interaction patterns of molecular dynamics simulations data of morphine, fentanyl and endomorphin-2 and one degradation product Phe-Phe-NH2, using molecular fingerprints and the mathematical framework ISOKANN. Results: Our analyses revealed that both the clinically relevant opioids, morphine and fentanyl, as well as the endogenous opioid endomorphin-2, adopt a set of recurring binding conformations within the &amp;amp;mu;-opioid receptor binding pocket, maintaining overlapping interaction motifs throughout the simulations. In contrast, Phe-Phe-NH2 failed to maintain a persistent binding mode over the simulated timescale. This instability arises from the dipeptidyl peptidase IV mediated cleavage of endomorphin-2, which generates Phe-Phe-NH2 and removes critical proline and tyrosine residues, thereby leading to the loss of stabilizing hydrophobic contacts with receptor residues Tyr1503,33, Val2385,43 and Val3026,55. Conclusion: By mapping structural interaction motifs essential for stable &amp;amp;mu;-opioid receptor binding, this study provides mechanistic insights into how endogenous degradation reshapes ligand&amp;amp;ndash;receptor interactions.</p>
	]]></content:encoded>

	<dc:title>Analyzing the Molecular Effects of Endomorphin-2 Degradation on Stabilizing Interactions at the &amp;amp;mu;-Opioid Receptor</dc:title>
			<dc:creator>Celvic Coomber</dc:creator>
			<dc:creator>Jakob J. Kresse</dc:creator>
			<dc:creator>Surahit Chewle</dc:creator>
			<dc:creator>Marcus Weber</dc:creator>
			<dc:creator>Christof Schütte</dc:creator>
			<dc:creator>Vikram Sunkara</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5020015</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-04-28</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-04-28</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/receptors5020015</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/2/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/2/14">

	<title>Receptors, Vol. 5, Pages 14: Classical Immune Pattern Recognition Receptors Involved in Inflammatory Trigger of Sickle Cell Anemia</title>
	<link>https://www.mdpi.com/2813-2564/5/2/14</link>
	<description>Sickle cell anemia (SCA) is a genetic disorder characterized by chronic hemolysis, primarily driven by red blood cell lysis. Its pathophysiology is centered, though not exclusively, on the increased release of intracellular components, such as hemoglobin degradation products, which are known to stimulate innate immune responses and promote prothrombotic states. Current therapies alleviate symptoms, yet patients remain exposed to a chronic inflammatory milieu punctuated by episodes of acute pain. The recurrence of these crises can be life-threatening due to ischemia&amp;amp;ndash;reperfusion injury, hypercoagulability, and respiratory complications. Central mechanisms are marked by elevated hemolysis, heightened inflammatory signaling, and increased procoagulant activity, largely driven by soluble molecules released into the plasma, such as hemoglobin, nuclear molecules and other products. These compounds are recognized from sensors on immune and endothelial cells, named Pattern Recognition Receptors (PRRs), and constitute canonical pathways for intracellular activation. Four main types have been extensively studied in the literature over recent years in both infectious and sterile inflammatory contexts; still, only a few have elucidated the mechanisms underlying acute and chronic inflammation in patients with SCA. Although Toll receptors were shown to be major in triggering immunity, other receptors were found to be important regarding this function, which suggested a multifactorial mechanism for this triggering. Therefore, here, we propose a comprehensive review of previously published findings regarding the expression, activation, and dynamics of Toll-like, NOD-like, and RIG-I&amp;amp;ndash;like receptors in the progression of SCA and its associated inflammatory features.</description>
	<pubDate>2026-04-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 14: Classical Immune Pattern Recognition Receptors Involved in Inflammatory Trigger of Sickle Cell Anemia</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/2/14">doi: 10.3390/receptors5020014</a></p>
	<p>Authors:
		Hershiley Oliveira Jácome
		Jonatas Alencar Castro Campelo
		Alexander Leonardo Silva-Junior
		</p>
	<p>Sickle cell anemia (SCA) is a genetic disorder characterized by chronic hemolysis, primarily driven by red blood cell lysis. Its pathophysiology is centered, though not exclusively, on the increased release of intracellular components, such as hemoglobin degradation products, which are known to stimulate innate immune responses and promote prothrombotic states. Current therapies alleviate symptoms, yet patients remain exposed to a chronic inflammatory milieu punctuated by episodes of acute pain. The recurrence of these crises can be life-threatening due to ischemia&amp;amp;ndash;reperfusion injury, hypercoagulability, and respiratory complications. Central mechanisms are marked by elevated hemolysis, heightened inflammatory signaling, and increased procoagulant activity, largely driven by soluble molecules released into the plasma, such as hemoglobin, nuclear molecules and other products. These compounds are recognized from sensors on immune and endothelial cells, named Pattern Recognition Receptors (PRRs), and constitute canonical pathways for intracellular activation. Four main types have been extensively studied in the literature over recent years in both infectious and sterile inflammatory contexts; still, only a few have elucidated the mechanisms underlying acute and chronic inflammation in patients with SCA. Although Toll receptors were shown to be major in triggering immunity, other receptors were found to be important regarding this function, which suggested a multifactorial mechanism for this triggering. Therefore, here, we propose a comprehensive review of previously published findings regarding the expression, activation, and dynamics of Toll-like, NOD-like, and RIG-I&amp;amp;ndash;like receptors in the progression of SCA and its associated inflammatory features.</p>
	]]></content:encoded>

	<dc:title>Classical Immune Pattern Recognition Receptors Involved in Inflammatory Trigger of Sickle Cell Anemia</dc:title>
			<dc:creator>Hershiley Oliveira Jácome</dc:creator>
			<dc:creator>Jonatas Alencar Castro Campelo</dc:creator>
			<dc:creator>Alexander Leonardo Silva-Junior</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5020014</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-04-21</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-04-21</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/receptors5020014</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/2/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/2/13">

	<title>Receptors, Vol. 5, Pages 13: Does Biochemical Life Exist for a Receptor Agonist Outside Its Receptor? The Case of Melatonin</title>
	<link>https://www.mdpi.com/2813-2564/5/2/13</link>
	<description>Melatonin is reported to exert two types of actions: those based on its interaction with cognate receptors (characterized by very high affinities&amp;amp;mdash;1 nM and below), and those mediated by unknown targets (characterized by high concentrations&amp;amp;mdash;100 &amp;amp;micro;M and above). Whereas receptor-mediated activities are known to regulate circadian rhythm, the high-dose effects are reported to be independent of these receptors and to produce literally dozens of beneficial effects in almost all human diseases, including cancer, neurodegenerative disorders, viral infections, obesity and many others. In the present opinion paper, we discuss this extensive set of claims and place them in perspective with a sum of evidence that collectively challenges the validity of these alleged beneficial effects.</description>
	<pubDate>2026-04-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 13: Does Biochemical Life Exist for a Receptor Agonist Outside Its Receptor? The Case of Melatonin</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/2/13">doi: 10.3390/receptors5020013</a></p>
	<p>Authors:
		Jean A. Boutin
		Jérôme Leprince
		</p>
	<p>Melatonin is reported to exert two types of actions: those based on its interaction with cognate receptors (characterized by very high affinities&amp;amp;mdash;1 nM and below), and those mediated by unknown targets (characterized by high concentrations&amp;amp;mdash;100 &amp;amp;micro;M and above). Whereas receptor-mediated activities are known to regulate circadian rhythm, the high-dose effects are reported to be independent of these receptors and to produce literally dozens of beneficial effects in almost all human diseases, including cancer, neurodegenerative disorders, viral infections, obesity and many others. In the present opinion paper, we discuss this extensive set of claims and place them in perspective with a sum of evidence that collectively challenges the validity of these alleged beneficial effects.</p>
	]]></content:encoded>

	<dc:title>Does Biochemical Life Exist for a Receptor Agonist Outside Its Receptor? The Case of Melatonin</dc:title>
			<dc:creator>Jean A. Boutin</dc:creator>
			<dc:creator>Jérôme Leprince</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5020013</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-04-15</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-04-15</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/receptors5020013</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/2/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/2/12">

	<title>Receptors, Vol. 5, Pages 12: From the Plate to the Nucleus: Dietary Control of Nuclear Receptors in the Development and Prevention of Metabolic Diseases</title>
	<link>https://www.mdpi.com/2813-2564/5/2/12</link>
	<description>Nutrient-sensing nuclear receptors (NSNRs), including PPARs, FXR, LXRs, RAR/RXR, VDR, and related orphan receptors, integrate a molecular interface that allows diet to communicate directly with the genome. By binding fatty acids, bile acids, sterols, vitamins, polyphenols, and other food-derived metabolites, NSNRs translate qualitative and quantitative features of the diet into coordinated transcriptional programmes across metabolically active organs. This ligand-dependent signalling network integrates dietary information to orchestrate inter-organ lipid and glucose metabolism, mitochondrial function, thermogenesis, and immune response, thereby enabling the organism to adapt dynamically to fasting&amp;amp;ndash;feeding cycles. In this review, we synthesise current evidence on the integrated roles of major NSNRs in the liver, skeletal muscle, white and brown adipose tissue, and kidney, emphasising how receptor networks within and between metabolic organs collectively govern energy expenditure, substrate partitioning, and systemic metabolic flexibility. We propose a conceptual framework in which diet functions as an &amp;amp;ldquo;external endocrine organ&amp;amp;rdquo;, acting as the primary source of chemically diverse NSNR ligands, while metabolic tissues serve as secondary signal amplifiers and integrators. Through circulating lipid species, bile acids, oxysterols, and other metabolites, these organs engage in continuous bidirectional communication that reprograms NSNR activity across tissues. We then examine how the global shift from minimally processed, nutrient-rich foods to nutrient-poor, energy-dense ultra-processed diets leads to a reduction in NSNR ligand diversity, promoting hepatic steatosis, muscle metabolic inflexibility, adipose tissue dysfunction, renal lipotoxicity, and chronic low-grade inflammation, ultimately causing obesity, type 2 diabetes, and cardiometabolic disease. Finally, we explore strategies to restore NSNR function, including Mediterranean and plant-based dietary patterns, as well as diets enriched with &amp;amp;omega;-3 polyunsaturated fatty acids, monounsaturated fats, and polyphenols. By integrating molecular, physiological, and clinical evidence, this review aims to clarify how NSNR networks translate dietary cues into coordinated inter-organ metabolism and how nutrient-poor diets lead to metabolic diseases trough a loss of metabolic information, rather than merely by energy excess. This framework supports a paradigm shift from calorie-centred nutrition to diet quality as the main therapeutic target for preventing metabolic diseases and promoting health.</description>
	<pubDate>2026-04-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 12: From the Plate to the Nucleus: Dietary Control of Nuclear Receptors in the Development and Prevention of Metabolic Diseases</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/2/12">doi: 10.3390/receptors5020012</a></p>
	<p>Authors:
		Ivan Torre-Villalvazo
		Claudia Tovar-Palacio
		Andrea Díaz-Villaseñor
		Berenice Palacios-González
		</p>
	<p>Nutrient-sensing nuclear receptors (NSNRs), including PPARs, FXR, LXRs, RAR/RXR, VDR, and related orphan receptors, integrate a molecular interface that allows diet to communicate directly with the genome. By binding fatty acids, bile acids, sterols, vitamins, polyphenols, and other food-derived metabolites, NSNRs translate qualitative and quantitative features of the diet into coordinated transcriptional programmes across metabolically active organs. This ligand-dependent signalling network integrates dietary information to orchestrate inter-organ lipid and glucose metabolism, mitochondrial function, thermogenesis, and immune response, thereby enabling the organism to adapt dynamically to fasting&amp;amp;ndash;feeding cycles. In this review, we synthesise current evidence on the integrated roles of major NSNRs in the liver, skeletal muscle, white and brown adipose tissue, and kidney, emphasising how receptor networks within and between metabolic organs collectively govern energy expenditure, substrate partitioning, and systemic metabolic flexibility. We propose a conceptual framework in which diet functions as an &amp;amp;ldquo;external endocrine organ&amp;amp;rdquo;, acting as the primary source of chemically diverse NSNR ligands, while metabolic tissues serve as secondary signal amplifiers and integrators. Through circulating lipid species, bile acids, oxysterols, and other metabolites, these organs engage in continuous bidirectional communication that reprograms NSNR activity across tissues. We then examine how the global shift from minimally processed, nutrient-rich foods to nutrient-poor, energy-dense ultra-processed diets leads to a reduction in NSNR ligand diversity, promoting hepatic steatosis, muscle metabolic inflexibility, adipose tissue dysfunction, renal lipotoxicity, and chronic low-grade inflammation, ultimately causing obesity, type 2 diabetes, and cardiometabolic disease. Finally, we explore strategies to restore NSNR function, including Mediterranean and plant-based dietary patterns, as well as diets enriched with &amp;amp;omega;-3 polyunsaturated fatty acids, monounsaturated fats, and polyphenols. By integrating molecular, physiological, and clinical evidence, this review aims to clarify how NSNR networks translate dietary cues into coordinated inter-organ metabolism and how nutrient-poor diets lead to metabolic diseases trough a loss of metabolic information, rather than merely by energy excess. This framework supports a paradigm shift from calorie-centred nutrition to diet quality as the main therapeutic target for preventing metabolic diseases and promoting health.</p>
	]]></content:encoded>

	<dc:title>From the Plate to the Nucleus: Dietary Control of Nuclear Receptors in the Development and Prevention of Metabolic Diseases</dc:title>
			<dc:creator>Ivan Torre-Villalvazo</dc:creator>
			<dc:creator>Claudia Tovar-Palacio</dc:creator>
			<dc:creator>Andrea Díaz-Villaseñor</dc:creator>
			<dc:creator>Berenice Palacios-González</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5020012</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-04-09</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-04-09</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/receptors5020012</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/2/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/2/11">

	<title>Receptors, Vol. 5, Pages 11: FAM3 Cytokine-like Proteins, Their Putative Receptors and Signaling Pathways in Metabolic Diseases and Cancers</title>
	<link>https://www.mdpi.com/2813-2564/5/2/11</link>
	<description>FAM3A, FAM3B, FAM3C and FAM3D are members of the &amp;amp;ldquo;family with sequence similarity 3&amp;amp;rdquo; (FAM3) gene family, an emerging class of cytokine-like proteins with a unique structural globular &amp;amp;beta;-&amp;amp;beta;-&amp;amp;alpha; fold and distinct biological functions. With widespread expression in tissue, organs and in many cell types, their specific roles in human diseases have been the focus of much research. FAM3A acts as a positive regulator of metabolic health, typically activating canonical pro-survival and metabolic pathways. FAM3B, also called PANDER (PANcreatic DERived Factor), exerts critical physiological functions in the regulation of glycemic levels via promotion of hepatic glucose production and pancreatic &amp;amp;beta;-cell insulin secretion. FAM3C, also named ILEI (Interleukin-like EMT inducer), is involved as an inducer of epithelial&amp;amp;ndash;mesenchymal transition (EMT) and cancer metastasis, as well as osteoblast differentiation and bone mineralization. FAM3D is a gut-secreted protein and potential regulator of gastrointestinal homeostasis and microbiota-induced inflammation. Here we provide an overview of previous studies supporting that FAM3 proteins act through putative membrane receptors and co-partners, including fibroblast growth factor receptor (FGFR), leukemia inhibitory factor receptor (LIFR), formyl peptide receptor (FPR1/2), to activate diverse downstream signaling pathways on different cellular contexts. Basic and clinical studies suggest that the FAM3 family influences both obesity, diabetes, and other metabolic disorders; thus, its expression may have diagnostic potential. The differential and often cancer-specific expression patterns make members of the FAM3 family promising candidates for biomarkers and therapeutic targets of some types of neoplasia.</description>
	<pubDate>2026-03-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 11: FAM3 Cytokine-like Proteins, Their Putative Receptors and Signaling Pathways in Metabolic Diseases and Cancers</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/2/11">doi: 10.3390/receptors5020011</a></p>
	<p>Authors:
		José E. Belizário
		Izabela D. S. Caldeira
		Bruna Moreira
		João Marcelo Occhiucci
		Brant Burkhardt
		Humberto M. Garay-Malpartida
		</p>
	<p>FAM3A, FAM3B, FAM3C and FAM3D are members of the &amp;amp;ldquo;family with sequence similarity 3&amp;amp;rdquo; (FAM3) gene family, an emerging class of cytokine-like proteins with a unique structural globular &amp;amp;beta;-&amp;amp;beta;-&amp;amp;alpha; fold and distinct biological functions. With widespread expression in tissue, organs and in many cell types, their specific roles in human diseases have been the focus of much research. FAM3A acts as a positive regulator of metabolic health, typically activating canonical pro-survival and metabolic pathways. FAM3B, also called PANDER (PANcreatic DERived Factor), exerts critical physiological functions in the regulation of glycemic levels via promotion of hepatic glucose production and pancreatic &amp;amp;beta;-cell insulin secretion. FAM3C, also named ILEI (Interleukin-like EMT inducer), is involved as an inducer of epithelial&amp;amp;ndash;mesenchymal transition (EMT) and cancer metastasis, as well as osteoblast differentiation and bone mineralization. FAM3D is a gut-secreted protein and potential regulator of gastrointestinal homeostasis and microbiota-induced inflammation. Here we provide an overview of previous studies supporting that FAM3 proteins act through putative membrane receptors and co-partners, including fibroblast growth factor receptor (FGFR), leukemia inhibitory factor receptor (LIFR), formyl peptide receptor (FPR1/2), to activate diverse downstream signaling pathways on different cellular contexts. Basic and clinical studies suggest that the FAM3 family influences both obesity, diabetes, and other metabolic disorders; thus, its expression may have diagnostic potential. The differential and often cancer-specific expression patterns make members of the FAM3 family promising candidates for biomarkers and therapeutic targets of some types of neoplasia.</p>
	]]></content:encoded>

	<dc:title>FAM3 Cytokine-like Proteins, Their Putative Receptors and Signaling Pathways in Metabolic Diseases and Cancers</dc:title>
			<dc:creator>José E. Belizário</dc:creator>
			<dc:creator>Izabela D. S. Caldeira</dc:creator>
			<dc:creator>Bruna Moreira</dc:creator>
			<dc:creator>João Marcelo Occhiucci</dc:creator>
			<dc:creator>Brant Burkhardt</dc:creator>
			<dc:creator>Humberto M. Garay-Malpartida</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5020011</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-03-30</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-03-30</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/receptors5020011</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/2/10">

	<title>Receptors, Vol. 5, Pages 10: Ion Channels as Targets of the Vitamin D Receptor: A Long Journey with a Promising Future</title>
	<link>https://www.mdpi.com/2813-2564/5/2/10</link>
	<description>The vitamin D receptor (VDR) acts as both a nuclear transcription factor and a non-genomic mediator that regulates a broad spectrum of physiological processes beyond calcium and phosphate homeostasis. VDR plays an important role in the modulation of ion channels across multiple tissues, including osteoblasts, renal and intestinal epithelial cells, neurons, and vascular smooth muscle. These regulatory mechanisms encompass genomic actions through vitamin D response elements in target genes&amp;amp;mdash;such as TRPV5, TRPV6, KCNK3, and KCNH1&amp;amp;mdash;as well as rapid, non-genomic actions at the plasma membrane involving protein disulfide isomerase A3 and associated signaling cascades. VDR-mediated transcriptional control of calcium, potassium, and chloride channels contributes to the fine-tuning of cellular excitability, calcium transport, and mitochondrial function. Evidence also implicates VDR&amp;amp;ndash;ion channel crosstalk in various pathological contexts, including renal cell carcinoma, breast and cervical cancers, pulmonary arterial hypertension, and osteoporosis. Understanding the molecular interplay between VDR and ion channels provides new perspectives on the pleiotropic effects of vitamin D and offers promising therapeutic opportunities in oncology, cardiovascular disease, and skeletal disorders. This review synthesizes previous and current evidence on the genomic and non-genomic mechanisms underlying VDR&amp;amp;ndash;ion channel regulation and highlights novel frontiers in vitamin D signaling relevant to human health and disease.</description>
	<pubDate>2026-03-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 10: Ion Channels as Targets of the Vitamin D Receptor: A Long Journey with a Promising Future</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/2/10">doi: 10.3390/receptors5020010</a></p>
	<p>Authors:
		Verna Cázares-Ordoñez
		Ramiro José González-Duarte
		Michiyasu Ishizawa
		Luis A. Pardo
		Makoto Makishima
		</p>
	<p>The vitamin D receptor (VDR) acts as both a nuclear transcription factor and a non-genomic mediator that regulates a broad spectrum of physiological processes beyond calcium and phosphate homeostasis. VDR plays an important role in the modulation of ion channels across multiple tissues, including osteoblasts, renal and intestinal epithelial cells, neurons, and vascular smooth muscle. These regulatory mechanisms encompass genomic actions through vitamin D response elements in target genes&amp;amp;mdash;such as TRPV5, TRPV6, KCNK3, and KCNH1&amp;amp;mdash;as well as rapid, non-genomic actions at the plasma membrane involving protein disulfide isomerase A3 and associated signaling cascades. VDR-mediated transcriptional control of calcium, potassium, and chloride channels contributes to the fine-tuning of cellular excitability, calcium transport, and mitochondrial function. Evidence also implicates VDR&amp;amp;ndash;ion channel crosstalk in various pathological contexts, including renal cell carcinoma, breast and cervical cancers, pulmonary arterial hypertension, and osteoporosis. Understanding the molecular interplay between VDR and ion channels provides new perspectives on the pleiotropic effects of vitamin D and offers promising therapeutic opportunities in oncology, cardiovascular disease, and skeletal disorders. This review synthesizes previous and current evidence on the genomic and non-genomic mechanisms underlying VDR&amp;amp;ndash;ion channel regulation and highlights novel frontiers in vitamin D signaling relevant to human health and disease.</p>
	]]></content:encoded>

	<dc:title>Ion Channels as Targets of the Vitamin D Receptor: A Long Journey with a Promising Future</dc:title>
			<dc:creator>Verna Cázares-Ordoñez</dc:creator>
			<dc:creator>Ramiro José González-Duarte</dc:creator>
			<dc:creator>Michiyasu Ishizawa</dc:creator>
			<dc:creator>Luis A. Pardo</dc:creator>
			<dc:creator>Makoto Makishima</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5020010</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-03-26</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-03-26</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/receptors5020010</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/9">

	<title>Receptors, Vol. 5, Pages 9: Function and Modulation of Sphingosine-1-Phosphate Receptors in the Central Nervous System</title>
	<link>https://www.mdpi.com/2813-2564/5/1/9</link>
	<description>Sphingolipids, first discovered in 1874 by Johann Thudicum, are among the eight recognized classes of lipids and are present in essentially all plants, animals, and fungi, as well as some viruses and prokaryotes. In mammals, sphingolipids are enriched in the central nervous system (CNS), where they play vital roles in tissue development; membrane structure; cell adhesion and recognition; and, importantly, signaling. A subset of sphingolipids including ceramide, glucosylceramide, and sphingosine has been shown to have bioactive properties, but two sphingolipids in particular (ceramide-1-phosphate and sphingosine-1-phosphate) have been shown to exert their effects at least in part due to the activation of cell surface-expressed G protein-coupled receptors. In the CNS, sphingosine-1-phosphate signaling has specifically emerged as a productive therapeutic target for the treatment of neurodegenerative disease, with the first small molecule targeting sphingosine-1-phosphate receptors approved roughly 15 years ago for the treatment of multiple sclerosis. As more specific activators and inhibitors of these receptors have been developed and entered the clinical trial pipeline, now is an appropriate time to examine the current state of our knowledge of the role that these receptors play in the CNS and highlight the current landscape of available modulators targeting these pathways.</description>
	<pubDate>2026-03-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 9: Function and Modulation of Sphingosine-1-Phosphate Receptors in the Central Nervous System</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/9">doi: 10.3390/receptors5010009</a></p>
	<p>Authors:
		Elizabeth Gulliksen
		Sriya Darsi
		Ladan Haidarbaigi
		Lucas J. Codispoti
		Devam Purohit
		Ashley Jung
		Aishwarya Chilamula
		Jason Newton
		</p>
	<p>Sphingolipids, first discovered in 1874 by Johann Thudicum, are among the eight recognized classes of lipids and are present in essentially all plants, animals, and fungi, as well as some viruses and prokaryotes. In mammals, sphingolipids are enriched in the central nervous system (CNS), where they play vital roles in tissue development; membrane structure; cell adhesion and recognition; and, importantly, signaling. A subset of sphingolipids including ceramide, glucosylceramide, and sphingosine has been shown to have bioactive properties, but two sphingolipids in particular (ceramide-1-phosphate and sphingosine-1-phosphate) have been shown to exert their effects at least in part due to the activation of cell surface-expressed G protein-coupled receptors. In the CNS, sphingosine-1-phosphate signaling has specifically emerged as a productive therapeutic target for the treatment of neurodegenerative disease, with the first small molecule targeting sphingosine-1-phosphate receptors approved roughly 15 years ago for the treatment of multiple sclerosis. As more specific activators and inhibitors of these receptors have been developed and entered the clinical trial pipeline, now is an appropriate time to examine the current state of our knowledge of the role that these receptors play in the CNS and highlight the current landscape of available modulators targeting these pathways.</p>
	]]></content:encoded>

	<dc:title>Function and Modulation of Sphingosine-1-Phosphate Receptors in the Central Nervous System</dc:title>
			<dc:creator>Elizabeth Gulliksen</dc:creator>
			<dc:creator>Sriya Darsi</dc:creator>
			<dc:creator>Ladan Haidarbaigi</dc:creator>
			<dc:creator>Lucas J. Codispoti</dc:creator>
			<dc:creator>Devam Purohit</dc:creator>
			<dc:creator>Ashley Jung</dc:creator>
			<dc:creator>Aishwarya Chilamula</dc:creator>
			<dc:creator>Jason Newton</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010009</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-03-17</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-03-17</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/receptors5010009</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/8">

	<title>Receptors, Vol. 5, Pages 8: The Role of Progesterone in the Reproductive Physiology of Females of Viviparous Squamata</title>
	<link>https://www.mdpi.com/2813-2564/5/1/8</link>
	<description>Progesterone (P4) regulates diverse reproductive processes across vertebrates through nuclear receptors; however, its mechanisms in squamate reptiles&amp;amp;mdash;particularly in viviparous species&amp;amp;mdash;remain poorly understood. In Squamata, P4 primarily acts through progesterone receptor (PR) isoforms A and B, although relatively few reptilian PR sequences have been characterized to date. Squamate PR exhibits ~50% overall sequence divergence from mammalian homologs yet retains striking conservation in both the ligand and DNA-binding domain across vertebrates. Despite the broadly conserved physiological roles of P4 (folliculogenesis, ovulation, courtship behavior, pregnancy maintenance, and parturition/oviposition), P4 dynamics in viviparous squamates remain unresolved due to heterogeneous circulating hormone concentrations and limited PR phylogeny and structure studies. While mammalian models dominate P4 research due to their biomedical relevance, squamates offer unique evolutionary insights: as the only reptile order exhibiting both oviparity and viviparity within the same clade, squamates represent an ideal model for investigating transitions in parity mode. Elucidating P4 mechanisms in squamates will help bridge this critical evolutionary gap, with important implications for reproductive biology and conservation.</description>
	<pubDate>2026-02-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 8: The Role of Progesterone in the Reproductive Physiology of Females of Viviparous Squamata</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/8">doi: 10.3390/receptors5010008</a></p>
	<p>Authors:
		Norma Berenice Cruz-Cano
		Uriel Ángel Sánchez-Rivera
		Carmen Álvarez-Rodríguez
		Hibraim Adán Pérez-Mendoza
		 Martínez-Torres
		</p>
	<p>Progesterone (P4) regulates diverse reproductive processes across vertebrates through nuclear receptors; however, its mechanisms in squamate reptiles&amp;amp;mdash;particularly in viviparous species&amp;amp;mdash;remain poorly understood. In Squamata, P4 primarily acts through progesterone receptor (PR) isoforms A and B, although relatively few reptilian PR sequences have been characterized to date. Squamate PR exhibits ~50% overall sequence divergence from mammalian homologs yet retains striking conservation in both the ligand and DNA-binding domain across vertebrates. Despite the broadly conserved physiological roles of P4 (folliculogenesis, ovulation, courtship behavior, pregnancy maintenance, and parturition/oviposition), P4 dynamics in viviparous squamates remain unresolved due to heterogeneous circulating hormone concentrations and limited PR phylogeny and structure studies. While mammalian models dominate P4 research due to their biomedical relevance, squamates offer unique evolutionary insights: as the only reptile order exhibiting both oviparity and viviparity within the same clade, squamates represent an ideal model for investigating transitions in parity mode. Elucidating P4 mechanisms in squamates will help bridge this critical evolutionary gap, with important implications for reproductive biology and conservation.</p>
	]]></content:encoded>

	<dc:title>The Role of Progesterone in the Reproductive Physiology of Females of Viviparous Squamata</dc:title>
			<dc:creator>Norma Berenice Cruz-Cano</dc:creator>
			<dc:creator>Uriel Ángel Sánchez-Rivera</dc:creator>
			<dc:creator>Carmen Álvarez-Rodríguez</dc:creator>
			<dc:creator>Hibraim Adán Pérez-Mendoza</dc:creator>
			<dc:creator> Martínez-Torres</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010008</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-02-27</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-02-27</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/receptors5010008</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/7">

	<title>Receptors, Vol. 5, Pages 7: Coevolution Between Three-Finger Toxins and Target Receptors</title>
	<link>https://www.mdpi.com/2813-2564/5/1/7</link>
	<description>Background: Three-finger toxins (3FTxs) are a major axis of functional diversification in advanced snake venoms, with canonical paralytic activity mediated through muscle-type nicotinic acetylcholine receptors (nAChRs) and a broader set of non-nicotinic targets. This review integrates evidence bearing on coevolution between 3FTxs and target receptors, spanning toxin origin, diversification, receptor evolution, and ecological context. Methods: The synthesis draws on comparative genomic and transcriptomic studies of 3FTx gene-family evolution, codon-model analyses of selection, structural characterisation of toxin&amp;amp;ndash;receptor interfaces, and functional assays (including receptor-mimicking peptide binding) that link sequence variation to binding and toxicity. Results: Across lineages, 3FTx diversification is repeatedly structured by strong constraint on the disulphide-rich scaffold with accelerated change concentrated in solvent-exposed loops, alongside birth&amp;amp;ndash;death dynamics and exon/segment-level innovation that expand binding specificity. On the receptor side, resistance-associated variation is most intensively characterised for the nAChR &amp;amp;alpha;1 orthosteric site and includes convergent, mechanistically distinct solutions such as electrostatic repulsion and glycosylation-mediated steric interference. Within the predominantly elapid systems currently examined, integrative datasets indicate that prey-selective binding and geographically variable susceptibility can arise from modest substitutions at toxin&amp;amp;ndash;receptor interfaces, but they also reveal substantial taxonomic and target-specific biases. Conclusions: Current evidence supports adaptive diversification in both toxins and receptors, while broader evolutionary interpretations are limited by uneven sampling and the frequent lack of matched toxin and receptor variants analysed within a common evolutionary framework. Development of predictive models will require joint pipelines linking genomics, structure-informed evolutionary inference, scalable functional assays, and explicit ecological network context.</description>
	<pubDate>2026-02-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 7: Coevolution Between Three-Finger Toxins and Target Receptors</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/7">doi: 10.3390/receptors5010007</a></p>
	<p>Authors:
		Jéssica Lopes de Oliveira
		Henrique Roman-Ramos
		</p>
	<p>Background: Three-finger toxins (3FTxs) are a major axis of functional diversification in advanced snake venoms, with canonical paralytic activity mediated through muscle-type nicotinic acetylcholine receptors (nAChRs) and a broader set of non-nicotinic targets. This review integrates evidence bearing on coevolution between 3FTxs and target receptors, spanning toxin origin, diversification, receptor evolution, and ecological context. Methods: The synthesis draws on comparative genomic and transcriptomic studies of 3FTx gene-family evolution, codon-model analyses of selection, structural characterisation of toxin&amp;amp;ndash;receptor interfaces, and functional assays (including receptor-mimicking peptide binding) that link sequence variation to binding and toxicity. Results: Across lineages, 3FTx diversification is repeatedly structured by strong constraint on the disulphide-rich scaffold with accelerated change concentrated in solvent-exposed loops, alongside birth&amp;amp;ndash;death dynamics and exon/segment-level innovation that expand binding specificity. On the receptor side, resistance-associated variation is most intensively characterised for the nAChR &amp;amp;alpha;1 orthosteric site and includes convergent, mechanistically distinct solutions such as electrostatic repulsion and glycosylation-mediated steric interference. Within the predominantly elapid systems currently examined, integrative datasets indicate that prey-selective binding and geographically variable susceptibility can arise from modest substitutions at toxin&amp;amp;ndash;receptor interfaces, but they also reveal substantial taxonomic and target-specific biases. Conclusions: Current evidence supports adaptive diversification in both toxins and receptors, while broader evolutionary interpretations are limited by uneven sampling and the frequent lack of matched toxin and receptor variants analysed within a common evolutionary framework. Development of predictive models will require joint pipelines linking genomics, structure-informed evolutionary inference, scalable functional assays, and explicit ecological network context.</p>
	]]></content:encoded>

	<dc:title>Coevolution Between Three-Finger Toxins and Target Receptors</dc:title>
			<dc:creator>Jéssica Lopes de Oliveira</dc:creator>
			<dc:creator>Henrique Roman-Ramos</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010007</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-02-14</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-02-14</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/receptors5010007</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/6">

	<title>Receptors, Vol. 5, Pages 6: Essential Envelope Spike Motifs for Cell Entry of Transmissible Gastroenteritis Virus and Its Evolution in Coronavirus</title>
	<link>https://www.mdpi.com/2813-2564/5/1/6</link>
	<description>Background: Transmissible gastroenteritis virus (TGEV), a coronavirus (CoV) infecting pigs, uses its spike (S) glycoprotein to bind porcine aminopeptidase N (pAPN) for cell entry. Although structural studies have identified receptor-binding motifs (RBMs) within the receptor-binding domain (RBD) of the S protein, the functional relevance of individual residues for TGEV receptor recognition, cell entry, and infection remain unclear. Methods: In this study, we performed structure-guided mutagenesis of the TGEV RBD to evaluate the contribution of specific residues to receptor binding and viral infectivity. Results: Using soluble RBD proteins, we found that most of the RBD residues within the pAPN-binding interface contribute to the binding interaction. Nonetheless, TGEV reverse genetics experiments revealed that just three RBD residues (Gly527, Tyr528, and Trp571) were indispensable for viral cell entry. Mutations at these positions, which are conserved among group 1 alpha-CoVs abolished infectivity, highlighting their central role in the virus&amp;amp;ndash;receptor interface. Conclusions: Our findings provide a detailed functional map of the TGEV RBD and offer insights into the evolution of receptor recognition across CoV.</description>
	<pubDate>2026-01-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 6: Essential Envelope Spike Motifs for Cell Entry of Transmissible Gastroenteritis Virus and Its Evolution in Coronavirus</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/6">doi: 10.3390/receptors5010006</a></p>
	<p>Authors:
		Gaurav Mudgal
		Fernando Almazán
		Tadeo Moreno-Chicano
		Alberto Martínez-Colom
		Cesar Santiago
		Luis Enjuanes
		José M. Casasnovas
		</p>
	<p>Background: Transmissible gastroenteritis virus (TGEV), a coronavirus (CoV) infecting pigs, uses its spike (S) glycoprotein to bind porcine aminopeptidase N (pAPN) for cell entry. Although structural studies have identified receptor-binding motifs (RBMs) within the receptor-binding domain (RBD) of the S protein, the functional relevance of individual residues for TGEV receptor recognition, cell entry, and infection remain unclear. Methods: In this study, we performed structure-guided mutagenesis of the TGEV RBD to evaluate the contribution of specific residues to receptor binding and viral infectivity. Results: Using soluble RBD proteins, we found that most of the RBD residues within the pAPN-binding interface contribute to the binding interaction. Nonetheless, TGEV reverse genetics experiments revealed that just three RBD residues (Gly527, Tyr528, and Trp571) were indispensable for viral cell entry. Mutations at these positions, which are conserved among group 1 alpha-CoVs abolished infectivity, highlighting their central role in the virus&amp;amp;ndash;receptor interface. Conclusions: Our findings provide a detailed functional map of the TGEV RBD and offer insights into the evolution of receptor recognition across CoV.</p>
	]]></content:encoded>

	<dc:title>Essential Envelope Spike Motifs for Cell Entry of Transmissible Gastroenteritis Virus and Its Evolution in Coronavirus</dc:title>
			<dc:creator>Gaurav Mudgal</dc:creator>
			<dc:creator>Fernando Almazán</dc:creator>
			<dc:creator>Tadeo Moreno-Chicano</dc:creator>
			<dc:creator>Alberto Martínez-Colom</dc:creator>
			<dc:creator>Cesar Santiago</dc:creator>
			<dc:creator>Luis Enjuanes</dc:creator>
			<dc:creator>José M. Casasnovas</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010006</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-01-30</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-01-30</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/receptors5010006</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/5">

	<title>Receptors, Vol. 5, Pages 5: Exploring Nuclear Receptor Functions in Multipotent Mesenchymal Stromal Stem Cell Differentiation</title>
	<link>https://www.mdpi.com/2813-2564/5/1/5</link>
	<description>Multipotent mesenchymal stromal stem cells have captivated the scientific community in recent years due to their ability to differentiate into multiple adult cell types. Central to this potential are many members of the nuclear hormone receptor superfamily, comprising 48 ligand-modulated transcription factors involved in key biological processes such as metabolism, physiology, embryonic development, and reproduction. These transcription factors influence cellular fate by regulating gene expression networks critical for MSC specification, commitment, and differentiation. This review explores the role of nuclear receptors in MSC development, focusing on interactions with chromatin structure, co-regulatory complexes, and responsiveness to extracellular stimuli such as hormones, metabolic cues, and endocrine-disrupting chemicals. We conclude with a discussion of the dangers posed by exogenous and aberrant signaling through nuclear receptors.</description>
	<pubDate>2026-01-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 5: Exploring Nuclear Receptor Functions in Multipotent Mesenchymal Stromal Stem Cell Differentiation</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/5">doi: 10.3390/receptors5010005</a></p>
	<p>Authors:
		Alivia Dougherty
		Bruce Blumberg
		</p>
	<p>Multipotent mesenchymal stromal stem cells have captivated the scientific community in recent years due to their ability to differentiate into multiple adult cell types. Central to this potential are many members of the nuclear hormone receptor superfamily, comprising 48 ligand-modulated transcription factors involved in key biological processes such as metabolism, physiology, embryonic development, and reproduction. These transcription factors influence cellular fate by regulating gene expression networks critical for MSC specification, commitment, and differentiation. This review explores the role of nuclear receptors in MSC development, focusing on interactions with chromatin structure, co-regulatory complexes, and responsiveness to extracellular stimuli such as hormones, metabolic cues, and endocrine-disrupting chemicals. We conclude with a discussion of the dangers posed by exogenous and aberrant signaling through nuclear receptors.</p>
	]]></content:encoded>

	<dc:title>Exploring Nuclear Receptor Functions in Multipotent Mesenchymal Stromal Stem Cell Differentiation</dc:title>
			<dc:creator>Alivia Dougherty</dc:creator>
			<dc:creator>Bruce Blumberg</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010005</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-01-19</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-01-19</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/receptors5010005</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/4">

	<title>Receptors, Vol. 5, Pages 4: The GLI3&amp;ndash;Androgen Receptor Axis: A Feedback Circuit Sustaining Shh Signaling in Prostate Cancer</title>
	<link>https://www.mdpi.com/2813-2564/5/1/4</link>
	<description>The Hedgehog (Hh) signaling pathway regulates key cellular processes, such as proliferation, differentiation, and morphogenesis. Although its canonical activation involves ligand binding to PTCH1, which activates Smoothened (SMO), noncanonical features of the pathway significantly contribute to cancer progression, particularly in prostate cancer (PCa). GLI3, a central transcription factor in the Hh pathway, can act as a repressor or activator depending on posttranslational modifications. In androgen-deprived PCa, GLI3 plays a critical role in driving castration-resistant phenotypes by interacting with the androgen receptor (AR), particularly the AR-V7 variant. This interaction enhances tumor survival and growth even under androgen deprivation therapy (ADT). Aberrant GLI3 activity is further driven by mutations in upstream regulators such as SPOP and MED12, which contribute to the progression of both prostate and other malignancies. Preclinical studies have shown promise in reducing tumor cell proliferation and migration, and in inducing apoptosis, by pharmacologically inhibiting the GLI3 pathway with SMO antagonists or GSK3&amp;amp;beta; inhibitors. Recent evidence also highlights reciprocal interactions between Sonic Hedgehog (Shh) signaling and the AR that sustain tumor growth under ADT. GLI3 engagement with AR reinforces AR-dependent transcription, supporting tumor progression through noncanonical pathways. These findings suggest that targeting GLI3, particularly in combination with AR inhibition, could effectively overcome castration resistance and improve outcomes in patients with castration-resistant prostate cancer (CRPC). This review explores the role of GLI3 in both canonical and noncanonical Hh signaling, its potential as a therapeutic target, and future directions for overcoming resistance in Hh-driven cancers.</description>
	<pubDate>2026-01-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 4: The GLI3&amp;ndash;Androgen Receptor Axis: A Feedback Circuit Sustaining Shh Signaling in Prostate Cancer</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/4">doi: 10.3390/receptors5010004</a></p>
	<p>Authors:
		Stephanie I. Nuñez-Olvera
		Enoc Mariano Cortés-Malagón
		Isela Montúfar-Robles
		José Javier Flores-Estrada
		María Elizbeth Alvarez-Sánchez
		Jonathan Puente-Rivera
		</p>
	<p>The Hedgehog (Hh) signaling pathway regulates key cellular processes, such as proliferation, differentiation, and morphogenesis. Although its canonical activation involves ligand binding to PTCH1, which activates Smoothened (SMO), noncanonical features of the pathway significantly contribute to cancer progression, particularly in prostate cancer (PCa). GLI3, a central transcription factor in the Hh pathway, can act as a repressor or activator depending on posttranslational modifications. In androgen-deprived PCa, GLI3 plays a critical role in driving castration-resistant phenotypes by interacting with the androgen receptor (AR), particularly the AR-V7 variant. This interaction enhances tumor survival and growth even under androgen deprivation therapy (ADT). Aberrant GLI3 activity is further driven by mutations in upstream regulators such as SPOP and MED12, which contribute to the progression of both prostate and other malignancies. Preclinical studies have shown promise in reducing tumor cell proliferation and migration, and in inducing apoptosis, by pharmacologically inhibiting the GLI3 pathway with SMO antagonists or GSK3&amp;amp;beta; inhibitors. Recent evidence also highlights reciprocal interactions between Sonic Hedgehog (Shh) signaling and the AR that sustain tumor growth under ADT. GLI3 engagement with AR reinforces AR-dependent transcription, supporting tumor progression through noncanonical pathways. These findings suggest that targeting GLI3, particularly in combination with AR inhibition, could effectively overcome castration resistance and improve outcomes in patients with castration-resistant prostate cancer (CRPC). This review explores the role of GLI3 in both canonical and noncanonical Hh signaling, its potential as a therapeutic target, and future directions for overcoming resistance in Hh-driven cancers.</p>
	]]></content:encoded>

	<dc:title>The GLI3&amp;amp;ndash;Androgen Receptor Axis: A Feedback Circuit Sustaining Shh Signaling in Prostate Cancer</dc:title>
			<dc:creator>Stephanie I. Nuñez-Olvera</dc:creator>
			<dc:creator>Enoc Mariano Cortés-Malagón</dc:creator>
			<dc:creator>Isela Montúfar-Robles</dc:creator>
			<dc:creator>José Javier Flores-Estrada</dc:creator>
			<dc:creator>María Elizbeth Alvarez-Sánchez</dc:creator>
			<dc:creator>Jonathan Puente-Rivera</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010004</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2026-01-19</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2026-01-19</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/receptors5010004</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/3">

	<title>Receptors, Vol. 5, Pages 3: NR4A Receptors in Immunity: Bridging Neuroendocrine and Inflammatory Pathways</title>
	<link>https://www.mdpi.com/2813-2564/5/1/3</link>
	<description>Nuclear receptors (NRs) are ligand-activated transcription factors that mediate diverse cellular processes, including signalling, survival, proliferation, immune response and metabolism, through both genomic and non-genomic mechanisms in response to hormones and metabolic ligands. Given their central role in inter-organ, tissue, and cellular communication, NRs are critical for maintaining homeostasis and have become a major focus in biomedical research and drug discovery due to their association with numerous diseases. Among NRs, the NR4A subfamily (NR4A1/Nur77, NR4A2/Nurr1, and NR4A3/Nor1) responds to various stimuli&amp;amp;mdash;such as insulin, growth factors, inflammatory cytokines, and &amp;amp;beta;-adrenergic signals&amp;amp;mdash;though their endogenous ligands remain unidentified. Their expression is tissue-dependent, particularly in energy-demanding tissues, where they modulate leukocyte function and promote an anti-inflammatory profile. Like other NRs, NR4As regulate acute and chronic inflammation by suppressing pro-inflammatory transcription factors (e.g., NF-&amp;amp;kappa;B) or enhancing their inhibitors, thereby polarising macrophages toward an anti-inflammatory phenotype. This review summarises current knowledge on the role of NR4A receptors in immune responses. Given their well-documented involvement in autoimmune diseases, inflammatory conditions, and cancer, elucidating their contributions to neuro&amp;amp;ndash;immune&amp;amp;ndash;endocrine crosstalk may uncover their therapeutic potential for immunopathological disorders.</description>
	<pubDate>2025-12-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 3: NR4A Receptors in Immunity: Bridging Neuroendocrine and Inflammatory Pathways</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/3">doi: 10.3390/receptors5010003</a></p>
	<p>Authors:
		Simone Lemes Ferreira
		Natalia Santucci
		</p>
	<p>Nuclear receptors (NRs) are ligand-activated transcription factors that mediate diverse cellular processes, including signalling, survival, proliferation, immune response and metabolism, through both genomic and non-genomic mechanisms in response to hormones and metabolic ligands. Given their central role in inter-organ, tissue, and cellular communication, NRs are critical for maintaining homeostasis and have become a major focus in biomedical research and drug discovery due to their association with numerous diseases. Among NRs, the NR4A subfamily (NR4A1/Nur77, NR4A2/Nurr1, and NR4A3/Nor1) responds to various stimuli&amp;amp;mdash;such as insulin, growth factors, inflammatory cytokines, and &amp;amp;beta;-adrenergic signals&amp;amp;mdash;though their endogenous ligands remain unidentified. Their expression is tissue-dependent, particularly in energy-demanding tissues, where they modulate leukocyte function and promote an anti-inflammatory profile. Like other NRs, NR4As regulate acute and chronic inflammation by suppressing pro-inflammatory transcription factors (e.g., NF-&amp;amp;kappa;B) or enhancing their inhibitors, thereby polarising macrophages toward an anti-inflammatory phenotype. This review summarises current knowledge on the role of NR4A receptors in immune responses. Given their well-documented involvement in autoimmune diseases, inflammatory conditions, and cancer, elucidating their contributions to neuro&amp;amp;ndash;immune&amp;amp;ndash;endocrine crosstalk may uncover their therapeutic potential for immunopathological disorders.</p>
	]]></content:encoded>

	<dc:title>NR4A Receptors in Immunity: Bridging Neuroendocrine and Inflammatory Pathways</dc:title>
			<dc:creator>Simone Lemes Ferreira</dc:creator>
			<dc:creator>Natalia Santucci</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010003</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-12-25</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-12-25</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/receptors5010003</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/2">

	<title>Receptors, Vol. 5, Pages 2: Astrocytic Receptor Systems of the Basal Ganglia</title>
	<link>https://www.mdpi.com/2813-2564/5/1/2</link>
	<description>Astrocytes are increasingly recognized as active participants of synaptic communication, yet their role in the basal ganglia circuitry remains poorly defined. Emerging evidence indicates that astrocytes in this region express a diverse array of neurotransmitter receptors thought to regulate intracellular calcium signaling, gliotransmitter release, synaptic plasticity, and neuroimmune responses. However, the literature is limited by methodological variability and a pronounced focus on the striatum, with comparatively little data on other basal ganglia nuclei. This review aims to organize the current literature on astrocytic receptor systems within the basal ganglia, including dopaminergic (D1&amp;amp;ndash;D5), glutamatergic (AMPA, NMDA, mGluRs), GABAergic (GABA-A, GABA-B), purinergic (P1, P2), and adrenergic (&amp;amp;alpha;, &amp;amp;beta;) receptors. By organizing receptor-specific findings across basal ganglia structures, this review provides a foundation for future investigations into astrocytic function in this complex neural network.</description>
	<pubDate>2025-12-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 2: Astrocytic Receptor Systems of the Basal Ganglia</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/2">doi: 10.3390/receptors5010002</a></p>
	<p>Authors:
		Aleksandar Tushevski
		Linus Happe
		Elena Stocco
		Raffaele De Caro
		Veronica Macchi
		Andrea Porzionato
		Aron Emmi
		</p>
	<p>Astrocytes are increasingly recognized as active participants of synaptic communication, yet their role in the basal ganglia circuitry remains poorly defined. Emerging evidence indicates that astrocytes in this region express a diverse array of neurotransmitter receptors thought to regulate intracellular calcium signaling, gliotransmitter release, synaptic plasticity, and neuroimmune responses. However, the literature is limited by methodological variability and a pronounced focus on the striatum, with comparatively little data on other basal ganglia nuclei. This review aims to organize the current literature on astrocytic receptor systems within the basal ganglia, including dopaminergic (D1&amp;amp;ndash;D5), glutamatergic (AMPA, NMDA, mGluRs), GABAergic (GABA-A, GABA-B), purinergic (P1, P2), and adrenergic (&amp;amp;alpha;, &amp;amp;beta;) receptors. By organizing receptor-specific findings across basal ganglia structures, this review provides a foundation for future investigations into astrocytic function in this complex neural network.</p>
	]]></content:encoded>

	<dc:title>Astrocytic Receptor Systems of the Basal Ganglia</dc:title>
			<dc:creator>Aleksandar Tushevski</dc:creator>
			<dc:creator>Linus Happe</dc:creator>
			<dc:creator>Elena Stocco</dc:creator>
			<dc:creator>Raffaele De Caro</dc:creator>
			<dc:creator>Veronica Macchi</dc:creator>
			<dc:creator>Andrea Porzionato</dc:creator>
			<dc:creator>Aron Emmi</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010002</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-12-23</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-12-23</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/receptors5010002</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/5/1/1">

	<title>Receptors, Vol. 5, Pages 1: Distribution and Levels of Insulin-like Growth Factor 2 Receptor Across Mouse Brain Cell Types</title>
	<link>https://www.mdpi.com/2813-2564/5/1/1</link>
	<description>Background: The insulin-like growth factor 2 receptor (IGF-2R), also known as the cation-independent mannose 6-phosphate receptor (CI-M6PR), is emerging as a critical receptor for brain function and disease. IGF-2R, in fact, plays a key role in long-term memory, and its activation by several ligands shows beneficial effects in multiple neurodevelopmental and neurodegenerative disease models. Thus, its targeting is very promising for neuropsychiatric therapeutic interventions. IGF-2R&amp;amp;rsquo;s main known functions are transport of lysosomal enzymes and regulation of developmental tissue growth, but in the brain, it also controls learning-dependent protein synthesis underlying long-term memory. However, little is known about this receptor in brain cells, including its cell-type-specific and subcellular expression. Methods: We conducted a comprehensive investigation to comparatively assess IGF-2R protein levels in different brain cell types across various brain regions in adult male C57BL/6J mice using dual and multiplex immunofluorescent staining with cell-type-specific markers. The IGF-2R protein distribution was also compared with Igf2r mRNA expression in publicly available single-cell RNA sequencing databases. Results: A ranking of IGF-2R levels in the soma of various cell types in the hippocampus and cortical regions revealed that the highest enrichment is, by far, in excitatory and inhibitory neurons, followed by vascular mural cells and subpopulations of oligodendrocyte lineage cells, with low to undetectable levels in astrocytes, microglia, vascular endothelial cells, and perivascular fibroblasts. High levels of IGF-2R were also found in ependymal cells, choroid plexus epithelial cells, and a subpopulation of meningeal fibroblast-like cells. IGF-2R was found in dendritic and putative axonal compartments throughout the brain, with particularly high levels in the stratum lucidum. The receptor&amp;amp;rsquo;s protein distribution aligned with that of the mRNA in mouse brain databases. Conclusions: These results suggest that IGF-2R-mediated functions in the brain vary across different cell types and subcellular compartments, with the most active roles in specific subpopulations of neurons, mural cells, ependymal cells, meningeal cells, and cells of the oligodendrocyte lineage. This study advances our understanding of IGF-2R&amp;amp;rsquo;s distribution in the brain, which is essential for formulating new hypotheses about its functions and therapeutic targeting.</description>
	<pubDate>2025-12-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 5, Pages 1: Distribution and Levels of Insulin-like Growth Factor 2 Receptor Across Mouse Brain Cell Types</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/5/1/1">doi: 10.3390/receptors5010001</a></p>
	<p>Authors:
		Jessica R. Gaunt
		Gokul Manoj
		Cristina M. Alberini
		</p>
	<p>Background: The insulin-like growth factor 2 receptor (IGF-2R), also known as the cation-independent mannose 6-phosphate receptor (CI-M6PR), is emerging as a critical receptor for brain function and disease. IGF-2R, in fact, plays a key role in long-term memory, and its activation by several ligands shows beneficial effects in multiple neurodevelopmental and neurodegenerative disease models. Thus, its targeting is very promising for neuropsychiatric therapeutic interventions. IGF-2R&amp;amp;rsquo;s main known functions are transport of lysosomal enzymes and regulation of developmental tissue growth, but in the brain, it also controls learning-dependent protein synthesis underlying long-term memory. However, little is known about this receptor in brain cells, including its cell-type-specific and subcellular expression. Methods: We conducted a comprehensive investigation to comparatively assess IGF-2R protein levels in different brain cell types across various brain regions in adult male C57BL/6J mice using dual and multiplex immunofluorescent staining with cell-type-specific markers. The IGF-2R protein distribution was also compared with Igf2r mRNA expression in publicly available single-cell RNA sequencing databases. Results: A ranking of IGF-2R levels in the soma of various cell types in the hippocampus and cortical regions revealed that the highest enrichment is, by far, in excitatory and inhibitory neurons, followed by vascular mural cells and subpopulations of oligodendrocyte lineage cells, with low to undetectable levels in astrocytes, microglia, vascular endothelial cells, and perivascular fibroblasts. High levels of IGF-2R were also found in ependymal cells, choroid plexus epithelial cells, and a subpopulation of meningeal fibroblast-like cells. IGF-2R was found in dendritic and putative axonal compartments throughout the brain, with particularly high levels in the stratum lucidum. The receptor&amp;amp;rsquo;s protein distribution aligned with that of the mRNA in mouse brain databases. Conclusions: These results suggest that IGF-2R-mediated functions in the brain vary across different cell types and subcellular compartments, with the most active roles in specific subpopulations of neurons, mural cells, ependymal cells, meningeal cells, and cells of the oligodendrocyte lineage. This study advances our understanding of IGF-2R&amp;amp;rsquo;s distribution in the brain, which is essential for formulating new hypotheses about its functions and therapeutic targeting.</p>
	]]></content:encoded>

	<dc:title>Distribution and Levels of Insulin-like Growth Factor 2 Receptor Across Mouse Brain Cell Types</dc:title>
			<dc:creator>Jessica R. Gaunt</dc:creator>
			<dc:creator>Gokul Manoj</dc:creator>
			<dc:creator>Cristina M. Alberini</dc:creator>
		<dc:identifier>doi: 10.3390/receptors5010001</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-12-23</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-12-23</prism:publicationDate>
	<prism:volume>5</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/receptors5010001</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/5/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/24">

	<title>Receptors, Vol. 4, Pages 24: Role of Transient Receptor Potential Vanilloid Channels in Gastrointestinal Physiology and Pathology</title>
	<link>https://www.mdpi.com/2813-2564/4/4/24</link>
	<description>Transient Receptor Potential Vanilloid (TRPV) channels represent one of the seven subfamilies of TRP receptors and are widely expressed throughout the human body where they play pivotal roles in various physiological processes. In the gastrointestinal (GI) system, TRPV channels regulate critical functions such as nutrient absorption, motility, and secretions. Beyond maintaining cellular homeostasis, these channels are involved in pain and inflammation, contributing to diverse pathologies. Their central role in the pathophysiology of different digestive system disorders has made TRPV channels a significant focus of research. Moreover, the involvement of TRPV channels in numerous GI cancers has further heightened research interest in the role of these channels. Accordingly, this review elucidates the structural components and intricate signaling pathways of TRPV channels, focusing on the unique characteristics of each family member (TRPV1&amp;amp;ndash;6) in GI physiology. Furthermore, we explore the therapeutic potential of targeting these channels to modulate their physiological and pathological roles, highlighting their promise in treating GI disorders. Additionally, we address the challenges associated with their therapeutic application, considering their interactions in different systems, inherent biochemical characteristics, and the alterations required for effective design.</description>
	<pubDate>2025-11-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 24: Role of Transient Receptor Potential Vanilloid Channels in Gastrointestinal Physiology and Pathology</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/24">doi: 10.3390/receptors4040024</a></p>
	<p>Authors:
		Omar Tluli
		Ahmed Arabi
		Humam Emad Rajha
		Lana Abugharbieh
		Faissal Al Zeir
		Maryam Hamdan
		Ayeda Abuqaba
		Ammar Boudaka
		</p>
	<p>Transient Receptor Potential Vanilloid (TRPV) channels represent one of the seven subfamilies of TRP receptors and are widely expressed throughout the human body where they play pivotal roles in various physiological processes. In the gastrointestinal (GI) system, TRPV channels regulate critical functions such as nutrient absorption, motility, and secretions. Beyond maintaining cellular homeostasis, these channels are involved in pain and inflammation, contributing to diverse pathologies. Their central role in the pathophysiology of different digestive system disorders has made TRPV channels a significant focus of research. Moreover, the involvement of TRPV channels in numerous GI cancers has further heightened research interest in the role of these channels. Accordingly, this review elucidates the structural components and intricate signaling pathways of TRPV channels, focusing on the unique characteristics of each family member (TRPV1&amp;amp;ndash;6) in GI physiology. Furthermore, we explore the therapeutic potential of targeting these channels to modulate their physiological and pathological roles, highlighting their promise in treating GI disorders. Additionally, we address the challenges associated with their therapeutic application, considering their interactions in different systems, inherent biochemical characteristics, and the alterations required for effective design.</p>
	]]></content:encoded>

	<dc:title>Role of Transient Receptor Potential Vanilloid Channels in Gastrointestinal Physiology and Pathology</dc:title>
			<dc:creator>Omar Tluli</dc:creator>
			<dc:creator>Ahmed Arabi</dc:creator>
			<dc:creator>Humam Emad Rajha</dc:creator>
			<dc:creator>Lana Abugharbieh</dc:creator>
			<dc:creator>Faissal Al Zeir</dc:creator>
			<dc:creator>Maryam Hamdan</dc:creator>
			<dc:creator>Ayeda Abuqaba</dc:creator>
			<dc:creator>Ammar Boudaka</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040024</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-11-10</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-11-10</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>24</prism:startingPage>
		<prism:doi>10.3390/receptors4040024</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/23">

	<title>Receptors, Vol. 4, Pages 23: Neurokinin-1 Receptor Regulation of Fibroblast Phenotype and Function</title>
	<link>https://www.mdpi.com/2813-2564/4/4/23</link>
	<description>Injury to tissue induces the normal wound healing process to repair damage. This is a normal and critical response developed by the body to maintain short-term organ function, and therefore, survival. Should this process become aberrant, then fibrosis can develop. Fibrosis is the excess accumulation of extracellular matrix proteins. Unlike normal wound healing that is designed to maintain organ/tissue function, fibrosis interferes with the normal architecture of the organ and has long-term functional implications. Fibroblasts are the cells responsible for producing extracellular matrix in both wound healing and fibrosis. Substance P is the cognate ligand for the neurokinin-1 receptor, and both substance P and the neurokinin-1 receptor have been demonstrated to be involved in organ remodeling; this includes regulation of fibroblast function. In this review we will focus on substance P/neurokinin-1 receptor regulation of fibroblast function in the setting of both wound healing and fibrosis. This review describes actions of substance P and the neurokinin-1 receptor on fibroblasts from multiple organs, thus identifying central actions common to all fibroblasts studied. This review also identifies gaps in the literature and future directions needed to improve understanding of substance P and the neurokinin-1 receptor regulation of fibroblast phenotype.</description>
	<pubDate>2025-11-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 23: Neurokinin-1 Receptor Regulation of Fibroblast Phenotype and Function</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/23">doi: 10.3390/receptors4040023</a></p>
	<p>Authors:
		Scott P. Levick
		</p>
	<p>Injury to tissue induces the normal wound healing process to repair damage. This is a normal and critical response developed by the body to maintain short-term organ function, and therefore, survival. Should this process become aberrant, then fibrosis can develop. Fibrosis is the excess accumulation of extracellular matrix proteins. Unlike normal wound healing that is designed to maintain organ/tissue function, fibrosis interferes with the normal architecture of the organ and has long-term functional implications. Fibroblasts are the cells responsible for producing extracellular matrix in both wound healing and fibrosis. Substance P is the cognate ligand for the neurokinin-1 receptor, and both substance P and the neurokinin-1 receptor have been demonstrated to be involved in organ remodeling; this includes regulation of fibroblast function. In this review we will focus on substance P/neurokinin-1 receptor regulation of fibroblast function in the setting of both wound healing and fibrosis. This review describes actions of substance P and the neurokinin-1 receptor on fibroblasts from multiple organs, thus identifying central actions common to all fibroblasts studied. This review also identifies gaps in the literature and future directions needed to improve understanding of substance P and the neurokinin-1 receptor regulation of fibroblast phenotype.</p>
	]]></content:encoded>

	<dc:title>Neurokinin-1 Receptor Regulation of Fibroblast Phenotype and Function</dc:title>
			<dc:creator>Scott P. Levick</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040023</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-11-06</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-11-06</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>23</prism:startingPage>
		<prism:doi>10.3390/receptors4040023</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/22">

	<title>Receptors, Vol. 4, Pages 22: Neuroprotective Role of Cannabinoids in Retinal Disease</title>
	<link>https://www.mdpi.com/2813-2564/4/4/22</link>
	<description>Cannabinoids, compounds that interact with the endocannabinoid system, have shown promising neuroprotective effects in various neurodegenerative diseases, including those affecting the retina. This review evaluates evidence for the presence and action of cannabinoids in the retina, their function in protecting against oxidative stress and modulating neuroinflammation, and the outcomes observed in animal models of retinal diseases such as glaucoma and age-related macular degeneration (AMD), the most common causes of vision loss. Cannabinoids have proven effective in reducing the neurodegeneration seen in these eye diseases, acting via the CB1 and CB2 cannabinoid receptors. The cannabinoid neuroprotective effect is often of a similar magnitude to the other proven therapy of medical dosage of vitamins, though it confers a greater risk due to neurotoxicity with high THC:CBD ratios, making the vitamin therapy of greater efficacy when time is available. Given the increased ratio of THC:CBD in commercial cannabis strains, rising from 10:1 at the beginning of this century to 100:1 now, the risk of neurotoxicity has increased, reducing the neuroprotective benefit. The proven safety and efficacy of vitamin therapy may be a more viable neuroprotective method than cannabinoid use for chronic conditions, with cannabinoids proving their utility in more acute conditions. This review evaluates both the method of action of cannabinoids and the receptor pathway utilized and compares the suggested therapeutic applicability of cannabinoids with proven vitamin therapy.</description>
	<pubDate>2025-11-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 22: Neuroprotective Role of Cannabinoids in Retinal Disease</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/22">doi: 10.3390/receptors4040022</a></p>
	<p>Authors:
		George Ayoub
		</p>
	<p>Cannabinoids, compounds that interact with the endocannabinoid system, have shown promising neuroprotective effects in various neurodegenerative diseases, including those affecting the retina. This review evaluates evidence for the presence and action of cannabinoids in the retina, their function in protecting against oxidative stress and modulating neuroinflammation, and the outcomes observed in animal models of retinal diseases such as glaucoma and age-related macular degeneration (AMD), the most common causes of vision loss. Cannabinoids have proven effective in reducing the neurodegeneration seen in these eye diseases, acting via the CB1 and CB2 cannabinoid receptors. The cannabinoid neuroprotective effect is often of a similar magnitude to the other proven therapy of medical dosage of vitamins, though it confers a greater risk due to neurotoxicity with high THC:CBD ratios, making the vitamin therapy of greater efficacy when time is available. Given the increased ratio of THC:CBD in commercial cannabis strains, rising from 10:1 at the beginning of this century to 100:1 now, the risk of neurotoxicity has increased, reducing the neuroprotective benefit. The proven safety and efficacy of vitamin therapy may be a more viable neuroprotective method than cannabinoid use for chronic conditions, with cannabinoids proving their utility in more acute conditions. This review evaluates both the method of action of cannabinoids and the receptor pathway utilized and compares the suggested therapeutic applicability of cannabinoids with proven vitamin therapy.</p>
	]]></content:encoded>

	<dc:title>Neuroprotective Role of Cannabinoids in Retinal Disease</dc:title>
			<dc:creator>George Ayoub</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040022</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-11-04</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-11-04</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>22</prism:startingPage>
		<prism:doi>10.3390/receptors4040022</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/21">

	<title>Receptors, Vol. 4, Pages 21: Impaired Hemostasis and the Role of Oxidative Stress-Induced Signaling in Thrombotic Disorders&amp;mdash;Where We Stand Today</title>
	<link>https://www.mdpi.com/2813-2564/4/4/21</link>
	<description>Both primary and secondary hemostasis consist of finely regulated pathways, forming a blood clot to stop bleeding. These orchestrated mechanisms involve multiple plasma- and platelet/endothelial-derived receptors, factors, enzymes, and proteins, such as the von Willebrand factor (vWF), fibrinogen, and thrombin. Over-activation or improper resolution of the coagulation cascade leads to severe pathological disorders, arterial and venous. Despite the fact that the genetic etiology of thrombophilia has gained the main research interest, there is growing evidence that the disturbed redox network of key hemostatic pathways signals thrombus formation. Oxidized LDL in dyslipidemias and many endogenous and exogenous compounds act as pro-oxidant stimuli that lead to post-translational modifications of proteins, such as sulfenylation, nitrosation, disulfide formation, glutathionylation, etc. Oxidation of cysteine and methionine residues of vWF, fibrinogen, and thrombomodulin has been detected at thrombotic episodes. Increased homocysteine levels due to, but not restricted to, methylenetetrahydrofolate reductase gene (MTHFR) mutations have been incriminated as a causative factor for oxidative stress, leading to a pro-thrombotic phenotype. Alterations in the vascular architecture, impaired vascular relaxation through decreased bioavailability of NO, accumulation of N&amp;amp;epsilon;-homocysteinylated proteins, ER stress, and endothelial cells&amp;amp;rsquo; apoptosis are among the pro-oxidant mechanisms of homocysteine. This review article focuses on describing key concepts on the oxidant-based molecular pathways that contribute to thrombotic episodes, with emphasis on the endogenous compound, homocysteine, aiming to promote further molecular, clinical, and pharmacological research in this field.</description>
	<pubDate>2025-10-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 21: Impaired Hemostasis and the Role of Oxidative Stress-Induced Signaling in Thrombotic Disorders&amp;mdash;Where We Stand Today</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/21">doi: 10.3390/receptors4040021</a></p>
	<p>Authors:
		Sofia K. Georgiou-Siafis
		Paraskevi Kotsi
		</p>
	<p>Both primary and secondary hemostasis consist of finely regulated pathways, forming a blood clot to stop bleeding. These orchestrated mechanisms involve multiple plasma- and platelet/endothelial-derived receptors, factors, enzymes, and proteins, such as the von Willebrand factor (vWF), fibrinogen, and thrombin. Over-activation or improper resolution of the coagulation cascade leads to severe pathological disorders, arterial and venous. Despite the fact that the genetic etiology of thrombophilia has gained the main research interest, there is growing evidence that the disturbed redox network of key hemostatic pathways signals thrombus formation. Oxidized LDL in dyslipidemias and many endogenous and exogenous compounds act as pro-oxidant stimuli that lead to post-translational modifications of proteins, such as sulfenylation, nitrosation, disulfide formation, glutathionylation, etc. Oxidation of cysteine and methionine residues of vWF, fibrinogen, and thrombomodulin has been detected at thrombotic episodes. Increased homocysteine levels due to, but not restricted to, methylenetetrahydrofolate reductase gene (MTHFR) mutations have been incriminated as a causative factor for oxidative stress, leading to a pro-thrombotic phenotype. Alterations in the vascular architecture, impaired vascular relaxation through decreased bioavailability of NO, accumulation of N&amp;amp;epsilon;-homocysteinylated proteins, ER stress, and endothelial cells&amp;amp;rsquo; apoptosis are among the pro-oxidant mechanisms of homocysteine. This review article focuses on describing key concepts on the oxidant-based molecular pathways that contribute to thrombotic episodes, with emphasis on the endogenous compound, homocysteine, aiming to promote further molecular, clinical, and pharmacological research in this field.</p>
	]]></content:encoded>

	<dc:title>Impaired Hemostasis and the Role of Oxidative Stress-Induced Signaling in Thrombotic Disorders&amp;amp;mdash;Where We Stand Today</dc:title>
			<dc:creator>Sofia K. Georgiou-Siafis</dc:creator>
			<dc:creator>Paraskevi Kotsi</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040021</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-10-31</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-10-31</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>21</prism:startingPage>
		<prism:doi>10.3390/receptors4040021</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/20">

	<title>Receptors, Vol. 4, Pages 20: Pharmacological Intervention of PIEZO1 for Butterfly Eyespot Color Patterns in Junonia&amp;nbsp;orithya</title>
	<link>https://www.mdpi.com/2813-2564/4/4/20</link>
	<description>Background: PIEZO channels are mechanoreceptors expressed in various cells. Their contributions to animal development are not entirely clear. According to the physical distortion hypothesis, developmental organizers for butterfly wing eyespots receive and release mechanical signals in pupal wing tissues during development, initiating a calcium signaling cascade and gene expression changes. Objectives: We tested the possible involvement of PIEZO1 in butterfly wing color pattern formation, according to the physical distortion hypothesis. Methods: We performed a pharmacological intervention of PIEZO1, focusing on the eyespots of Junonia orithya. Chemical modulators of PIEZO1 and the actin cytoskeleton were injected into pupae immediately after pupation during the critical period of color pattern determination, and the eyespot color patterns of the emerging adult wings were analyzed. We also tested dimethyl sulfoxide (DMSO) because it was used as a solvent. Results: DMSO significantly enlarged most eyespots examined. In contrast, the specific PIEZO1 activator Jedi2 induced significant reduction in the dorsal hindwing eyespots. Another specific PIEZO1 activator, Yoda1, also induced similar changes, although less clearly. The mechanosensitive channel blocker GsMTx4 produced compromised eyespots in an individual, although statistical support for modification was weak. The actin polymerization activator phalloidin induced blue foci in the ventral forewing eyespots. PIEZO expression in the pupal wings was demonstrated by RT-PCR. Conclusions: These results suggest that eyespot organizers in butterfly wings may employ a PIEZO-mediated mechanotransduction pathway to regulate eyespot color patterns, supporting the physical distortion hypothesis. These results highlight the importance of PIEZO in developmental organizers in animals.</description>
	<pubDate>2025-10-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 20: Pharmacological Intervention of PIEZO1 for Butterfly Eyespot Color Patterns in Junonia&amp;nbsp;orithya</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/20">doi: 10.3390/receptors4040020</a></p>
	<p>Authors:
		Momo Ozaki
		Joji M. Otaki
		</p>
	<p>Background: PIEZO channels are mechanoreceptors expressed in various cells. Their contributions to animal development are not entirely clear. According to the physical distortion hypothesis, developmental organizers for butterfly wing eyespots receive and release mechanical signals in pupal wing tissues during development, initiating a calcium signaling cascade and gene expression changes. Objectives: We tested the possible involvement of PIEZO1 in butterfly wing color pattern formation, according to the physical distortion hypothesis. Methods: We performed a pharmacological intervention of PIEZO1, focusing on the eyespots of Junonia orithya. Chemical modulators of PIEZO1 and the actin cytoskeleton were injected into pupae immediately after pupation during the critical period of color pattern determination, and the eyespot color patterns of the emerging adult wings were analyzed. We also tested dimethyl sulfoxide (DMSO) because it was used as a solvent. Results: DMSO significantly enlarged most eyespots examined. In contrast, the specific PIEZO1 activator Jedi2 induced significant reduction in the dorsal hindwing eyespots. Another specific PIEZO1 activator, Yoda1, also induced similar changes, although less clearly. The mechanosensitive channel blocker GsMTx4 produced compromised eyespots in an individual, although statistical support for modification was weak. The actin polymerization activator phalloidin induced blue foci in the ventral forewing eyespots. PIEZO expression in the pupal wings was demonstrated by RT-PCR. Conclusions: These results suggest that eyespot organizers in butterfly wings may employ a PIEZO-mediated mechanotransduction pathway to regulate eyespot color patterns, supporting the physical distortion hypothesis. These results highlight the importance of PIEZO in developmental organizers in animals.</p>
	]]></content:encoded>

	<dc:title>Pharmacological Intervention of PIEZO1 for Butterfly Eyespot Color Patterns in Junonia&amp;amp;nbsp;orithya</dc:title>
			<dc:creator>Momo Ozaki</dc:creator>
			<dc:creator>Joji M. Otaki</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040020</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-10-21</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-10-21</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>20</prism:startingPage>
		<prism:doi>10.3390/receptors4040020</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/19">

	<title>Receptors, Vol. 4, Pages 19: Critical Evaluation of Adipogenic Cell Models: Impact of the Receptor Toolkit on Adipogenic Potential</title>
	<link>https://www.mdpi.com/2813-2564/4/4/19</link>
	<description>Adipocyte cell models are essential for investigating adipogenesis, yet methodological inconsistencies pose challenges to obtaining reproducible and physiologically relevant results. Murine cell lines, such as 3T3-L1 and OP9, are commonly utilized due to their established adipogenic capabilities. However, differences in its metabolic, genetic regulation, and receptor signaling raise concerns about their applicability to human adipose biology. Human-derived models, including mesenchymal stem cells (hMSCs) and preadipocyte cell lines, offer a closer approximation to in vivo adipogenesis but display significant variability in differentiation efficiency. This variability is often compounded by heterogeneous differentiation protocols, variations in cell confluence, and unstandardized pharmacological induction strategies. A pivotal factor influencing adipogenic potential is the receptor toolkit, which dictates cellular responses to differentiation stimuli. This study systematically evaluates key receptors&amp;amp;mdash;PPAR&amp;amp;gamma;, glucocorticoid receptors (GR), insulin receptor (IR), thyroid hormone receptors (TR), estrogen receptors (ER), and adenosine receptors (AR)&amp;amp;mdash;across commonly used adipocyte models to assess their roles in adipogenic regulation. Additionally, we examine the impact of pharmacological agents capable of inducing adipogenesis (adipogens) and the methodological inconsistencies that contribute to variations in adipocyte differentiation. By addressing these factors, we aim to elucidate the extent to which receptor variability influences experimental outcomes and propose a more structured approach to interpreting adipogenesis research. This critical assessment underscores the need for greater methodological transparency and receptor profiling to enhance the reliability of adipocyte models in metabolic research. Standardizing differentiation methodologies while accounting for receptor diversity will be essential for refining in vitro models and improving their translational potential in the study of obesity, diabetes, and other metabolic disorders.</description>
	<pubDate>2025-10-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 19: Critical Evaluation of Adipogenic Cell Models: Impact of the Receptor Toolkit on Adipogenic Potential</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/19">doi: 10.3390/receptors4040019</a></p>
	<p>Authors:
		Andrea Gutiérrez-García
		Francisco Javier Olivas-Aguirre
		Miguel Olivas-Aguirre
		</p>
	<p>Adipocyte cell models are essential for investigating adipogenesis, yet methodological inconsistencies pose challenges to obtaining reproducible and physiologically relevant results. Murine cell lines, such as 3T3-L1 and OP9, are commonly utilized due to their established adipogenic capabilities. However, differences in its metabolic, genetic regulation, and receptor signaling raise concerns about their applicability to human adipose biology. Human-derived models, including mesenchymal stem cells (hMSCs) and preadipocyte cell lines, offer a closer approximation to in vivo adipogenesis but display significant variability in differentiation efficiency. This variability is often compounded by heterogeneous differentiation protocols, variations in cell confluence, and unstandardized pharmacological induction strategies. A pivotal factor influencing adipogenic potential is the receptor toolkit, which dictates cellular responses to differentiation stimuli. This study systematically evaluates key receptors&amp;amp;mdash;PPAR&amp;amp;gamma;, glucocorticoid receptors (GR), insulin receptor (IR), thyroid hormone receptors (TR), estrogen receptors (ER), and adenosine receptors (AR)&amp;amp;mdash;across commonly used adipocyte models to assess their roles in adipogenic regulation. Additionally, we examine the impact of pharmacological agents capable of inducing adipogenesis (adipogens) and the methodological inconsistencies that contribute to variations in adipocyte differentiation. By addressing these factors, we aim to elucidate the extent to which receptor variability influences experimental outcomes and propose a more structured approach to interpreting adipogenesis research. This critical assessment underscores the need for greater methodological transparency and receptor profiling to enhance the reliability of adipocyte models in metabolic research. Standardizing differentiation methodologies while accounting for receptor diversity will be essential for refining in vitro models and improving their translational potential in the study of obesity, diabetes, and other metabolic disorders.</p>
	]]></content:encoded>

	<dc:title>Critical Evaluation of Adipogenic Cell Models: Impact of the Receptor Toolkit on Adipogenic Potential</dc:title>
			<dc:creator>Andrea Gutiérrez-García</dc:creator>
			<dc:creator>Francisco Javier Olivas-Aguirre</dc:creator>
			<dc:creator>Miguel Olivas-Aguirre</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040019</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-10-15</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-10-15</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>19</prism:startingPage>
		<prism:doi>10.3390/receptors4040019</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/4/18">

	<title>Receptors, Vol. 4, Pages 18: Functional HER1/HER2-Expressing Murine Tumor Models for Preclinical Evaluation of Targeted Therapies</title>
	<link>https://www.mdpi.com/2813-2564/4/4/18</link>
	<description>Background: HER1 and HER2 are critical receptors involved in tumorigenesis and the development of targeted therapies for various carcinomas. However, most antibodies and drugs currently in development do not recognize murine orthologs, which restricts their evaluation in immunocompetent models. Methods: We generated nine tumor models through the lentiviral transduction of murine prostate (RM1), lung (3LL-D122), and breast (4T1) carcinoma cell lines, subsequently validating them in immunocompetent BALB/c and C57BL/6 hosts. Receptor expression and functionality were characterized using flow cytometry, immunoblotting, proliferation assays, and therapeutic sensitivity testing. Results: Transduced cells exhibited stable membrane expression of HER1/HER2 and ligand-induced phosphorylation, confirming receptor functionality. In all three tumor models generated, the expression of HER1 and/or HER2 significantly enhanced cell proliferation compared to parental lines. Furthermore, treatment with specific monoclonal antibodies and the tyrosine kinase inhibitor markedly reduced the viability of cells expressing HER1 and/or HER2, without affecting negative controls. Conclusions: These models provide a robust and reproducible platform for the preclinical evaluation of HER1/HER2-targeted therapies in immunocompetent hosts. Although the current model relies on subcutaneous implantation and does not fully replicate the native tumor microenvironment, it represents a crucial first step toward the development of orthotopic and immunologically relevant models for translational cancer research.</description>
	<pubDate>2025-09-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 18: Functional HER1/HER2-Expressing Murine Tumor Models for Preclinical Evaluation of Targeted Therapies</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/4/18">doi: 10.3390/receptors4040018</a></p>
	<p>Authors:
		Talia Fundora-Barrios
		Amanda R. Hechavarría-Bajuelo
		Lisset Chao García
		Miguel Angel Gonzalez-Cruz
		Najara Gonzalez-Suarez
		Gretchen Bergado-Baez
		Belinda Sánchez-Ramírez
		</p>
	<p>Background: HER1 and HER2 are critical receptors involved in tumorigenesis and the development of targeted therapies for various carcinomas. However, most antibodies and drugs currently in development do not recognize murine orthologs, which restricts their evaluation in immunocompetent models. Methods: We generated nine tumor models through the lentiviral transduction of murine prostate (RM1), lung (3LL-D122), and breast (4T1) carcinoma cell lines, subsequently validating them in immunocompetent BALB/c and C57BL/6 hosts. Receptor expression and functionality were characterized using flow cytometry, immunoblotting, proliferation assays, and therapeutic sensitivity testing. Results: Transduced cells exhibited stable membrane expression of HER1/HER2 and ligand-induced phosphorylation, confirming receptor functionality. In all three tumor models generated, the expression of HER1 and/or HER2 significantly enhanced cell proliferation compared to parental lines. Furthermore, treatment with specific monoclonal antibodies and the tyrosine kinase inhibitor markedly reduced the viability of cells expressing HER1 and/or HER2, without affecting negative controls. Conclusions: These models provide a robust and reproducible platform for the preclinical evaluation of HER1/HER2-targeted therapies in immunocompetent hosts. Although the current model relies on subcutaneous implantation and does not fully replicate the native tumor microenvironment, it represents a crucial first step toward the development of orthotopic and immunologically relevant models for translational cancer research.</p>
	]]></content:encoded>

	<dc:title>Functional HER1/HER2-Expressing Murine Tumor Models for Preclinical Evaluation of Targeted Therapies</dc:title>
			<dc:creator>Talia Fundora-Barrios</dc:creator>
			<dc:creator>Amanda R. Hechavarría-Bajuelo</dc:creator>
			<dc:creator>Lisset Chao García</dc:creator>
			<dc:creator>Miguel Angel Gonzalez-Cruz</dc:creator>
			<dc:creator>Najara Gonzalez-Suarez</dc:creator>
			<dc:creator>Gretchen Bergado-Baez</dc:creator>
			<dc:creator>Belinda Sánchez-Ramírez</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4040018</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-09-24</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-09-24</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:doi>10.3390/receptors4040018</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/4/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/3/17">

	<title>Receptors, Vol. 4, Pages 17: G-Protein-Coupled Receptor Kinase 2 Limits CCL21-Induced T Cell Migration via Phospholipase C&amp;gamma;1</title>
	<link>https://www.mdpi.com/2813-2564/4/3/17</link>
	<description>Background/Objectives: G protein-coupled receptors (GPCRs) can promote ligand-biased signaling, yet the mechanisms that promote bias are not well understood. We have shown that C-C Chemokine Ligand 19 (CCL19) and CCL21 promote ligand-biased internalization and signaling of C-C Chemokine Receptor 7 (CCR7) in T cells. The roles of GPCR kinases (GRKs) in regulating biased CCR7 internalization and biased signaling in T cells are unclear. GRK2 is a serine/threonine kinase that phosphorylates GPCRs in response to ligand binding and is recruited to the plasma membrane via its C-terminal pleckstrin homology domain to phosphatidylinositol 4,5-bisphosphate (PIP2). Methods: Human embryonic kidney cells (HEK293) transfected to express wild-type and mutant GRK2 and human CCR7, human T cell lines harboring heterozygous deletions of GRK2, and na&amp;amp;iuml;ve primary T cells from GRK2 heterozygous (GRK2+/&amp;amp;minus;) or GRK2f/f CD4-Cre mice were used to examine the effects of GRK2 on ligand-induced CCR7 signaling in T cells. We used flow cytometry to assay the effect of GRK2 on CCR7 internalization, Fluorescence Resonance Energy Transfer (FRET) to define the effect of GRK2 on CCR7 activation of G&amp;amp;alpha;i isoforms and transwell migration assays to examine the effect of GRK2 on chemotaxis. Since chemotaxis via CCR7 is mediated by phospholipase C&amp;amp;gamma;1 (PLC&amp;amp;gamma;1), Western blot assays were used to measure the effect of GRK2 during downstream signaling via phosphorylation of PLC&amp;amp;gamma;1. Results: We found that following CCL19 binding, GRK2 promoted kinase-dependent CCR7 recruitment of arrestin-3, rapid CCR7 internalization and G&amp;amp;alpha;i3 recruitment to CCR7. In contrast, following binding of CCL21 to CCR7, GRK2 slowed CCR7 internalization, induced recruitment of G&amp;amp;alpha;i2 to the activated receptor, and promoted chemotaxis. Since we have shown that CCL21 promotes chemotaxis via PLC&amp;amp;gamma;1, we examined the effect of GRK2 on PLC&amp;amp;gamma;1 activation and found that GRK2 had no effect on CCL21-mediated PLC&amp;amp;gamma;1 phosphorylation. Conclusions: GRK2 promotes differential signaling downstream of CCR7 activation by CCL19 and CCL21 and provides a model for biased signaling downstream of a GPCR driven by GRK2.</description>
	<pubDate>2025-09-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 17: G-Protein-Coupled Receptor Kinase 2 Limits CCL21-Induced T Cell Migration via Phospholipase C&amp;gamma;1</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/3/17">doi: 10.3390/receptors4030017</a></p>
	<p>Authors:
		Anahi Sanchez
		Caitlin T. Winebrenner
		Natalia Garcia
		Brian Kaiser
		Lyndsey Kilgore
		Cesar I. Cardona
		Daniel W. Bassuk
		Mary E. Miller
		Charles A. Bill
		Laura A. Shannon
		Brant M. Wagener
		Amy Wagler
		Manuel Llano
		Colin A. Bill
		Charlotte M. Vines
		</p>
	<p>Background/Objectives: G protein-coupled receptors (GPCRs) can promote ligand-biased signaling, yet the mechanisms that promote bias are not well understood. We have shown that C-C Chemokine Ligand 19 (CCL19) and CCL21 promote ligand-biased internalization and signaling of C-C Chemokine Receptor 7 (CCR7) in T cells. The roles of GPCR kinases (GRKs) in regulating biased CCR7 internalization and biased signaling in T cells are unclear. GRK2 is a serine/threonine kinase that phosphorylates GPCRs in response to ligand binding and is recruited to the plasma membrane via its C-terminal pleckstrin homology domain to phosphatidylinositol 4,5-bisphosphate (PIP2). Methods: Human embryonic kidney cells (HEK293) transfected to express wild-type and mutant GRK2 and human CCR7, human T cell lines harboring heterozygous deletions of GRK2, and na&amp;amp;iuml;ve primary T cells from GRK2 heterozygous (GRK2+/&amp;amp;minus;) or GRK2f/f CD4-Cre mice were used to examine the effects of GRK2 on ligand-induced CCR7 signaling in T cells. We used flow cytometry to assay the effect of GRK2 on CCR7 internalization, Fluorescence Resonance Energy Transfer (FRET) to define the effect of GRK2 on CCR7 activation of G&amp;amp;alpha;i isoforms and transwell migration assays to examine the effect of GRK2 on chemotaxis. Since chemotaxis via CCR7 is mediated by phospholipase C&amp;amp;gamma;1 (PLC&amp;amp;gamma;1), Western blot assays were used to measure the effect of GRK2 during downstream signaling via phosphorylation of PLC&amp;amp;gamma;1. Results: We found that following CCL19 binding, GRK2 promoted kinase-dependent CCR7 recruitment of arrestin-3, rapid CCR7 internalization and G&amp;amp;alpha;i3 recruitment to CCR7. In contrast, following binding of CCL21 to CCR7, GRK2 slowed CCR7 internalization, induced recruitment of G&amp;amp;alpha;i2 to the activated receptor, and promoted chemotaxis. Since we have shown that CCL21 promotes chemotaxis via PLC&amp;amp;gamma;1, we examined the effect of GRK2 on PLC&amp;amp;gamma;1 activation and found that GRK2 had no effect on CCL21-mediated PLC&amp;amp;gamma;1 phosphorylation. Conclusions: GRK2 promotes differential signaling downstream of CCR7 activation by CCL19 and CCL21 and provides a model for biased signaling downstream of a GPCR driven by GRK2.</p>
	]]></content:encoded>

	<dc:title>G-Protein-Coupled Receptor Kinase 2 Limits CCL21-Induced T Cell Migration via Phospholipase C&amp;amp;gamma;1</dc:title>
			<dc:creator>Anahi Sanchez</dc:creator>
			<dc:creator>Caitlin T. Winebrenner</dc:creator>
			<dc:creator>Natalia Garcia</dc:creator>
			<dc:creator>Brian Kaiser</dc:creator>
			<dc:creator>Lyndsey Kilgore</dc:creator>
			<dc:creator>Cesar I. Cardona</dc:creator>
			<dc:creator>Daniel W. Bassuk</dc:creator>
			<dc:creator>Mary E. Miller</dc:creator>
			<dc:creator>Charles A. Bill</dc:creator>
			<dc:creator>Laura A. Shannon</dc:creator>
			<dc:creator>Brant M. Wagener</dc:creator>
			<dc:creator>Amy Wagler</dc:creator>
			<dc:creator>Manuel Llano</dc:creator>
			<dc:creator>Colin A. Bill</dc:creator>
			<dc:creator>Charlotte M. Vines</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4030017</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-09-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-09-03</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>17</prism:startingPage>
		<prism:doi>10.3390/receptors4030017</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/3/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/3/16">

	<title>Receptors, Vol. 4, Pages 16: The State-of-the-Art Review on FSHR, LHCGR, AR, ESR1, and ESR2 Key Mutations and Their Impact on the Effectiveness of Infertility Therapies&amp;mdash;What We Know So Far</title>
	<link>https://www.mdpi.com/2813-2564/4/3/16</link>
	<description>Mutations in hormone receptors significantly influence infertility and the outcomes of assisted reproductive technologies (ART). This review explores the functional interplay among mutations in FSHR, LHCGR, AR, ESR1, and ESR2 hormone receptors and their combined effects on hormonal regulation, ovarian response, and implantation. Rather than analyzing receptor mutations in isolation, we explore how mutations in these genes interact within a complex hormonal signaling network, shaping reproductive outcomes. We detail the molecular mechanisms of receptor dysfunction, their associated clinical phenotypes, and the role of genetic screening in guiding personalized ART protocols. A comprehensive understanding of these interactions is crucial for optimizing treatment strategies, improving reproductive success, and advancing targeted therapeutic approaches in reproductive medicine.</description>
	<pubDate>2025-08-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 16: The State-of-the-Art Review on FSHR, LHCGR, AR, ESR1, and ESR2 Key Mutations and Their Impact on the Effectiveness of Infertility Therapies&amp;mdash;What We Know So Far</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/3/16">doi: 10.3390/receptors4030016</a></p>
	<p>Authors:
		Daniela Hristov
		Done Stojanov
		</p>
	<p>Mutations in hormone receptors significantly influence infertility and the outcomes of assisted reproductive technologies (ART). This review explores the functional interplay among mutations in FSHR, LHCGR, AR, ESR1, and ESR2 hormone receptors and their combined effects on hormonal regulation, ovarian response, and implantation. Rather than analyzing receptor mutations in isolation, we explore how mutations in these genes interact within a complex hormonal signaling network, shaping reproductive outcomes. We detail the molecular mechanisms of receptor dysfunction, their associated clinical phenotypes, and the role of genetic screening in guiding personalized ART protocols. A comprehensive understanding of these interactions is crucial for optimizing treatment strategies, improving reproductive success, and advancing targeted therapeutic approaches in reproductive medicine.</p>
	]]></content:encoded>

	<dc:title>The State-of-the-Art Review on FSHR, LHCGR, AR, ESR1, and ESR2 Key Mutations and Their Impact on the Effectiveness of Infertility Therapies&amp;amp;mdash;What We Know So Far</dc:title>
			<dc:creator>Daniela Hristov</dc:creator>
			<dc:creator>Done Stojanov</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4030016</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-08-14</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-08-14</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/receptors4030016</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/3/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/3/15">

	<title>Receptors, Vol. 4, Pages 15: The Binding and Effects of Boron-Containing Compounds on G Protein-Coupled Receptors: A Scoping Review</title>
	<link>https://www.mdpi.com/2813-2564/4/3/15</link>
	<description>Boron-containing compounds (BCCs) have emerged as potential drugs. Their drug-like effects are mainly explained by their mechanisms of action in enzymes. Nowadays, some experimental data support the effects of specific BCCs on GPCRs, provided there are crystal structures that show them bound to G protein-coupled receptors (GPCRs). Some BCCs are recognized as potential ligands of GPCRs&amp;amp;mdash;the drug targets of many diseases. Objective: The aim of this study was to collecte up-to-date data on the interactions of BCCs with GPCRs. Methods: Data were collected from the National Center of Biotechnology Information, PubMed, Global Health, Embase, the Web of Science, and Google Scholar databases and reviewed. Results: Some experimental reports support the interactions of BCCs with several GPCRs, acting as their labels, agonists, or antagonists. These interactions can be inferred based on in silico and in vitro results if there are no available crystal structures for validating them. Conclusions: The actions of BCCs on GPCRs are no longer hypothetical, as the existing evidence supports BCCs&amp;amp;rsquo; interactions with and actions on GPCRs.</description>
	<pubDate>2025-08-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 15: The Binding and Effects of Boron-Containing Compounds on G Protein-Coupled Receptors: A Scoping Review</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/3/15">doi: 10.3390/receptors4030015</a></p>
	<p>Authors:
		José M. Santiago-Quintana
		Alina Barquet-Nieto
		Bhaskar C. Das
		Rafael Barrientos-López
		Melvin N. Rosalez
		Ruth M. Lopez-Mayorga
		Marvin A. Soriano-Ursúa
		</p>
	<p>Boron-containing compounds (BCCs) have emerged as potential drugs. Their drug-like effects are mainly explained by their mechanisms of action in enzymes. Nowadays, some experimental data support the effects of specific BCCs on GPCRs, provided there are crystal structures that show them bound to G protein-coupled receptors (GPCRs). Some BCCs are recognized as potential ligands of GPCRs&amp;amp;mdash;the drug targets of many diseases. Objective: The aim of this study was to collecte up-to-date data on the interactions of BCCs with GPCRs. Methods: Data were collected from the National Center of Biotechnology Information, PubMed, Global Health, Embase, the Web of Science, and Google Scholar databases and reviewed. Results: Some experimental reports support the interactions of BCCs with several GPCRs, acting as their labels, agonists, or antagonists. These interactions can be inferred based on in silico and in vitro results if there are no available crystal structures for validating them. Conclusions: The actions of BCCs on GPCRs are no longer hypothetical, as the existing evidence supports BCCs&amp;amp;rsquo; interactions with and actions on GPCRs.</p>
	]]></content:encoded>

	<dc:title>The Binding and Effects of Boron-Containing Compounds on G Protein-Coupled Receptors: A Scoping Review</dc:title>
			<dc:creator>José M. Santiago-Quintana</dc:creator>
			<dc:creator>Alina Barquet-Nieto</dc:creator>
			<dc:creator>Bhaskar C. Das</dc:creator>
			<dc:creator>Rafael Barrientos-López</dc:creator>
			<dc:creator>Melvin N. Rosalez</dc:creator>
			<dc:creator>Ruth M. Lopez-Mayorga</dc:creator>
			<dc:creator>Marvin A. Soriano-Ursúa</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4030015</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-08-05</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-08-05</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/receptors4030015</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/3/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/3/14">

	<title>Receptors, Vol. 4, Pages 14: The Hidden Roles of Receptors in Intercellular Synchronization and Its Mathematical Generality</title>
	<link>https://www.mdpi.com/2813-2564/4/3/14</link>
	<description>Dictyostelium discoideum (Dicty) is a type of unicellular amoeba, but when starved, a large number of amoebas gather together to form a multicellular organism. In this review, we first introduce our cellular dynamics method for Dicty, including intracellular biochemical reactions. We then introduce a number of hidden roles of receptors revealed by our simulation studies. Of particular note is that receptor&amp;amp;ndash;receptor interactions are strengthened under starvation conditions, resulting in diverse dynamic functions that cannot be predicted from the action of a single receptor, such as intercellular synchronization. Furthermore, we introduce a mathematical generalization of Dicty&amp;amp;rsquo;s receptor function and demonstrate its potential applications not only in the biological field but also in the engineering field.</description>
	<pubDate>2025-07-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 14: The Hidden Roles of Receptors in Intercellular Synchronization and Its Mathematical Generality</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/3/14">doi: 10.3390/receptors4030014</a></p>
	<p>Authors:
		Seido Nagano
		</p>
	<p>Dictyostelium discoideum (Dicty) is a type of unicellular amoeba, but when starved, a large number of amoebas gather together to form a multicellular organism. In this review, we first introduce our cellular dynamics method for Dicty, including intracellular biochemical reactions. We then introduce a number of hidden roles of receptors revealed by our simulation studies. Of particular note is that receptor&amp;amp;ndash;receptor interactions are strengthened under starvation conditions, resulting in diverse dynamic functions that cannot be predicted from the action of a single receptor, such as intercellular synchronization. Furthermore, we introduce a mathematical generalization of Dicty&amp;amp;rsquo;s receptor function and demonstrate its potential applications not only in the biological field but also in the engineering field.</p>
	]]></content:encoded>

	<dc:title>The Hidden Roles of Receptors in Intercellular Synchronization and Its Mathematical Generality</dc:title>
			<dc:creator>Seido Nagano</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4030014</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-07-15</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-07-15</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/receptors4030014</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/3/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/3/13">

	<title>Receptors, Vol. 4, Pages 13: Therapeutic Potential of Mineralocorticoid Receptors in Skeletal Muscle Aging</title>
	<link>https://www.mdpi.com/2813-2564/4/3/13</link>
	<description>Skeletal muscle aging, or sarcopenia, involves progressive muscle mass and function loss, which limits mobility and independence in elderly populations. This decline is driven by chronic inflammation, oxidative stress, and insulin resistance, all of which impair muscle regeneration and accelerate protein breakdown. Mineralocorticoid receptors (MRs), known for their roles in electrolyte balance, have emerged as key regulators of these processes in skeletal muscle. MR activation promotes inflammatory signaling, increases oxidative stress, and worsens insulin resistance, accelerating sarcopenia progression. This review examines the impact of MRs on muscle health and highlights the therapeutic potential of targeting these receptors to counteract age-related muscle loss. MR antagonists, such as spironolactone, show promise in reducing inflammation and oxidative damage, potentially slowing sarcopenia. Physical exercise, an established intervention for muscle health, may enhance MR antagonism effects by improving insulin sensitivity and reducing inflammation. However, more research is needed to determine the efficacy and safety of combined MR antagonists and exercise protocols for preventing sarcopenia in older adults.</description>
	<pubDate>2025-07-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 13: Therapeutic Potential of Mineralocorticoid Receptors in Skeletal Muscle Aging</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/3/13">doi: 10.3390/receptors4030013</a></p>
	<p>Authors:
		Ricardo Aparecido Baptista Nucci
		Otávio de Toledo Nóbrega
		Wilson Jacob-Filho
		</p>
	<p>Skeletal muscle aging, or sarcopenia, involves progressive muscle mass and function loss, which limits mobility and independence in elderly populations. This decline is driven by chronic inflammation, oxidative stress, and insulin resistance, all of which impair muscle regeneration and accelerate protein breakdown. Mineralocorticoid receptors (MRs), known for their roles in electrolyte balance, have emerged as key regulators of these processes in skeletal muscle. MR activation promotes inflammatory signaling, increases oxidative stress, and worsens insulin resistance, accelerating sarcopenia progression. This review examines the impact of MRs on muscle health and highlights the therapeutic potential of targeting these receptors to counteract age-related muscle loss. MR antagonists, such as spironolactone, show promise in reducing inflammation and oxidative damage, potentially slowing sarcopenia. Physical exercise, an established intervention for muscle health, may enhance MR antagonism effects by improving insulin sensitivity and reducing inflammation. However, more research is needed to determine the efficacy and safety of combined MR antagonists and exercise protocols for preventing sarcopenia in older adults.</p>
	]]></content:encoded>

	<dc:title>Therapeutic Potential of Mineralocorticoid Receptors in Skeletal Muscle Aging</dc:title>
			<dc:creator>Ricardo Aparecido Baptista Nucci</dc:creator>
			<dc:creator>Otávio de Toledo Nóbrega</dc:creator>
			<dc:creator>Wilson Jacob-Filho</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4030013</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-07-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-07-03</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/receptors4030013</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/3/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/3/12">

	<title>Receptors, Vol. 4, Pages 12: Human Stem Cell-Derived Neural Organoids for the Discovery of Antiseizure Agents</title>
	<link>https://www.mdpi.com/2813-2564/4/3/12</link>
	<description>Background: The development of cerebral organoids created from human pluripotent stem cells in 3D culture may greatly improve the discovery of neuropsychiatric medicines. Methods: In the current study we differentiated neural organoids from a human pluripotent stem cell line in vitro, recorded the development of neurophysiological activity using multielectrode arrays (MEAs) and characterized the neuropharmacology of synaptic signaling over 8 months in vitro. In addition, we investigated the ability of these organoids to display epileptiform activity in response to a convulsant agent and the effects of antiseizure medicines to inhibit this abnormal activity. Results: Single and bursts of action potentials from individual neurons and network bursts were recorded on the MEA plates and significantly increased and became more complex from week 7 to week 30, consistent with neural network formation. Neural spiking was reduced by the Na channel blocker tetrodotoxin but increased by the inhibitor of KV7 potassium channels XE991, confirming the involvement of voltage-gated sodium and potassium channels in action potential activity. The GABA antagonists bicuculline and picrotoxin each increased the spike rate, consistent with inhibitory synaptic signaling. In contrast, the glutamate receptor antagonist kynurenic acid inhibited the spike rate, consistent with excitatory synaptic transmission in the organoids. The convulsant 4-aminopyridine increased spiking, bursts and synchronized firing, consistent with epileptiform activity in vitro. The anticonvulsants carbamazepine, ethosuximide and diazepam each inhibited this epileptiform neural activity. Conclusions: Together, our data demonstrate that neural organoids form inhibitory and excitatory synaptic circuits, generate epileptiform activity in response to a convulsant agent and detect the antiseizure properties of diverse antiepileptic drugs, supporting their value in drug discovery.</description>
	<pubDate>2025-06-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 12: Human Stem Cell-Derived Neural Organoids for the Discovery of Antiseizure Agents</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/3/12">doi: 10.3390/receptors4030012</a></p>
	<p>Authors:
		Hamed Salmanzadeh
		Robert F. Halliwell
		</p>
	<p>Background: The development of cerebral organoids created from human pluripotent stem cells in 3D culture may greatly improve the discovery of neuropsychiatric medicines. Methods: In the current study we differentiated neural organoids from a human pluripotent stem cell line in vitro, recorded the development of neurophysiological activity using multielectrode arrays (MEAs) and characterized the neuropharmacology of synaptic signaling over 8 months in vitro. In addition, we investigated the ability of these organoids to display epileptiform activity in response to a convulsant agent and the effects of antiseizure medicines to inhibit this abnormal activity. Results: Single and bursts of action potentials from individual neurons and network bursts were recorded on the MEA plates and significantly increased and became more complex from week 7 to week 30, consistent with neural network formation. Neural spiking was reduced by the Na channel blocker tetrodotoxin but increased by the inhibitor of KV7 potassium channels XE991, confirming the involvement of voltage-gated sodium and potassium channels in action potential activity. The GABA antagonists bicuculline and picrotoxin each increased the spike rate, consistent with inhibitory synaptic signaling. In contrast, the glutamate receptor antagonist kynurenic acid inhibited the spike rate, consistent with excitatory synaptic transmission in the organoids. The convulsant 4-aminopyridine increased spiking, bursts and synchronized firing, consistent with epileptiform activity in vitro. The anticonvulsants carbamazepine, ethosuximide and diazepam each inhibited this epileptiform neural activity. Conclusions: Together, our data demonstrate that neural organoids form inhibitory and excitatory synaptic circuits, generate epileptiform activity in response to a convulsant agent and detect the antiseizure properties of diverse antiepileptic drugs, supporting their value in drug discovery.</p>
	]]></content:encoded>

	<dc:title>Human Stem Cell-Derived Neural Organoids for the Discovery of Antiseizure Agents</dc:title>
			<dc:creator>Hamed Salmanzadeh</dc:creator>
			<dc:creator>Robert F. Halliwell</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4030012</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-06-20</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-06-20</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/receptors4030012</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/3/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/2/11">

	<title>Receptors, Vol. 4, Pages 11: Odorant Receptors and Cancer</title>
	<link>https://www.mdpi.com/2813-2564/4/2/11</link>
	<description>Odorant receptors (ORs) constitute the largest family of G protein-coupled receptors (GPCRs), with nearly 400 receptors identified in humans. The &amp;amp;ldquo;omics&amp;amp;rdquo; era has revealed an unexpected expression of ORs beyond olfactory tissues. For many decades these receptors were neglected from cancer research, largely due to the assumption that their expression in cancerous tissues was a background leakage, unrelated to conventional cancer pathways such as cell replication, differentiation, or DNA damage response. The Cancer Genome Atlas (TCGA) data shows, however, that OR expression profiles are specific to each tumor type. This evidence supports that ORs may be related to tumor malignancy. In this review, we explore the extranasal expression of ORs in cancer and discuss the potential implications of their presence in cancerous tissues.</description>
	<pubDate>2025-06-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 11: Odorant Receptors and Cancer</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/2/11">doi: 10.3390/receptors4020011</a></p>
	<p>Authors:
		Rafaella G. Naressi
		Bettina Malnic
		Luciana M. Gutiyama
		</p>
	<p>Odorant receptors (ORs) constitute the largest family of G protein-coupled receptors (GPCRs), with nearly 400 receptors identified in humans. The &amp;amp;ldquo;omics&amp;amp;rdquo; era has revealed an unexpected expression of ORs beyond olfactory tissues. For many decades these receptors were neglected from cancer research, largely due to the assumption that their expression in cancerous tissues was a background leakage, unrelated to conventional cancer pathways such as cell replication, differentiation, or DNA damage response. The Cancer Genome Atlas (TCGA) data shows, however, that OR expression profiles are specific to each tumor type. This evidence supports that ORs may be related to tumor malignancy. In this review, we explore the extranasal expression of ORs in cancer and discuss the potential implications of their presence in cancerous tissues.</p>
	]]></content:encoded>

	<dc:title>Odorant Receptors and Cancer</dc:title>
			<dc:creator>Rafaella G. Naressi</dc:creator>
			<dc:creator>Bettina Malnic</dc:creator>
			<dc:creator>Luciana M. Gutiyama</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4020011</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-06-09</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-06-09</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/receptors4020011</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/2/10">

	<title>Receptors, Vol. 4, Pages 10: Gelsolin Facilitates Estrogen Receptor Beta Nuclear Translocation and Transcriptional Repression of Genes Associated with Alzheimer Disease</title>
	<link>https://www.mdpi.com/2813-2564/4/2/10</link>
	<description>Background/Objectives: Gelsolin (GSN) is an actin-binding protein that helps maintain neuronal structure and shape, regulates neuronal growth, and apoptosis. Our previous work demonstrated that GSN associated with estrogen receptor beta (ER&amp;amp;beta;1) in the brains of female rats, but this association was lost in advanced age. GSN was also required for ER&amp;amp;beta;1-mediated transcriptional repression at activator protein-1 (AP-1) motifs upstream of a minimal gene promoter. However, the consequences of the loss of GSN:ER&amp;amp;beta;1 protein interaction on ER&amp;amp;beta;1 nuclear translocation and transcriptional repression at AP-1 sites located within complex endogenous gene promoters remained unclear. Methods: We used immunofluorescent super resolution microscopy and luciferase reporter assays to test the hypothesis that GSN facilitates ER&amp;amp;beta;1 nuclear translocation and transcriptional repression of two genes relevant for Alzheimer Disease: APP (amyloid-beta precursor protein) and ITPKB (inositol-1,4,5-trisphosphate 3-kinase B). Results: Our results revealed the novel finding that GSN is required for ER&amp;amp;beta;1 ligand-independent nuclear translocation in neuronal cells. Moreover, we show that GSN increased APP and ITPKB promoter activity, which was repressed by ER&amp;amp;beta;1. Conclusions: Together, these data revealed the importance of the cytoskeletal protein, GSN, in regulating intracellular trafficking of nuclear receptors and demonstrate the first evidence of ER&amp;amp;beta;1 directly regulating two genes that are implicated in the progression of AD.</description>
	<pubDate>2025-05-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 10: Gelsolin Facilitates Estrogen Receptor Beta Nuclear Translocation and Transcriptional Repression of Genes Associated with Alzheimer Disease</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/2/10">doi: 10.3390/receptors4020010</a></p>
	<p>Authors:
		Yoldas Yildiz
		Angela H. S. Fan
		Amanda A. Hartoun
		Sarah Flury
		Yan Ngai
		Toni R. Pak
		</p>
	<p>Background/Objectives: Gelsolin (GSN) is an actin-binding protein that helps maintain neuronal structure and shape, regulates neuronal growth, and apoptosis. Our previous work demonstrated that GSN associated with estrogen receptor beta (ER&amp;amp;beta;1) in the brains of female rats, but this association was lost in advanced age. GSN was also required for ER&amp;amp;beta;1-mediated transcriptional repression at activator protein-1 (AP-1) motifs upstream of a minimal gene promoter. However, the consequences of the loss of GSN:ER&amp;amp;beta;1 protein interaction on ER&amp;amp;beta;1 nuclear translocation and transcriptional repression at AP-1 sites located within complex endogenous gene promoters remained unclear. Methods: We used immunofluorescent super resolution microscopy and luciferase reporter assays to test the hypothesis that GSN facilitates ER&amp;amp;beta;1 nuclear translocation and transcriptional repression of two genes relevant for Alzheimer Disease: APP (amyloid-beta precursor protein) and ITPKB (inositol-1,4,5-trisphosphate 3-kinase B). Results: Our results revealed the novel finding that GSN is required for ER&amp;amp;beta;1 ligand-independent nuclear translocation in neuronal cells. Moreover, we show that GSN increased APP and ITPKB promoter activity, which was repressed by ER&amp;amp;beta;1. Conclusions: Together, these data revealed the importance of the cytoskeletal protein, GSN, in regulating intracellular trafficking of nuclear receptors and demonstrate the first evidence of ER&amp;amp;beta;1 directly regulating two genes that are implicated in the progression of AD.</p>
	]]></content:encoded>

	<dc:title>Gelsolin Facilitates Estrogen Receptor Beta Nuclear Translocation and Transcriptional Repression of Genes Associated with Alzheimer Disease</dc:title>
			<dc:creator>Yoldas Yildiz</dc:creator>
			<dc:creator>Angela H. S. Fan</dc:creator>
			<dc:creator>Amanda A. Hartoun</dc:creator>
			<dc:creator>Sarah Flury</dc:creator>
			<dc:creator>Yan Ngai</dc:creator>
			<dc:creator>Toni R. Pak</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4020010</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-05-01</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-05-01</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/receptors4020010</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/2/9">

	<title>Receptors, Vol. 4, Pages 9: Bioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies</title>
	<link>https://www.mdpi.com/2813-2564/4/2/9</link>
	<description>Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, as abnormal membrane potentials and ion channel activity can drive tumor progression. In breast cancer, ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial&amp;amp;ndash;mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Neuroreceptors also play a key role, with dopamine receptor D2 activation reducing breast tumor growth by 40% in preclinical models, while serotonin signaling has been shown to promote epithelial&amp;amp;ndash;mesenchymal transition (EMT), increasing invasiveness. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Examining the modulation of bioelectricity through neuroreceptor pharmacology to influence breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.</description>
	<pubDate>2025-04-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 9: Bioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/2/9">doi: 10.3390/receptors4020009</a></p>
	<p>Authors:
		Chitaranjan Mahapatra
		Jineetkumar Gawad
		Chandrakant Bonde
		Mahesh B. Palkar
		</p>
	<p>Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, as abnormal membrane potentials and ion channel activity can drive tumor progression. In breast cancer, ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial&amp;amp;ndash;mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Neuroreceptors also play a key role, with dopamine receptor D2 activation reducing breast tumor growth by 40% in preclinical models, while serotonin signaling has been shown to promote epithelial&amp;amp;ndash;mesenchymal transition (EMT), increasing invasiveness. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Examining the modulation of bioelectricity through neuroreceptor pharmacology to influence breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.</p>
	]]></content:encoded>

	<dc:title>Bioelectric Membrane Potential and Breast Cancer: Advances in Neuroreceptor Pharmacology for Targeted Therapeutic Strategies</dc:title>
			<dc:creator>Chitaranjan Mahapatra</dc:creator>
			<dc:creator>Jineetkumar Gawad</dc:creator>
			<dc:creator>Chandrakant Bonde</dc:creator>
			<dc:creator>Mahesh B. Palkar</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4020009</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-04-02</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-04-02</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/receptors4020009</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/2/8">

	<title>Receptors, Vol. 4, Pages 8: Role of Glucocorticoid Receptor in Triple-Negative Breast Cancer</title>
	<link>https://www.mdpi.com/2813-2564/4/2/8</link>
	<description>Triple-negative breast cancer (TNBC) is an aggressive tumor among breast cancer subtypes with much lower overall survival at metastasis compared to other subtypes and with limited treatment options due to a lack of targeted therapies. This has led to the investigation of molecular targets to advance the development of novel therapeutic agents aimed at treating TNBC patients. Recent studies have led us to believe that glucocorticoid receptor (GR) expression may be predictive of decreased survival and increased risk of metastasis in TNBC tumors. Thus, a detailed understanding of GR signaling in TNBC may help understand the role of GR in TNBC proliferation as well as its role as a potential biomarker and therapeutic target. Recent research findings indicate that GR-induced gene regulations may provide an important platform for the development of GR-based therapeutic targets in TNBC. Emerging data from laboratories indicate that targeting GR has the potential to inhibit cancer cell proliferation and reduce tumor growth in TNBC. Therefore, future research focused on underlying molecular mechanisms of GR action in TNBC could lead to a new effective treatment option for TNBC patients, which is urgently needed.</description>
	<pubDate>2025-04-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 8: Role of Glucocorticoid Receptor in Triple-Negative Breast Cancer</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/2/8">doi: 10.3390/receptors4020008</a></p>
	<p>Authors:
		Raj Kumar
		</p>
	<p>Triple-negative breast cancer (TNBC) is an aggressive tumor among breast cancer subtypes with much lower overall survival at metastasis compared to other subtypes and with limited treatment options due to a lack of targeted therapies. This has led to the investigation of molecular targets to advance the development of novel therapeutic agents aimed at treating TNBC patients. Recent studies have led us to believe that glucocorticoid receptor (GR) expression may be predictive of decreased survival and increased risk of metastasis in TNBC tumors. Thus, a detailed understanding of GR signaling in TNBC may help understand the role of GR in TNBC proliferation as well as its role as a potential biomarker and therapeutic target. Recent research findings indicate that GR-induced gene regulations may provide an important platform for the development of GR-based therapeutic targets in TNBC. Emerging data from laboratories indicate that targeting GR has the potential to inhibit cancer cell proliferation and reduce tumor growth in TNBC. Therefore, future research focused on underlying molecular mechanisms of GR action in TNBC could lead to a new effective treatment option for TNBC patients, which is urgently needed.</p>
	]]></content:encoded>

	<dc:title>Role of Glucocorticoid Receptor in Triple-Negative Breast Cancer</dc:title>
			<dc:creator>Raj Kumar</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4020008</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-04-01</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-04-01</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Perspective</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/receptors4020008</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/2/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/7">

	<title>Receptors, Vol. 4, Pages 7: Evaluation of [125I]&amp;alpha;-Bungarotoxin Binding to &amp;alpha;7 Nicotinic Acetylcholinergic Receptors in Hippocampus&amp;ndash;Subiculum of Postmortem Human Alzheimer&amp;rsquo;s Disease Brain</title>
	<link>https://www.mdpi.com/2813-2564/4/1/7</link>
	<description>Background/Objectives: Alzheimer&amp;amp;rsquo;s disease (AD) severely hinders cognitive function in the hippocampus (HP) and subiculum (SUB), impacting the expression of nicotinic acetylcholine receptors (nAChRs) such as the &amp;amp;alpha;7-subtype. To investigate &amp;amp;alpha;7 nAChRs as a potential PET imaging biomarker, we report the quantitative binding of [125I]&amp;amp;alpha;-Bungarotoxin ([125I]&amp;amp;alpha;-Bgtx) for binding to postmortem human AD (n = 29; 13 males, 16 females) HP compared to cognitively normal (CN) (n = 28; 13 male, 15 female) HP. Methods: For comparisons with common AD biomarkers, adjacent slices were anti-A&amp;amp;beta; and anti-Tau immunostained for analysis using QuPath. Results: The [125I]&amp;amp;alpha;-Bgtx average SUB/HP ratio was 0.5 among the CN subjects, suggesting higher [125I]&amp;amp;alpha;-Bgtx binding in the HP gray matter regions. The AD subjects showed overall less binding than the CN subjects, with no statistical significance. A positive correlation was found in the [125I]&amp;amp;alpha;-Bgtx binding in the AD subjects as the age increased. The Braak stage comparisons of [125I]&amp;amp;alpha;-Bgtx were made with [18F]flotaza binding to A&amp;amp;beta; plaques and [125I]IPPI binding to Tau. A positive correlation was found between [125I]&amp;amp;alpha;-Bgtx and [18F]flotaza and there was a negative correlation between [125I]&amp;amp;alpha;-Bgtx and [125I]IPPI, implicating intricate relationships between the different AD biomarkers. Conclusions: [125I]&amp;amp;alpha;-Bgtx shows complimentary potential as a &amp;amp;alpha;7 nAChR imaging agent but needs more preclinical assessments to confirm effectiveness for translational PET studies using &amp;amp;alpha;7 nAChR radioligands.</description>
	<pubDate>2025-03-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 7: Evaluation of [125I]&amp;alpha;-Bungarotoxin Binding to &amp;alpha;7 Nicotinic Acetylcholinergic Receptors in Hippocampus&amp;ndash;Subiculum of Postmortem Human Alzheimer&amp;rsquo;s Disease Brain</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/7">doi: 10.3390/receptors4010007</a></p>
	<p>Authors:
		Allyson Ngo
		Fariha Karim
		Oshini V. Keerthisinghe
		Tram B. Danh
		Christopher Liang
		Jogeshwar Mukherjee
		</p>
	<p>Background/Objectives: Alzheimer&amp;amp;rsquo;s disease (AD) severely hinders cognitive function in the hippocampus (HP) and subiculum (SUB), impacting the expression of nicotinic acetylcholine receptors (nAChRs) such as the &amp;amp;alpha;7-subtype. To investigate &amp;amp;alpha;7 nAChRs as a potential PET imaging biomarker, we report the quantitative binding of [125I]&amp;amp;alpha;-Bungarotoxin ([125I]&amp;amp;alpha;-Bgtx) for binding to postmortem human AD (n = 29; 13 males, 16 females) HP compared to cognitively normal (CN) (n = 28; 13 male, 15 female) HP. Methods: For comparisons with common AD biomarkers, adjacent slices were anti-A&amp;amp;beta; and anti-Tau immunostained for analysis using QuPath. Results: The [125I]&amp;amp;alpha;-Bgtx average SUB/HP ratio was 0.5 among the CN subjects, suggesting higher [125I]&amp;amp;alpha;-Bgtx binding in the HP gray matter regions. The AD subjects showed overall less binding than the CN subjects, with no statistical significance. A positive correlation was found in the [125I]&amp;amp;alpha;-Bgtx binding in the AD subjects as the age increased. The Braak stage comparisons of [125I]&amp;amp;alpha;-Bgtx were made with [18F]flotaza binding to A&amp;amp;beta; plaques and [125I]IPPI binding to Tau. A positive correlation was found between [125I]&amp;amp;alpha;-Bgtx and [18F]flotaza and there was a negative correlation between [125I]&amp;amp;alpha;-Bgtx and [125I]IPPI, implicating intricate relationships between the different AD biomarkers. Conclusions: [125I]&amp;amp;alpha;-Bgtx shows complimentary potential as a &amp;amp;alpha;7 nAChR imaging agent but needs more preclinical assessments to confirm effectiveness for translational PET studies using &amp;amp;alpha;7 nAChR radioligands.</p>
	]]></content:encoded>

	<dc:title>Evaluation of [125I]&amp;amp;alpha;-Bungarotoxin Binding to &amp;amp;alpha;7 Nicotinic Acetylcholinergic Receptors in Hippocampus&amp;amp;ndash;Subiculum of Postmortem Human Alzheimer&amp;amp;rsquo;s Disease Brain</dc:title>
			<dc:creator>Allyson Ngo</dc:creator>
			<dc:creator>Fariha Karim</dc:creator>
			<dc:creator>Oshini V. Keerthisinghe</dc:creator>
			<dc:creator>Tram B. Danh</dc:creator>
			<dc:creator>Christopher Liang</dc:creator>
			<dc:creator>Jogeshwar Mukherjee</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010007</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-03-20</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-03-20</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/receptors4010007</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/6">

	<title>Receptors, Vol. 4, Pages 6: Machine Learning Classification of 3D Intracellular Trafficking Using Custom and Imaris-Derived Motion Features</title>
	<link>https://www.mdpi.com/2813-2564/4/1/6</link>
	<description>Background: Detecting intracellular diffusion dynamics with high spatiotemporal resolution is critical for understanding the complex molecular mechanisms that govern viral infection, drug delivery, and sustained receptor signaling within cellular compartments. Although considerable progress has been made, accurately distinguishing between different types of diffusion in three dimensions remains a significant challenge. Methods: This study extends a previously established two-dimensional, machine learning-based diffusional fingerprinting approach into a three-dimensional framework to overcome this limitation. It presents an algorithm that predicts intracellular motion types based on a comprehensive feature set, including custom statistical descriptors and standard Imaris-derived trajectory features, which capture subtle variations in individual trajectories. The approach employs an extended gradient-boosted decision trees classifier trained on an array of synthetic trajectories designed to simulate diffusion behaviors typical of intracellular environments. Results: The machine learning classifier demonstrated a classification accuracy of over 90% on synthetic datasets, effectively capturing and distinguishing complex diffusion patterns. Subsequent validation using an experimental dataset confirmed the robustness of the approach. The incorporation of the Imaris track features streamlined diffusion classification and enhanced adaptability across diverse volumetric imaging modalities. Conclusions: This work advances our ability to classify intracellular diffusion dynamics in three dimensions and provides a method that is well-suited for high-resolution analysis of intracellular receptor trafficking, intracellular transport of pathogenic agents, and drug delivery mechanisms.</description>
	<pubDate>2025-03-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 6: Machine Learning Classification of 3D Intracellular Trafficking Using Custom and Imaris-Derived Motion Features</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/6">doi: 10.3390/receptors4010006</a></p>
	<p>Authors:
		Oleg Kovtun
		</p>
	<p>Background: Detecting intracellular diffusion dynamics with high spatiotemporal resolution is critical for understanding the complex molecular mechanisms that govern viral infection, drug delivery, and sustained receptor signaling within cellular compartments. Although considerable progress has been made, accurately distinguishing between different types of diffusion in three dimensions remains a significant challenge. Methods: This study extends a previously established two-dimensional, machine learning-based diffusional fingerprinting approach into a three-dimensional framework to overcome this limitation. It presents an algorithm that predicts intracellular motion types based on a comprehensive feature set, including custom statistical descriptors and standard Imaris-derived trajectory features, which capture subtle variations in individual trajectories. The approach employs an extended gradient-boosted decision trees classifier trained on an array of synthetic trajectories designed to simulate diffusion behaviors typical of intracellular environments. Results: The machine learning classifier demonstrated a classification accuracy of over 90% on synthetic datasets, effectively capturing and distinguishing complex diffusion patterns. Subsequent validation using an experimental dataset confirmed the robustness of the approach. The incorporation of the Imaris track features streamlined diffusion classification and enhanced adaptability across diverse volumetric imaging modalities. Conclusions: This work advances our ability to classify intracellular diffusion dynamics in three dimensions and provides a method that is well-suited for high-resolution analysis of intracellular receptor trafficking, intracellular transport of pathogenic agents, and drug delivery mechanisms.</p>
	]]></content:encoded>

	<dc:title>Machine Learning Classification of 3D Intracellular Trafficking Using Custom and Imaris-Derived Motion Features</dc:title>
			<dc:creator>Oleg Kovtun</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010006</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-03-12</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-03-12</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/receptors4010006</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/5">

	<title>Receptors, Vol. 4, Pages 5: Systemic Chronic Inflammation: Integrative Strategies for Health Improvement and Prevention of Inflammatory Receptor Overexpression</title>
	<link>https://www.mdpi.com/2813-2564/4/1/5</link>
	<description>The body&amp;amp;rsquo;s physiology during physical injuries and diseases depends heavily on the function of acute inflammation. On the other hand, many variables, including iatrogenic, immune system deficiencies, lifestyle, and social and environmental factors, are significant in developing systemic chronic inflammation (SCI). SCI is a major contributor to many diseases and a global cause of death and disability. Therefore, in the present article, we suggest integrative strategies for preventing SCI by addressing receptor overexpression and promoting health improvement. With the objective of reducing chronic inflammation by regulating cytokines, chemokines, and receptor modulation to try to reduce the risk of developing systemic chronic inflammatory diseases (also known as chronic-degenerative diseases, such as diabetes mellitus, cancer, cardiovascular disease, stroke, chronic kidney disease, neurodegenerative disorders, autoimmune diseases, and psychiatric disorders), the strategies we suggest are dietary modifications, exercise, and meditation. Accordingly, the prevention of SCI can be approached holistically with the help of the previous strategies, which may substantially impact public health.</description>
	<pubDate>2025-03-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 5: Systemic Chronic Inflammation: Integrative Strategies for Health Improvement and Prevention of Inflammatory Receptor Overexpression</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/5">doi: 10.3390/receptors4010005</a></p>
	<p>Authors:
		Abraham Puga-Olguín
		María Fernanda Hernández-Hernández
		Rafael Fernández-Demeneghi
		Carlos Iván López-Miranda
		Luis Ángel Flores-Aguilar
		</p>
	<p>The body&amp;amp;rsquo;s physiology during physical injuries and diseases depends heavily on the function of acute inflammation. On the other hand, many variables, including iatrogenic, immune system deficiencies, lifestyle, and social and environmental factors, are significant in developing systemic chronic inflammation (SCI). SCI is a major contributor to many diseases and a global cause of death and disability. Therefore, in the present article, we suggest integrative strategies for preventing SCI by addressing receptor overexpression and promoting health improvement. With the objective of reducing chronic inflammation by regulating cytokines, chemokines, and receptor modulation to try to reduce the risk of developing systemic chronic inflammatory diseases (also known as chronic-degenerative diseases, such as diabetes mellitus, cancer, cardiovascular disease, stroke, chronic kidney disease, neurodegenerative disorders, autoimmune diseases, and psychiatric disorders), the strategies we suggest are dietary modifications, exercise, and meditation. Accordingly, the prevention of SCI can be approached holistically with the help of the previous strategies, which may substantially impact public health.</p>
	]]></content:encoded>

	<dc:title>Systemic Chronic Inflammation: Integrative Strategies for Health Improvement and Prevention of Inflammatory Receptor Overexpression</dc:title>
			<dc:creator>Abraham Puga-Olguín</dc:creator>
			<dc:creator>María Fernanda Hernández-Hernández</dc:creator>
			<dc:creator>Rafael Fernández-Demeneghi</dc:creator>
			<dc:creator>Carlos Iván López-Miranda</dc:creator>
			<dc:creator>Luis Ángel Flores-Aguilar</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010005</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-03-09</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-03-09</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/receptors4010005</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/4">

	<title>Receptors, Vol. 4, Pages 4: Glutamate Receptor Signaling in Retina M&amp;uuml;ller Cells: Plausible Role in Neurodegeneration</title>
	<link>https://www.mdpi.com/2813-2564/4/1/4</link>
	<description>The retinal network relies on glutamate, the primary excitatory neurotransmitter involved in the visual cycle. Glutamate transactions are carried out by an array of distinct receptors and transporters distributed across both pre- and post-synaptic neurons and M&amp;amp;uuml;ller radial glial cells. Glutamate receptors are broadly divided into two types: ionotropic and metabotropic receptors that differ in their molecular architecture and signaling properties. Within the retina, M&amp;amp;uuml;ller glia cells span across its entire layers and possess specialized features that enable them to regulate glutamate extracellular levels and thus, its neuronal availability. In order to prevent an excitotoxic insult, retina extracellular glutamate levels have to be tightly regulated through uptake, predominantly into M&amp;amp;uuml;ller glial cells, by a family of Na+-dependent glutamate transporters known as excitatory amino acid transporters. An exquisite interplay between glutamate receptor signaling and glutamate transporter expression and function is fundamental for the integrity and proper function of the retina. This review examines our current understanding of the impact of M&amp;amp;uuml;ller glial glutamate signaling on glia/neuronal coupling.</description>
	<pubDate>2025-02-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 4: Glutamate Receptor Signaling in Retina M&amp;uuml;ller Cells: Plausible Role in Neurodegeneration</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/4">doi: 10.3390/receptors4010004</a></p>
	<p>Authors:
		Bolaji Oyetayo
		Yurixy Mendoza-Silva
		Temitayo Subair
		Luisa C Hernández-Kelly
		Marie-Paule Felder-Schmittbuhl
		Tatiana N. Olivares-Bañuelos
		Arturo Ortega
		</p>
	<p>The retinal network relies on glutamate, the primary excitatory neurotransmitter involved in the visual cycle. Glutamate transactions are carried out by an array of distinct receptors and transporters distributed across both pre- and post-synaptic neurons and M&amp;amp;uuml;ller radial glial cells. Glutamate receptors are broadly divided into two types: ionotropic and metabotropic receptors that differ in their molecular architecture and signaling properties. Within the retina, M&amp;amp;uuml;ller glia cells span across its entire layers and possess specialized features that enable them to regulate glutamate extracellular levels and thus, its neuronal availability. In order to prevent an excitotoxic insult, retina extracellular glutamate levels have to be tightly regulated through uptake, predominantly into M&amp;amp;uuml;ller glial cells, by a family of Na+-dependent glutamate transporters known as excitatory amino acid transporters. An exquisite interplay between glutamate receptor signaling and glutamate transporter expression and function is fundamental for the integrity and proper function of the retina. This review examines our current understanding of the impact of M&amp;amp;uuml;ller glial glutamate signaling on glia/neuronal coupling.</p>
	]]></content:encoded>

	<dc:title>Glutamate Receptor Signaling in Retina M&amp;amp;uuml;ller Cells: Plausible Role in Neurodegeneration</dc:title>
			<dc:creator>Bolaji Oyetayo</dc:creator>
			<dc:creator>Yurixy Mendoza-Silva</dc:creator>
			<dc:creator>Temitayo Subair</dc:creator>
			<dc:creator>Luisa C Hernández-Kelly</dc:creator>
			<dc:creator>Marie-Paule Felder-Schmittbuhl</dc:creator>
			<dc:creator>Tatiana N. Olivares-Bañuelos</dc:creator>
			<dc:creator>Arturo Ortega</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010004</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-02-26</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-02-26</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/receptors4010004</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/3">

	<title>Receptors, Vol. 4, Pages 3: RNase P-Associated External Guide Sequences Inhibit HIV-1 Infection by Shutting Down Human CCR5 Expression</title>
	<link>https://www.mdpi.com/2813-2564/4/1/3</link>
	<description>Background: External guide sequences (EGSs) are small RNA molecules capable of hybridizing to a target mRNA and rendering the target RNA susceptible to degradation by ribonuclease P (RNase P), a tRNA processing enzyme. Methods: In this study, natural tRNA-originated and engineered variant EGSs were constructed to target the mRNA encoding human CC-chemokine receptor 5 (CCR5), an HIV co-receptor. Results: The EGS variant was about 100-fold more efficient in inducing RNase P-mediated cleavage of the CCR5 mRNA sequence in vitro than a natural tRNA-derived EGS. Furthermore, the expressed variant and natural tRNA-originated EGSs decreased CCR5 expression by 98% and 73&amp;amp;ndash;77% and reduced infection by the CCR5-tropic HIVBa-L strain in cells by more than 900- and 50-fold, respectively. By contrast, cells expressing these EGSs exhibited no change in the expression of CXCR4, another HIV co-receptor, and showed no reduction in infection by the CXCR4-tropic HIVIIIB strain, which uses CXCR4 instead of CCR5 as the co-receptor. Thus, the EGSs specifically targeted CCR5 but not CXCR4. Conclusions: Our results demonstrate that EGSs are effective and specific in diminishing HIV infection and represent a novel class of gene-targeting agents for anti-HIV therapy.</description>
	<pubDate>2025-02-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 3: RNase P-Associated External Guide Sequences Inhibit HIV-1 Infection by Shutting Down Human CCR5 Expression</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/3">doi: 10.3390/receptors4010003</a></p>
	<p>Authors:
		Yujun Liu
		Bin Yan
		Isadora Zhang
		Fenyong Liu
		</p>
	<p>Background: External guide sequences (EGSs) are small RNA molecules capable of hybridizing to a target mRNA and rendering the target RNA susceptible to degradation by ribonuclease P (RNase P), a tRNA processing enzyme. Methods: In this study, natural tRNA-originated and engineered variant EGSs were constructed to target the mRNA encoding human CC-chemokine receptor 5 (CCR5), an HIV co-receptor. Results: The EGS variant was about 100-fold more efficient in inducing RNase P-mediated cleavage of the CCR5 mRNA sequence in vitro than a natural tRNA-derived EGS. Furthermore, the expressed variant and natural tRNA-originated EGSs decreased CCR5 expression by 98% and 73&amp;amp;ndash;77% and reduced infection by the CCR5-tropic HIVBa-L strain in cells by more than 900- and 50-fold, respectively. By contrast, cells expressing these EGSs exhibited no change in the expression of CXCR4, another HIV co-receptor, and showed no reduction in infection by the CXCR4-tropic HIVIIIB strain, which uses CXCR4 instead of CCR5 as the co-receptor. Thus, the EGSs specifically targeted CCR5 but not CXCR4. Conclusions: Our results demonstrate that EGSs are effective and specific in diminishing HIV infection and represent a novel class of gene-targeting agents for anti-HIV therapy.</p>
	]]></content:encoded>

	<dc:title>RNase P-Associated External Guide Sequences Inhibit HIV-1 Infection by Shutting Down Human CCR5 Expression</dc:title>
			<dc:creator>Yujun Liu</dc:creator>
			<dc:creator>Bin Yan</dc:creator>
			<dc:creator>Isadora Zhang</dc:creator>
			<dc:creator>Fenyong Liu</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010003</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-02-17</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-02-17</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/receptors4010003</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/2">

	<title>Receptors, Vol. 4, Pages 2: Exploring the Role of GLP-1 Receptor Agonists in Alzheimer&amp;rsquo;s Disease: A Review of Preclinical and Clinical Evidence</title>
	<link>https://www.mdpi.com/2813-2564/4/1/2</link>
	<description>Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) and obesity. These agents mimic the action of the endogenous incretin glucagon-like peptide-1 (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, and promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to have neuroprotective effects, suggesting their potential as treatment for neurodegenerative disorders, such as Alzheimer&amp;amp;rsquo;s disease (AD). AD and T2DM share several common pathophysiological mechanisms, including insulin resistance, chronic inflammation, oxidative stress, and mitochondrial dysfunction. These shared mechanisms suggest that therapeutic agents targeting metabolic dysfunction may also be beneficial for neurodegenerative conditions. Preclinical studies on GLP-1RAs in AD models, both in vitro and in vivo, have demonstrated promising neuroprotective effects, including reductions in amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, and enhanced neuronal survival. Despite the encouraging results from preclinical models, several challenges need to be addressed before GLP-1RAs can be widely used for AD treatment. Ongoing clinical trials are investigating the potential cognitive benefits of GLP-1RAs in AD patients, aiming to establish their role as a therapeutic option for AD. This review aimed to examine the current literature on preclinical and clinical studies investigating GLP-1 receptor agonists as potential therapeutic agents for AD.</description>
	<pubDate>2025-01-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 2: Exploring the Role of GLP-1 Receptor Agonists in Alzheimer&amp;rsquo;s Disease: A Review of Preclinical and Clinical Evidence</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/2">doi: 10.3390/receptors4010002</a></p>
	<p>Authors:
		Lívia C. R. Teixeira
		Marcelo R. Luizon
		Karina B. Gomes
		</p>
	<p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) and obesity. These agents mimic the action of the endogenous incretin glucagon-like peptide-1 (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, and promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to have neuroprotective effects, suggesting their potential as treatment for neurodegenerative disorders, such as Alzheimer&amp;amp;rsquo;s disease (AD). AD and T2DM share several common pathophysiological mechanisms, including insulin resistance, chronic inflammation, oxidative stress, and mitochondrial dysfunction. These shared mechanisms suggest that therapeutic agents targeting metabolic dysfunction may also be beneficial for neurodegenerative conditions. Preclinical studies on GLP-1RAs in AD models, both in vitro and in vivo, have demonstrated promising neuroprotective effects, including reductions in amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, and enhanced neuronal survival. Despite the encouraging results from preclinical models, several challenges need to be addressed before GLP-1RAs can be widely used for AD treatment. Ongoing clinical trials are investigating the potential cognitive benefits of GLP-1RAs in AD patients, aiming to establish their role as a therapeutic option for AD. This review aimed to examine the current literature on preclinical and clinical studies investigating GLP-1 receptor agonists as potential therapeutic agents for AD.</p>
	]]></content:encoded>

	<dc:title>Exploring the Role of GLP-1 Receptor Agonists in Alzheimer&amp;amp;rsquo;s Disease: A Review of Preclinical and Clinical Evidence</dc:title>
			<dc:creator>Lívia C. R. Teixeira</dc:creator>
			<dc:creator>Marcelo R. Luizon</dc:creator>
			<dc:creator>Karina B. Gomes</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010002</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-01-26</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-01-26</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/receptors4010002</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/4/1/1">

	<title>Receptors, Vol. 4, Pages 1: Unraveling the Role of CHRNA6, the Neuronal &amp;alpha;6 Nicotinic Acetylcholine Receptor Subunit</title>
	<link>https://www.mdpi.com/2813-2564/4/1/1</link>
	<description>The increased prevalence of electronic cigarettes, particularly among adolescents, has escalated concerns about nicotine addiction. Nicotine, a potent psychostimulant found in tobacco products, exerts its effects by interacting with nicotinic acetylcholine receptors (nAChRs) in the brain. Recent findings in both pre-clinical and clinical studies have enhanced our understanding of nAChRs, overcoming the limitations of pharmacological tools that previously hindered their investigation. Of particular interest is the &amp;amp;alpha;6 subunit, whose expression peaks during adolescence, a critical period of brain development often marked by the initiation of substance use. Pre-clinical studies have linked &amp;amp;alpha;6-containing nAChRs (&amp;amp;alpha;6*nAChRs) to nicotine-induced locomotion, dopamine release, and self-administration behavior. Furthermore, clinical studies suggest an association between the &amp;amp;alpha;6 subunit and increased smoking behavior in humans. Specifically, a single nucleotide polymorphism in the 3&amp;amp;prime; untranslated region of the CHRNA6 gene that encodes for this subunit is linked to smoking behavior and other substance use. A comprehensive understanding of this subunit&amp;amp;rsquo;s role in addiction is of high importance. This review aims to consolidate current knowledge regarding the &amp;amp;alpha;6 subunit&amp;amp;rsquo;s functions and implications in addiction and other disorders, with the hope of paving the way for future research and the development of targeted therapies to address this pressing public health concern.</description>
	<pubDate>2025-01-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 4, Pages 1: Unraveling the Role of CHRNA6, the Neuronal &amp;alpha;6 Nicotinic Acetylcholine Receptor Subunit</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/4/1/1">doi: 10.3390/receptors4010001</a></p>
	<p>Authors:
		Yasamin Hajy Heydary
		Emily M. Castro
		Shahrdad Lotfipour
		Frances M. Leslie
		</p>
	<p>The increased prevalence of electronic cigarettes, particularly among adolescents, has escalated concerns about nicotine addiction. Nicotine, a potent psychostimulant found in tobacco products, exerts its effects by interacting with nicotinic acetylcholine receptors (nAChRs) in the brain. Recent findings in both pre-clinical and clinical studies have enhanced our understanding of nAChRs, overcoming the limitations of pharmacological tools that previously hindered their investigation. Of particular interest is the &amp;amp;alpha;6 subunit, whose expression peaks during adolescence, a critical period of brain development often marked by the initiation of substance use. Pre-clinical studies have linked &amp;amp;alpha;6-containing nAChRs (&amp;amp;alpha;6*nAChRs) to nicotine-induced locomotion, dopamine release, and self-administration behavior. Furthermore, clinical studies suggest an association between the &amp;amp;alpha;6 subunit and increased smoking behavior in humans. Specifically, a single nucleotide polymorphism in the 3&amp;amp;prime; untranslated region of the CHRNA6 gene that encodes for this subunit is linked to smoking behavior and other substance use. A comprehensive understanding of this subunit&amp;amp;rsquo;s role in addiction is of high importance. This review aims to consolidate current knowledge regarding the &amp;amp;alpha;6 subunit&amp;amp;rsquo;s functions and implications in addiction and other disorders, with the hope of paving the way for future research and the development of targeted therapies to address this pressing public health concern.</p>
	]]></content:encoded>

	<dc:title>Unraveling the Role of CHRNA6, the Neuronal &amp;amp;alpha;6 Nicotinic Acetylcholine Receptor Subunit</dc:title>
			<dc:creator>Yasamin Hajy Heydary</dc:creator>
			<dc:creator>Emily M. Castro</dc:creator>
			<dc:creator>Shahrdad Lotfipour</dc:creator>
			<dc:creator>Frances M. Leslie</dc:creator>
		<dc:identifier>doi: 10.3390/receptors4010001</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2025-01-14</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2025-01-14</prism:publicationDate>
	<prism:volume>4</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/receptors4010001</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/4/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/29">

	<title>Receptors, Vol. 3, Pages 555-573: LPA3: Pharmacodynamic Differences Between Lysophosphatidic Acid and Oleoyl-Methoxy Glycerophosphothionate: Biased Agonism, Two Sites</title>
	<link>https://www.mdpi.com/2813-2564/3/4/29</link>
	<description>Background: Lysophosphatidic acid (LPA) receptor 3 (LPA3) is involved in many physiological and pathophysiological actions of this bioactive lipid, particularly in cancer. The actions of LPA and oleoyl-methoxy glycerophosphothionate (OMPT) were compared in LPA3-transfected HEK 293 cells. Methods: Receptor phosphorylation, ERK 1/2 activation, LPA3-&amp;amp;beta;-arrestin 2 interaction, and changes in intracellular calcium were analyzed. Results: Our data indicate that LPA and OMPT increased LPA3 phosphorylation, OMPT being considerably more potent than LPA. OMPT was also more potent than LPA to activate ERK 1/2. In contrast, OMPT was less effective in increasing intracellular calcium than LPA. The LPA-induced LPA3-&amp;amp;beta;-arrestin 2 interaction was fast and robust, whereas that induced by OMPT was only detected at 60 min of incubation. LPA- and OMPT-induced receptor internalization was fast, but that induced by OMPT was more marked. LPA-induced internalization was blocked by Pitstop 2, whereas OMPT-induced receptor internalization was partially inhibited by Pitstop 2 and Filipin and entirely by the combination of both. When LPA-stimulated cells were rechallenged with 1 &amp;amp;micro;M LPA, hardly any response was detected, i.e., a &amp;amp;ldquo;refractory&amp;amp;rdquo; state was induced. However, a conspicuous and robust response was observed if OMPT was used as the second stimulus. Conclusions: The differences in these agents&amp;amp;rsquo; actions suggest that OMPT is a biased agonist. These findings suggest that two binding sites for these agonists might exist in the LPA3 receptor, one showing a very high affinity for OMPT and another likely shared by LPA and OMPT (structural analogs) with lower affinity.</description>
	<pubDate>2024-12-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 555-573: LPA3: Pharmacodynamic Differences Between Lysophosphatidic Acid and Oleoyl-Methoxy Glycerophosphothionate: Biased Agonism, Two Sites</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/29">doi: 10.3390/receptors3040029</a></p>
	<p>Authors:
		K. Helivier Solís
		M. Teresa Romero-Ávila
		Ruth Rincón-Heredia
		Juan Carlos Martínez-Morales
		J. Adolfo García-Sáinz
		</p>
	<p>Background: Lysophosphatidic acid (LPA) receptor 3 (LPA3) is involved in many physiological and pathophysiological actions of this bioactive lipid, particularly in cancer. The actions of LPA and oleoyl-methoxy glycerophosphothionate (OMPT) were compared in LPA3-transfected HEK 293 cells. Methods: Receptor phosphorylation, ERK 1/2 activation, LPA3-&amp;amp;beta;-arrestin 2 interaction, and changes in intracellular calcium were analyzed. Results: Our data indicate that LPA and OMPT increased LPA3 phosphorylation, OMPT being considerably more potent than LPA. OMPT was also more potent than LPA to activate ERK 1/2. In contrast, OMPT was less effective in increasing intracellular calcium than LPA. The LPA-induced LPA3-&amp;amp;beta;-arrestin 2 interaction was fast and robust, whereas that induced by OMPT was only detected at 60 min of incubation. LPA- and OMPT-induced receptor internalization was fast, but that induced by OMPT was more marked. LPA-induced internalization was blocked by Pitstop 2, whereas OMPT-induced receptor internalization was partially inhibited by Pitstop 2 and Filipin and entirely by the combination of both. When LPA-stimulated cells were rechallenged with 1 &amp;amp;micro;M LPA, hardly any response was detected, i.e., a &amp;amp;ldquo;refractory&amp;amp;rdquo; state was induced. However, a conspicuous and robust response was observed if OMPT was used as the second stimulus. Conclusions: The differences in these agents&amp;amp;rsquo; actions suggest that OMPT is a biased agonist. These findings suggest that two binding sites for these agonists might exist in the LPA3 receptor, one showing a very high affinity for OMPT and another likely shared by LPA and OMPT (structural analogs) with lower affinity.</p>
	]]></content:encoded>

	<dc:title>LPA3: Pharmacodynamic Differences Between Lysophosphatidic Acid and Oleoyl-Methoxy Glycerophosphothionate: Biased Agonism, Two Sites</dc:title>
			<dc:creator>K. Helivier Solís</dc:creator>
			<dc:creator>M. Teresa Romero-Ávila</dc:creator>
			<dc:creator>Ruth Rincón-Heredia</dc:creator>
			<dc:creator>Juan Carlos Martínez-Morales</dc:creator>
			<dc:creator>J. Adolfo García-Sáinz</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040029</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-12-20</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-12-20</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>555</prism:startingPage>
		<prism:doi>10.3390/receptors3040029</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/29</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/28">

	<title>Receptors, Vol. 3, Pages 541-554: The New Nitric Oxide Donor, FOR 911B, Induces Relaxation in Isolated Rat Aorta Involving the NO/sGC/cGMP Pathway and K+ Channels</title>
	<link>https://www.mdpi.com/2813-2564/3/4/28</link>
	<description>Background: Nitric oxide (NO) is a gaseous molecule considered to be a protagonist in the dilation of blood vessels, and its property and/or bioavailability are reduced in pathophysiological conditions such as cardiovascular diseases. Therefore, its exogenous administration becomes attractive, and new classes of compounds able to induce NO release have emerged to minimize the adverse effects found by existing NO donor drugs. Objective: Our aim was to investigate the vasorelaxant effect and mechanism of action induced by the ruthenium complex, which contains nitric oxide in its structure, [Ru(phen)2(TU)NO](PF6)3 (FOR 911B), in isolated rat aorta. Methods: The animals were euthanized, and the aorta artery was identified, removed, and immediately placed in modified Krebs&amp;amp;ndash;Henseleit solution. To verify tissue viability, a contraction was obtained with phenylephrine (Phe) (0.1 &amp;amp;mu;M), and to assess endothelial integrity, acetylcholine (ACh) (1 &amp;amp;mu;M) was added. Results: In the present study, we demonstrated, for the first time, that FOR 911B promotes vasorelaxation in a concentration-dependent manner in isolated rat aortic artery rings. After the removal of the vascular endothelium, the potency and efficacy of the relaxation were not altered. With pre-incubation with hydroxocobalamin, the relaxing response was abolished, and with the use of ODQ, the main NO receptor blocker, the vasorelaxant effect was attenuated with a shift of the curve to the right. To investigate the participation of K+ channels, the solution concentration was changed to KCl (20 and 60 mM), and it was pre-incubated with the non-selective K+ channels blocker (TEA). Under these conditions, relaxation was altered, demonstrating that K+ channels are activated by FOR 911B. By selectively blocking the different subtypes of K+ channels with specific blockers, we demonstrated that the subtypes KV, KIR, SKCa, and BKCa are involved in the vasodilator effect induced by FOR 911B. Conclusions: The results obtained demonstrated that FOR 911B promotes vascular relaxation in aortic artery rings in a concentration-dependent manner and independent of the vascular endothelium through the participation of the NO/sGC/cGMP pathway, as well as with the involvement of different K+ channels.</description>
	<pubDate>2024-12-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 541-554: The New Nitric Oxide Donor, FOR 911B, Induces Relaxation in Isolated Rat Aorta Involving the NO/sGC/cGMP Pathway and K+ Channels</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/28">doi: 10.3390/receptors3040028</a></p>
	<p>Authors:
		Mirelly Cunha da Silva
		Florêncio Sousa Gouveia Júnior
		Thyago Moreira de Queiroz
		</p>
	<p>Background: Nitric oxide (NO) is a gaseous molecule considered to be a protagonist in the dilation of blood vessels, and its property and/or bioavailability are reduced in pathophysiological conditions such as cardiovascular diseases. Therefore, its exogenous administration becomes attractive, and new classes of compounds able to induce NO release have emerged to minimize the adverse effects found by existing NO donor drugs. Objective: Our aim was to investigate the vasorelaxant effect and mechanism of action induced by the ruthenium complex, which contains nitric oxide in its structure, [Ru(phen)2(TU)NO](PF6)3 (FOR 911B), in isolated rat aorta. Methods: The animals were euthanized, and the aorta artery was identified, removed, and immediately placed in modified Krebs&amp;amp;ndash;Henseleit solution. To verify tissue viability, a contraction was obtained with phenylephrine (Phe) (0.1 &amp;amp;mu;M), and to assess endothelial integrity, acetylcholine (ACh) (1 &amp;amp;mu;M) was added. Results: In the present study, we demonstrated, for the first time, that FOR 911B promotes vasorelaxation in a concentration-dependent manner in isolated rat aortic artery rings. After the removal of the vascular endothelium, the potency and efficacy of the relaxation were not altered. With pre-incubation with hydroxocobalamin, the relaxing response was abolished, and with the use of ODQ, the main NO receptor blocker, the vasorelaxant effect was attenuated with a shift of the curve to the right. To investigate the participation of K+ channels, the solution concentration was changed to KCl (20 and 60 mM), and it was pre-incubated with the non-selective K+ channels blocker (TEA). Under these conditions, relaxation was altered, demonstrating that K+ channels are activated by FOR 911B. By selectively blocking the different subtypes of K+ channels with specific blockers, we demonstrated that the subtypes KV, KIR, SKCa, and BKCa are involved in the vasodilator effect induced by FOR 911B. Conclusions: The results obtained demonstrated that FOR 911B promotes vascular relaxation in aortic artery rings in a concentration-dependent manner and independent of the vascular endothelium through the participation of the NO/sGC/cGMP pathway, as well as with the involvement of different K+ channels.</p>
	]]></content:encoded>

	<dc:title>The New Nitric Oxide Donor, FOR 911B, Induces Relaxation in Isolated Rat Aorta Involving the NO/sGC/cGMP Pathway and K+ Channels</dc:title>
			<dc:creator>Mirelly Cunha da Silva</dc:creator>
			<dc:creator>Florêncio Sousa Gouveia Júnior</dc:creator>
			<dc:creator>Thyago Moreira de Queiroz</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040028</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-12-10</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-12-10</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>541</prism:startingPage>
		<prism:doi>10.3390/receptors3040028</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/28</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/27">

	<title>Receptors, Vol. 3, Pages 538-540: Intracellular ATP Levels: Challenge to the Current Consensus and Its Implications for Intracellular Signaling</title>
	<link>https://www.mdpi.com/2813-2564/3/4/27</link>
	<description>Work with novel indicators that report intracellular ATP concentrations with improved spatial and temporal resolution have challenged the current consensus that under physiological conditions, intracellular ATP concentrations are not rate-limiting to enzymatic reactions. Recent data from cardiac myocytes and cultured neurons show marked fluctuations of intracellular ATP levels, as well as evidence for compartmentalization. It is likely that the availability of these genetically encoded indicators will produce rapid progress in the mapping of the dynamics of intracellular ATP concentrations in various types of cells. Here, a brief account of the most recent indicators is provided as well as a review of how natural evolution appears to have obviated the potential shortage of the ATP supply to one of key enzymes of the cyclic AMP signaling cascade, adenylyl cyclase 9.</description>
	<pubDate>2024-11-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 538-540: Intracellular ATP Levels: Challenge to the Current Consensus and Its Implications for Intracellular Signaling</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/27">doi: 10.3390/receptors3040027</a></p>
	<p>Authors:
		Ferenc A. Antoni
		</p>
	<p>Work with novel indicators that report intracellular ATP concentrations with improved spatial and temporal resolution have challenged the current consensus that under physiological conditions, intracellular ATP concentrations are not rate-limiting to enzymatic reactions. Recent data from cardiac myocytes and cultured neurons show marked fluctuations of intracellular ATP levels, as well as evidence for compartmentalization. It is likely that the availability of these genetically encoded indicators will produce rapid progress in the mapping of the dynamics of intracellular ATP concentrations in various types of cells. Here, a brief account of the most recent indicators is provided as well as a review of how natural evolution appears to have obviated the potential shortage of the ATP supply to one of key enzymes of the cyclic AMP signaling cascade, adenylyl cyclase 9.</p>
	]]></content:encoded>

	<dc:title>Intracellular ATP Levels: Challenge to the Current Consensus and Its Implications for Intracellular Signaling</dc:title>
			<dc:creator>Ferenc A. Antoni</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040027</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-11-26</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-11-26</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Commentary</prism:section>
	<prism:startingPage>538</prism:startingPage>
		<prism:doi>10.3390/receptors3040027</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/27</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/26">

	<title>Receptors, Vol. 3, Pages 513-537: Mechanistic Insights into the Interaction Between Kinin Receptors and Histamine H2 Receptor Pathways in Oxidative Stress</title>
	<link>https://www.mdpi.com/2813-2564/3/4/26</link>
	<description>Reactive oxygen species (ROS) encompass various molecular oxygen derivatives naturally produced during aerobic metabolism, including superoxide anions, hydrogen peroxide, and hydroxyl radicals. Excessive ROS production leads to oxidative distress, causing cellular damage and contributing to various pathologies, often alongside inflammation. Endogenous sources of ROS include mitochondrial activity and NADPH oxidases. The antioxidant system, comprising enzymes such as superoxide dismutase, peroxiredoxin, and catalase, mitigates ROS-induced damage. This review explores the regulation of ROS by membrane receptors, focusing on B1 and B2 kinin receptors and histamine H2 receptors, which are implicated in vasodilation, angiogenesis, inflammation, and gastric acid secretion. Understanding these interactions provides insights into ROS modulation and its role in disease mechanisms.</description>
	<pubDate>2024-11-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 513-537: Mechanistic Insights into the Interaction Between Kinin Receptors and Histamine H2 Receptor Pathways in Oxidative Stress</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/26">doi: 10.3390/receptors3040026</a></p>
	<p>Authors:
		Marcos Fernandes Gregnani
		Leonardo Martins
		Wieslawa Agnieszka Fogel
		</p>
	<p>Reactive oxygen species (ROS) encompass various molecular oxygen derivatives naturally produced during aerobic metabolism, including superoxide anions, hydrogen peroxide, and hydroxyl radicals. Excessive ROS production leads to oxidative distress, causing cellular damage and contributing to various pathologies, often alongside inflammation. Endogenous sources of ROS include mitochondrial activity and NADPH oxidases. The antioxidant system, comprising enzymes such as superoxide dismutase, peroxiredoxin, and catalase, mitigates ROS-induced damage. This review explores the regulation of ROS by membrane receptors, focusing on B1 and B2 kinin receptors and histamine H2 receptors, which are implicated in vasodilation, angiogenesis, inflammation, and gastric acid secretion. Understanding these interactions provides insights into ROS modulation and its role in disease mechanisms.</p>
	]]></content:encoded>

	<dc:title>Mechanistic Insights into the Interaction Between Kinin Receptors and Histamine H2 Receptor Pathways in Oxidative Stress</dc:title>
			<dc:creator>Marcos Fernandes Gregnani</dc:creator>
			<dc:creator>Leonardo Martins</dc:creator>
			<dc:creator>Wieslawa Agnieszka Fogel</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040026</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-11-14</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-11-14</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>513</prism:startingPage>
		<prism:doi>10.3390/receptors3040026</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/26</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/25">

	<title>Receptors, Vol. 3, Pages 494-512: Molecular Perspectives on Prostate Cancer: The Role of microRNAs in Androgen Receptor Regulation</title>
	<link>https://www.mdpi.com/2813-2564/3/4/25</link>
	<description>Prostate cancer (PCa) is the most prevalent cancer among men globally. In addition to environmental risk factors, genetic factors play a crucial role in its development and progression, highlighting the regulation of key genes as an essential aspect. The androgen receptor gene (AR) plays a pivotal role in this disease, so its post-transcriptional regulation must be meticulously coordinated. In this review, we explore the role of microRNAs (miRNAs) in the regulation of AR in PCa, a field not yet fully investigated. We note that the AR, due to its extensive 3&amp;amp;prime;UTR region, is targeted by numerous miRNAs, and that this regulation can occur at different levels: directly, indirectly, and through mutual regulation, thus amplifying the influence of these molecules on AR regulation.</description>
	<pubDate>2024-11-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 494-512: Molecular Perspectives on Prostate Cancer: The Role of microRNAs in Androgen Receptor Regulation</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/25">doi: 10.3390/receptors3040025</a></p>
	<p>Authors:
		Asbiel Felipe Garibaldi-Ríos
		Alicia Rivera-Cameras
		Luis E. Figuera
		Guillermo Moisés Zúñiga-González
		Belinda Claudia Gómez-Meda
		José Elías García-Ortíz
		Martha Patricia Gallegos-Arreola
		</p>
	<p>Prostate cancer (PCa) is the most prevalent cancer among men globally. In addition to environmental risk factors, genetic factors play a crucial role in its development and progression, highlighting the regulation of key genes as an essential aspect. The androgen receptor gene (AR) plays a pivotal role in this disease, so its post-transcriptional regulation must be meticulously coordinated. In this review, we explore the role of microRNAs (miRNAs) in the regulation of AR in PCa, a field not yet fully investigated. We note that the AR, due to its extensive 3&amp;amp;prime;UTR region, is targeted by numerous miRNAs, and that this regulation can occur at different levels: directly, indirectly, and through mutual regulation, thus amplifying the influence of these molecules on AR regulation.</p>
	]]></content:encoded>

	<dc:title>Molecular Perspectives on Prostate Cancer: The Role of microRNAs in Androgen Receptor Regulation</dc:title>
			<dc:creator>Asbiel Felipe Garibaldi-Ríos</dc:creator>
			<dc:creator>Alicia Rivera-Cameras</dc:creator>
			<dc:creator>Luis E. Figuera</dc:creator>
			<dc:creator>Guillermo Moisés Zúñiga-González</dc:creator>
			<dc:creator>Belinda Claudia Gómez-Meda</dc:creator>
			<dc:creator>José Elías García-Ortíz</dc:creator>
			<dc:creator>Martha Patricia Gallegos-Arreola</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040025</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-11-12</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-11-12</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>494</prism:startingPage>
		<prism:doi>10.3390/receptors3040025</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/25</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/24">

	<title>Receptors, Vol. 3, Pages 474-493: The Regulation and Function of the Amino Acid Transporters LAT1, ASCT2, xCT in Urological Cancers</title>
	<link>https://www.mdpi.com/2813-2564/3/4/24</link>
	<description>Amino acid transporters play pivotal roles in cancer biology, including in urological cancers. Among them, L-type amino acid transporter 1 (LAT1), alanine-serine-cysteine transporter 2 (ASCT2), and cystine-glutamate transporter (xCT) have garnered significant attention due to their involvement in various aspects of tumor progression and response to therapy. This review focuses on elucidating the regulation and functions of these amino acid transporters in urological cancers, including prostate, bladder, and renal cancers. Understanding the intricate regulatory mechanisms governing these amino acid transporters is essential for developing effective therapeutic strategies. Furthermore, exploring their interactions with signaling pathways and microenvironmental cues in the context of urological cancers may uncover novel therapeutic vulnerabilities. This comprehensive overview highlights the importance of amino acid transporters, particularly LAT1, ASCT2, and xCT, in urological cancers and underscores the potential of their inhibitors as therapeutic targets for improving patient outcomes.</description>
	<pubDate>2024-10-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 474-493: The Regulation and Function of the Amino Acid Transporters LAT1, ASCT2, xCT in Urological Cancers</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/24">doi: 10.3390/receptors3040024</a></p>
	<p>Authors:
		Xue Zhao
		Shinichi Sakamoto
		Shinpei Saito
		Sangjon Pae
		Yasutaka Yamada
		Sanji Kanaoka
		Jiaxing Wei
		Yusuke Goto
		Tomokazu Sazuka
		Yusuke Imamura
		Naohiko Anzai
		Tomohiko Ichikawa
		</p>
	<p>Amino acid transporters play pivotal roles in cancer biology, including in urological cancers. Among them, L-type amino acid transporter 1 (LAT1), alanine-serine-cysteine transporter 2 (ASCT2), and cystine-glutamate transporter (xCT) have garnered significant attention due to their involvement in various aspects of tumor progression and response to therapy. This review focuses on elucidating the regulation and functions of these amino acid transporters in urological cancers, including prostate, bladder, and renal cancers. Understanding the intricate regulatory mechanisms governing these amino acid transporters is essential for developing effective therapeutic strategies. Furthermore, exploring their interactions with signaling pathways and microenvironmental cues in the context of urological cancers may uncover novel therapeutic vulnerabilities. This comprehensive overview highlights the importance of amino acid transporters, particularly LAT1, ASCT2, and xCT, in urological cancers and underscores the potential of their inhibitors as therapeutic targets for improving patient outcomes.</p>
	]]></content:encoded>

	<dc:title>The Regulation and Function of the Amino Acid Transporters LAT1, ASCT2, xCT in Urological Cancers</dc:title>
			<dc:creator>Xue Zhao</dc:creator>
			<dc:creator>Shinichi Sakamoto</dc:creator>
			<dc:creator>Shinpei Saito</dc:creator>
			<dc:creator>Sangjon Pae</dc:creator>
			<dc:creator>Yasutaka Yamada</dc:creator>
			<dc:creator>Sanji Kanaoka</dc:creator>
			<dc:creator>Jiaxing Wei</dc:creator>
			<dc:creator>Yusuke Goto</dc:creator>
			<dc:creator>Tomokazu Sazuka</dc:creator>
			<dc:creator>Yusuke Imamura</dc:creator>
			<dc:creator>Naohiko Anzai</dc:creator>
			<dc:creator>Tomohiko Ichikawa</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040024</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-10-31</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-10-31</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>474</prism:startingPage>
		<prism:doi>10.3390/receptors3040024</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/23">

	<title>Receptors, Vol. 3, Pages 457-473: Glycosyl Mobile Radical Structures of Folic Acid Receptors Impact the Internalization of Functionalized Folate Amphiphilic Alternating Copolymer in Cancer Cells</title>
	<link>https://www.mdpi.com/2813-2564/3/4/23</link>
	<description>Folate receptor alpha (FR&amp;amp;alpha;) is a glycosylphosphatidylinositol (GPI) membrane-anchored protein containing three N-glycosylated residues at the N47, N139, and N179 termini. These glycosylation sites have been reported to be crucial for the receptor&amp;amp;rsquo;s structural integrity and its ability to bind and internalize FA. Here, we investigated the role of FR&amp;amp;alpha; glycosylation in the binding and internalization efficacy of FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA in pancreatic PANC-1 cancer cells. There is a strong association of the FA copolymer with FR&amp;amp;alpha; with a Pearson coefficient R-value of 0.7179. PANC-1 cancer cells were pretreated with maackia amurensis lectin II (MAL-2), sambucus Nigra lectin (SNA-1), peanut agglutinin (PNA), and wheat germ agglutinin lectin (WGA) at different doses followed by 20 kDa and 350 kDa FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA loaded with coumarin 153 (C153). Increasing the dosage of MAL2, SNA-1, PNA, and WGA concomitantly and significantly increased the internalization of C153-loaded FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA in the cells. The half maximal effective lectin concentrations (EC50) to induce cellular internalization into the cytoplasm of the lectins for MAL-2 were 35.88 &amp;amp;micro;g/mL, 3.051 &amp;amp;micro;g/mL for SNA-1, 7.883 &amp;amp;micro;g/mL for PNA, and 0.898 &amp;amp;micro;g/mL for WGA. Live cell imaging of the internalization of 20 kDa and 350 kDa FA copolymers indicated an aggregation of 350 kDa copolymer with FR&amp;amp;alpha; in the cytoplasm. In contrast, the 20 kDa FA copolymer remained in the membrane. The data indicate for the first time that the mobile positions of the glycosyl radical groups and the receptor tilt in generating steric hindrance impacted the individual FR&amp;amp;alpha; receptors in the binding and internalization of 350 kDa FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA in cancer cells.</description>
	<pubDate>2024-10-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 457-473: Glycosyl Mobile Radical Structures of Folic Acid Receptors Impact the Internalization of Functionalized Folate Amphiphilic Alternating Copolymer in Cancer Cells</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/23">doi: 10.3390/receptors3040023</a></p>
	<p>Authors:
		Emilyn B. Aucoin
		Elizabeth Skapinker
		Abdulrahman M. Yaish
		Yunfan Li
		Haley L. Kombargi
		Daniel Jeyaraj
		Pankaj Garg
		Nicole Mendonza
		Cecile Malardier-Jugroot
		Myron R. Szewczuk
		</p>
	<p>Folate receptor alpha (FR&amp;amp;alpha;) is a glycosylphosphatidylinositol (GPI) membrane-anchored protein containing three N-glycosylated residues at the N47, N139, and N179 termini. These glycosylation sites have been reported to be crucial for the receptor&amp;amp;rsquo;s structural integrity and its ability to bind and internalize FA. Here, we investigated the role of FR&amp;amp;alpha; glycosylation in the binding and internalization efficacy of FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA in pancreatic PANC-1 cancer cells. There is a strong association of the FA copolymer with FR&amp;amp;alpha; with a Pearson coefficient R-value of 0.7179. PANC-1 cancer cells were pretreated with maackia amurensis lectin II (MAL-2), sambucus Nigra lectin (SNA-1), peanut agglutinin (PNA), and wheat germ agglutinin lectin (WGA) at different doses followed by 20 kDa and 350 kDa FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA loaded with coumarin 153 (C153). Increasing the dosage of MAL2, SNA-1, PNA, and WGA concomitantly and significantly increased the internalization of C153-loaded FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA in the cells. The half maximal effective lectin concentrations (EC50) to induce cellular internalization into the cytoplasm of the lectins for MAL-2 were 35.88 &amp;amp;micro;g/mL, 3.051 &amp;amp;micro;g/mL for SNA-1, 7.883 &amp;amp;micro;g/mL for PNA, and 0.898 &amp;amp;micro;g/mL for WGA. Live cell imaging of the internalization of 20 kDa and 350 kDa FA copolymers indicated an aggregation of 350 kDa copolymer with FR&amp;amp;alpha; in the cytoplasm. In contrast, the 20 kDa FA copolymer remained in the membrane. The data indicate for the first time that the mobile positions of the glycosyl radical groups and the receptor tilt in generating steric hindrance impacted the individual FR&amp;amp;alpha; receptors in the binding and internalization of 350 kDa FA&amp;amp;ndash;DABA&amp;amp;ndash;SMA in cancer cells.</p>
	]]></content:encoded>

	<dc:title>Glycosyl Mobile Radical Structures of Folic Acid Receptors Impact the Internalization of Functionalized Folate Amphiphilic Alternating Copolymer in Cancer Cells</dc:title>
			<dc:creator>Emilyn B. Aucoin</dc:creator>
			<dc:creator>Elizabeth Skapinker</dc:creator>
			<dc:creator>Abdulrahman M. Yaish</dc:creator>
			<dc:creator>Yunfan Li</dc:creator>
			<dc:creator>Haley L. Kombargi</dc:creator>
			<dc:creator>Daniel Jeyaraj</dc:creator>
			<dc:creator>Pankaj Garg</dc:creator>
			<dc:creator>Nicole Mendonza</dc:creator>
			<dc:creator>Cecile Malardier-Jugroot</dc:creator>
			<dc:creator>Myron R. Szewczuk</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040023</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-10-21</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-10-21</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>457</prism:startingPage>
		<prism:doi>10.3390/receptors3040023</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/22">

	<title>Receptors, Vol. 3, Pages 444-456: Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers</title>
	<link>https://www.mdpi.com/2813-2564/3/4/22</link>
	<description>This review focuses on the pivotal roles of nuclear receptors (NRs) in driving endocrine resistance in prostate and breast cancers. In prostate cancer (PCa), androgen receptor (AR) amplification, mutations, and altered coactivator interactions sustain tumor growth under androgen deprivation therapy (ADT), leading to castration-resistant prostate cancer (CRPC). Orphan NRs like ROR&amp;amp;beta;, TLX, and COUP-TFII further contribute to CRPC by regulating stemness and therapeutic resistance mechanisms. In breast cancer, NRs, including estrogen receptor alpha (ER&amp;amp;alpha;), androgen receptor (AR), glucocorticoid receptor (GR), and liver receptor homolog-1 (LRH-1), modulate estrogen signaling pathways and alternative survival mechanisms like PI3K/AKT/mTOR and NF&amp;amp;kappa;B, promoting resistance to endocrine therapies such as tamoxifen. Understanding these NR-mediated mechanisms is critical for developing targeted therapies to overcome endocrine resistance and improve patient outcomes in hormone-dependent cancers.</description>
	<pubDate>2024-10-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 444-456: Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/22">doi: 10.3390/receptors3040022</a></p>
	<p>Authors:
		Macrina Beatriz Silva-Cázares
		Stephanie I. Nuñez-Olvera
		Ricardo Hernández-Barrientos
		Enoc Mariano Cortés-Malagón
		María Elizbeth Alvarez-Sánchez
		Jonathan Puente-Rivera
		</p>
	<p>This review focuses on the pivotal roles of nuclear receptors (NRs) in driving endocrine resistance in prostate and breast cancers. In prostate cancer (PCa), androgen receptor (AR) amplification, mutations, and altered coactivator interactions sustain tumor growth under androgen deprivation therapy (ADT), leading to castration-resistant prostate cancer (CRPC). Orphan NRs like ROR&amp;amp;beta;, TLX, and COUP-TFII further contribute to CRPC by regulating stemness and therapeutic resistance mechanisms. In breast cancer, NRs, including estrogen receptor alpha (ER&amp;amp;alpha;), androgen receptor (AR), glucocorticoid receptor (GR), and liver receptor homolog-1 (LRH-1), modulate estrogen signaling pathways and alternative survival mechanisms like PI3K/AKT/mTOR and NF&amp;amp;kappa;B, promoting resistance to endocrine therapies such as tamoxifen. Understanding these NR-mediated mechanisms is critical for developing targeted therapies to overcome endocrine resistance and improve patient outcomes in hormone-dependent cancers.</p>
	]]></content:encoded>

	<dc:title>Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers</dc:title>
			<dc:creator>Macrina Beatriz Silva-Cázares</dc:creator>
			<dc:creator>Stephanie I. Nuñez-Olvera</dc:creator>
			<dc:creator>Ricardo Hernández-Barrientos</dc:creator>
			<dc:creator>Enoc Mariano Cortés-Malagón</dc:creator>
			<dc:creator>María Elizbeth Alvarez-Sánchez</dc:creator>
			<dc:creator>Jonathan Puente-Rivera</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040022</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-10-14</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-10-14</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>444</prism:startingPage>
		<prism:doi>10.3390/receptors3040022</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/4/21">

	<title>Receptors, Vol. 3, Pages 425-443: Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy</title>
	<link>https://www.mdpi.com/2813-2564/3/4/21</link>
	<description>This review article explores the fundamental role of receptor targeting in overcoming drug resistance in cancer therapy, an area of critical concern given the persistently high rates of cancer morbidity and mortality globally. We highlight how receptor biology intersects with the development of therapeutic resistance with a specific focus on anti-angiogenic agents, immune checkpoint inhibitors, and monoclonal antibodies, which directly or indirectly influence receptor pathways. We also explore how other receptor tyrosine kinases can initially suppress tumor growth, yet often lead to resistance, underscoring the need for novel combinatorial approaches that incorporate advanced receptor modulation techniques. Further, the review delves into the mechanisms by which modulation of the tumor microenvironment and immune system via receptor pathways can overcome resistance to traditional immunotherapies. Additionally, emerging technologies in receptor-targeted nanomedicine are also highlighted, showcasing their potential to revolutionize drug delivery and improve therapeutic outcomes by targeting specific receptor interactions. Ultimately, this review calls for a deeper understanding of receptor dynamics to develop more precise interventions, including insights from various healthcare settings that can prevent or circumvent drug resistance, thus enhancing patient outcomes in oncology.</description>
	<pubDate>2024-09-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 425-443: Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/4/21">doi: 10.3390/receptors3040021</a></p>
	<p>Authors:
		Naresh Sah
		Abdul Althaf Shaik
		Ganesh Acharya
		Manikantha Dunna
		Ashok Silwal
		Sejal Sharma
		Sabiha Khan
		Sounak Bagchi
		</p>
	<p>This review article explores the fundamental role of receptor targeting in overcoming drug resistance in cancer therapy, an area of critical concern given the persistently high rates of cancer morbidity and mortality globally. We highlight how receptor biology intersects with the development of therapeutic resistance with a specific focus on anti-angiogenic agents, immune checkpoint inhibitors, and monoclonal antibodies, which directly or indirectly influence receptor pathways. We also explore how other receptor tyrosine kinases can initially suppress tumor growth, yet often lead to resistance, underscoring the need for novel combinatorial approaches that incorporate advanced receptor modulation techniques. Further, the review delves into the mechanisms by which modulation of the tumor microenvironment and immune system via receptor pathways can overcome resistance to traditional immunotherapies. Additionally, emerging technologies in receptor-targeted nanomedicine are also highlighted, showcasing their potential to revolutionize drug delivery and improve therapeutic outcomes by targeting specific receptor interactions. Ultimately, this review calls for a deeper understanding of receptor dynamics to develop more precise interventions, including insights from various healthcare settings that can prevent or circumvent drug resistance, thus enhancing patient outcomes in oncology.</p>
	]]></content:encoded>

	<dc:title>Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy</dc:title>
			<dc:creator>Naresh Sah</dc:creator>
			<dc:creator>Abdul Althaf Shaik</dc:creator>
			<dc:creator>Ganesh Acharya</dc:creator>
			<dc:creator>Manikantha Dunna</dc:creator>
			<dc:creator>Ashok Silwal</dc:creator>
			<dc:creator>Sejal Sharma</dc:creator>
			<dc:creator>Sabiha Khan</dc:creator>
			<dc:creator>Sounak Bagchi</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3040021</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-09-24</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-09-24</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>425</prism:startingPage>
		<prism:doi>10.3390/receptors3040021</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/4/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/3/20">

	<title>Receptors, Vol. 3, Pages 408-424: Protein SUMOylation and Its Functional Role in Nuclear Receptor Control</title>
	<link>https://www.mdpi.com/2813-2564/3/3/20</link>
	<description>Post-translational protein modifications (PTMs) significantly enhance the functional diversity of proteins and are therefore important for the expansion and the dynamics of the cell&amp;amp;rsquo;s proteome. In addition to structurally simpler PTMs, substrates also undergo modification through the reversible attachment of small proteins. The best understood PTM of this nature to date is the covalent conjugation of ubiquitin and ubiquitin-like proteins (UBLs) to their substrates. The protein family of small ubiquitin-like modifier (SUMO) is one of these UBLs that has received increasing scientific attention. The pathway of SUMOylation is highly conserved in all eukaryotic cells and is crucial for their survival. It plays an essential role in many biological processes, such as the maintenance of genomic integrity, transcriptional regulation, gene expression, and the regulation of intracellular signal transduction, and thereby influences DNA damage repair, immune responses, cell cycle progression, and apoptosis. Several studies have already shown that in this context protein SUMOylation is involved in the control mechanisms of various cellular receptors. This article unites data from different studies focusing on the investigation of the strictly conserved three-step enzyme cascade of protein SUMOylation and the functional analysis of the involved proteins E1, E2, and E3 and SUMOylation target proteins. Furthermore, this review highlights the role of nuclear receptor SUMOylation and its importance for the cellular functionality and disease development arising from defects in correct protein SUMOylation.</description>
	<pubDate>2024-09-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 408-424: Protein SUMOylation and Its Functional Role in Nuclear Receptor Control</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/3/20">doi: 10.3390/receptors3030020</a></p>
	<p>Authors:
		Nele Wild
		Charlotte Sophia Kaiser
		Gerhard Wunderlich
		Eva Liebau
		Carsten Wrenger
		</p>
	<p>Post-translational protein modifications (PTMs) significantly enhance the functional diversity of proteins and are therefore important for the expansion and the dynamics of the cell&amp;amp;rsquo;s proteome. In addition to structurally simpler PTMs, substrates also undergo modification through the reversible attachment of small proteins. The best understood PTM of this nature to date is the covalent conjugation of ubiquitin and ubiquitin-like proteins (UBLs) to their substrates. The protein family of small ubiquitin-like modifier (SUMO) is one of these UBLs that has received increasing scientific attention. The pathway of SUMOylation is highly conserved in all eukaryotic cells and is crucial for their survival. It plays an essential role in many biological processes, such as the maintenance of genomic integrity, transcriptional regulation, gene expression, and the regulation of intracellular signal transduction, and thereby influences DNA damage repair, immune responses, cell cycle progression, and apoptosis. Several studies have already shown that in this context protein SUMOylation is involved in the control mechanisms of various cellular receptors. This article unites data from different studies focusing on the investigation of the strictly conserved three-step enzyme cascade of protein SUMOylation and the functional analysis of the involved proteins E1, E2, and E3 and SUMOylation target proteins. Furthermore, this review highlights the role of nuclear receptor SUMOylation and its importance for the cellular functionality and disease development arising from defects in correct protein SUMOylation.</p>
	]]></content:encoded>

	<dc:title>Protein SUMOylation and Its Functional Role in Nuclear Receptor Control</dc:title>
			<dc:creator>Nele Wild</dc:creator>
			<dc:creator>Charlotte Sophia Kaiser</dc:creator>
			<dc:creator>Gerhard Wunderlich</dc:creator>
			<dc:creator>Eva Liebau</dc:creator>
			<dc:creator>Carsten Wrenger</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3030020</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-09-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-09-03</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>408</prism:startingPage>
		<prism:doi>10.3390/receptors3030020</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/3/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/3/19">

	<title>Receptors, Vol. 3, Pages 397-407: The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding</title>
	<link>https://www.mdpi.com/2813-2564/3/3/19</link>
	<description>Chronic skin wounds are estimated to affect 6.5 million patients in the US, at a cost of over USD 25 billion. Efforts to prevent and/or treat such wounds will result in reduced morbidity and economic losses. This project is focused on the role of vitamin D signaling in the epidermis in the control of stem cell (SC) activation and function during the initial response to the wounding of the skin, a response that, if defective, contributes to poor wound healing or cancer. In this review, I first describe the anatomy of the skin, focusing first on the epidermis, describing the different cell layers which in a spatial way also represent the differentiation process of the interfollicular epidermis (IFE) as it undergoes continuous regeneration. I then describe the other components of the skin, particularly the hair follicle (HF), which undergoes a cyclic pattern of regeneration. Adult SCs residing in these regenerative tissues play essential roles in the maintenance of these tissues. However, when the skin is wounded, the progeny of SCs from all regions of the HF and IFE contribute to the healing process by changing their initial cell fate to take on an epithelial genotype/phenotype to heal the wound. Although earlier lineage tracing studies helped to define the contributions SCs from the different niches made to wound healing, scRNAseq studies have demonstrated a considerably more nuanced picture. The role of vitamin D signaling will be introduced by reviewing the unique role played by the epidermal keratinocyte first in producing vitamin D and then in metabolizing it into its active form 1,25(OH)2D. 1,25(OH)2D is the principal ligand for the vitamin D receptor (VDR), a transcription factor that helps to mediate the genomic changes in the stem cells in their response to wounding. In these actions, the VDR is regulated by coregulators, of which the steroid receptor coactivator complexes SRC 2 and 3 and the mediator complex (MED) play essential roles. The VDR generally acts in association with other transcription factors such as p63 and &amp;amp;beta;-catenin that can colocalize with the VDR in the genes it regulates. Although much remains to be understood, the role of the VDR in the stem cell response to wounding is clearly essential and quite different from its classic roles in regulating calcium metabolism, although calcium is essential for the actions of vitamin D signaling in the skin.</description>
	<pubDate>2024-08-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 397-407: The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/3/19">doi: 10.3390/receptors3030019</a></p>
	<p>Authors:
		Daniel D. Bikle
		</p>
	<p>Chronic skin wounds are estimated to affect 6.5 million patients in the US, at a cost of over USD 25 billion. Efforts to prevent and/or treat such wounds will result in reduced morbidity and economic losses. This project is focused on the role of vitamin D signaling in the epidermis in the control of stem cell (SC) activation and function during the initial response to the wounding of the skin, a response that, if defective, contributes to poor wound healing or cancer. In this review, I first describe the anatomy of the skin, focusing first on the epidermis, describing the different cell layers which in a spatial way also represent the differentiation process of the interfollicular epidermis (IFE) as it undergoes continuous regeneration. I then describe the other components of the skin, particularly the hair follicle (HF), which undergoes a cyclic pattern of regeneration. Adult SCs residing in these regenerative tissues play essential roles in the maintenance of these tissues. However, when the skin is wounded, the progeny of SCs from all regions of the HF and IFE contribute to the healing process by changing their initial cell fate to take on an epithelial genotype/phenotype to heal the wound. Although earlier lineage tracing studies helped to define the contributions SCs from the different niches made to wound healing, scRNAseq studies have demonstrated a considerably more nuanced picture. The role of vitamin D signaling will be introduced by reviewing the unique role played by the epidermal keratinocyte first in producing vitamin D and then in metabolizing it into its active form 1,25(OH)2D. 1,25(OH)2D is the principal ligand for the vitamin D receptor (VDR), a transcription factor that helps to mediate the genomic changes in the stem cells in their response to wounding. In these actions, the VDR is regulated by coregulators, of which the steroid receptor coactivator complexes SRC 2 and 3 and the mediator complex (MED) play essential roles. The VDR generally acts in association with other transcription factors such as p63 and &amp;amp;beta;-catenin that can colocalize with the VDR in the genes it regulates. Although much remains to be understood, the role of the VDR in the stem cell response to wounding is clearly essential and quite different from its classic roles in regulating calcium metabolism, although calcium is essential for the actions of vitamin D signaling in the skin.</p>
	]]></content:encoded>

	<dc:title>The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding</dc:title>
			<dc:creator>Daniel D. Bikle</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3030019</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-08-09</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-08-09</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>397</prism:startingPage>
		<prism:doi>10.3390/receptors3030019</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/3/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/3/18">

	<title>Receptors, Vol. 3, Pages 380-396: Comparison of Agonist Activity between CB1 and CB2 Receptors with Orthosteric Site Mutations</title>
	<link>https://www.mdpi.com/2813-2564/3/3/18</link>
	<description>Human endocannabinoid signaling is primarily mediated by the cannabinoid receptors, CB1 and CB2, which are G protein-coupled receptors (GPCRs). These receptors have been linked to a variety of physiological processes and are being pursued as prospective drug targets due to their potential in treating pain and inflammation. However, because of their homology and shared signaling mechanisms, investigating the individual physiological roles of these receptors and designing subtype-selective ligands has been challenging. Using active-state CB1 and CB2 structures as guides, homologous residues within the orthosteric pocket of each receptor were mutated to alanine to test whether they equally impair CB1 and CB2 activity in response to two high-affinity, nonselective agonists (CP55,940 and AM12033). Interestingly, mutating the Y5.39 position impairs CB1 but not CB2 function. Conversely, mutating residue C6.47 improves CB1 but impairs CB2 signaling. The F7.35A mutation leads to a decrease in CP55,940 potency at CB1 and impairs internalization; however, AM12033 gains potency and promotes CB1 internalization. In CB2, mutation of F7.35A decreases the potency of CP55,940 and neither agonist induces internalization. These observations provide some insight into functional sensitivity of CB1 and CB2 to different agonists when conserved residues are mutated in the orthosteric pocket.</description>
	<pubDate>2024-08-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 380-396: Comparison of Agonist Activity between CB1 and CB2 Receptors with Orthosteric Site Mutations</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/3/18">doi: 10.3390/receptors3030018</a></p>
	<p>Authors:
		Christina A. Brust
		Matthew A. Swanson
		Christos Iliopoulos Tsoutsouvas
		Snezana T. Dimova
		Vuong Q. Dang
		Edward L. Stahl
		Jo-Hao Ho
		Spyros P. Nikas
		Alexandros Makriyannis
		Laura M. Bohn
		</p>
	<p>Human endocannabinoid signaling is primarily mediated by the cannabinoid receptors, CB1 and CB2, which are G protein-coupled receptors (GPCRs). These receptors have been linked to a variety of physiological processes and are being pursued as prospective drug targets due to their potential in treating pain and inflammation. However, because of their homology and shared signaling mechanisms, investigating the individual physiological roles of these receptors and designing subtype-selective ligands has been challenging. Using active-state CB1 and CB2 structures as guides, homologous residues within the orthosteric pocket of each receptor were mutated to alanine to test whether they equally impair CB1 and CB2 activity in response to two high-affinity, nonselective agonists (CP55,940 and AM12033). Interestingly, mutating the Y5.39 position impairs CB1 but not CB2 function. Conversely, mutating residue C6.47 improves CB1 but impairs CB2 signaling. The F7.35A mutation leads to a decrease in CP55,940 potency at CB1 and impairs internalization; however, AM12033 gains potency and promotes CB1 internalization. In CB2, mutation of F7.35A decreases the potency of CP55,940 and neither agonist induces internalization. These observations provide some insight into functional sensitivity of CB1 and CB2 to different agonists when conserved residues are mutated in the orthosteric pocket.</p>
	]]></content:encoded>

	<dc:title>Comparison of Agonist Activity between CB1 and CB2 Receptors with Orthosteric Site Mutations</dc:title>
			<dc:creator>Christina A. Brust</dc:creator>
			<dc:creator>Matthew A. Swanson</dc:creator>
			<dc:creator>Christos Iliopoulos Tsoutsouvas</dc:creator>
			<dc:creator>Snezana T. Dimova</dc:creator>
			<dc:creator>Vuong Q. Dang</dc:creator>
			<dc:creator>Edward L. Stahl</dc:creator>
			<dc:creator>Jo-Hao Ho</dc:creator>
			<dc:creator>Spyros P. Nikas</dc:creator>
			<dc:creator>Alexandros Makriyannis</dc:creator>
			<dc:creator>Laura M. Bohn</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3030018</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-08-06</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-08-06</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>380</prism:startingPage>
		<prism:doi>10.3390/receptors3030018</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/3/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/3/17">

	<title>Receptors, Vol. 3, Pages 362-379: Current Evidence of Natural Products against Overweight and Obesity: Molecular Targets and Mechanisms of Action</title>
	<link>https://www.mdpi.com/2813-2564/3/3/17</link>
	<description>Overweight and obesity are global health and economic concerns. This disease can affect every system of the human body and can lead to complications such as metabolic syndrome, diabetes, cancer, dyslipidemia, cardiovascular diseases, and hypertension, among others. Treatment may sometimes include diet, exercise, drugs, and bariatric surgery. Nonetheless, not all people have access to these treatments, and public health strategies consider prevention the most important factor. In this regard, recent investigations are aiming to find alternatives and adjuvants for the treatment of obesity, its prevention, and the reversion of some of its complications, using natural sources of anti-obesogenic compounds like polyphenols, terpenes, alkaloids, and saponins, among others. In this review, we gather the most current information using PubMed, Google Scholar, Scopus, Cochrane, and the Web of Science. We present and discuss the current information about natural products that have shown anti-obesogenic effects at a molecular level. We also consider the impact of dietary habits and lifestyle on preventing overweight and obesity due to the evidence of the benefits of certain foods and compounds consumed regularly. We discuss mechanisms, pathways, and receptors involved in the modulation of obesity, especially those related to inflammation and oxidative stress linked to this disease, due to the relevance of these two aspects in developing complications.</description>
	<pubDate>2024-07-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 362-379: Current Evidence of Natural Products against Overweight and Obesity: Molecular Targets and Mechanisms of Action</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/3/17">doi: 10.3390/receptors3030017</a></p>
	<p>Authors:
		Cristina Alicia Elizalde-Romero
		Nayely Leyva-López
		Laura Aracely Contreras-Angulo
		Rigoberto Cabanillas Ponce de-León
		Libia Zulema Rodriguez-Anaya
		Josefina León-Félix
		J. Basilio Heredia
		Saul Armando Beltrán-Ontiveros
		Erick Paul Gutiérrez-Grijalva
		</p>
	<p>Overweight and obesity are global health and economic concerns. This disease can affect every system of the human body and can lead to complications such as metabolic syndrome, diabetes, cancer, dyslipidemia, cardiovascular diseases, and hypertension, among others. Treatment may sometimes include diet, exercise, drugs, and bariatric surgery. Nonetheless, not all people have access to these treatments, and public health strategies consider prevention the most important factor. In this regard, recent investigations are aiming to find alternatives and adjuvants for the treatment of obesity, its prevention, and the reversion of some of its complications, using natural sources of anti-obesogenic compounds like polyphenols, terpenes, alkaloids, and saponins, among others. In this review, we gather the most current information using PubMed, Google Scholar, Scopus, Cochrane, and the Web of Science. We present and discuss the current information about natural products that have shown anti-obesogenic effects at a molecular level. We also consider the impact of dietary habits and lifestyle on preventing overweight and obesity due to the evidence of the benefits of certain foods and compounds consumed regularly. We discuss mechanisms, pathways, and receptors involved in the modulation of obesity, especially those related to inflammation and oxidative stress linked to this disease, due to the relevance of these two aspects in developing complications.</p>
	]]></content:encoded>

	<dc:title>Current Evidence of Natural Products against Overweight and Obesity: Molecular Targets and Mechanisms of Action</dc:title>
			<dc:creator>Cristina Alicia Elizalde-Romero</dc:creator>
			<dc:creator>Nayely Leyva-López</dc:creator>
			<dc:creator>Laura Aracely Contreras-Angulo</dc:creator>
			<dc:creator>Rigoberto Cabanillas Ponce de-León</dc:creator>
			<dc:creator>Libia Zulema Rodriguez-Anaya</dc:creator>
			<dc:creator>Josefina León-Félix</dc:creator>
			<dc:creator>J. Basilio Heredia</dc:creator>
			<dc:creator>Saul Armando Beltrán-Ontiveros</dc:creator>
			<dc:creator>Erick Paul Gutiérrez-Grijalva</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3030017</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-07-11</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-07-11</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>362</prism:startingPage>
		<prism:doi>10.3390/receptors3030017</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/3/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/3/16">

	<title>Receptors, Vol. 3, Pages 323-361: Receptor-Targeted Nanomedicine for Cancer Therapy</title>
	<link>https://www.mdpi.com/2813-2564/3/3/16</link>
	<description>Receptor-targeted drug delivery has been extensively explored for active targeting of therapeutic moiety in cancer treatment. In this review, we discuss the receptors that are overexpressed on tumor cells and have the potential to be targeted by nanocarrier systems for cancer treatment. We also highlight the different types of nanocarrier systems and targeting ligands that researchers have explored. Our discussion covers various therapeutic modalities, including small molecules, aptamers, peptides, antibodies, and cell-based targeting strategies, and focuses on clinical developments. Additionally, this article highlights the challenges that arise during the clinical translation of nanocarrier-based targeting strategies. It also provides future directions for improving research in the area of clinically translatable cancer-targeted therapy to improve treatment efficacy while minimizing toxicity.</description>
	<pubDate>2024-07-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 323-361: Receptor-Targeted Nanomedicine for Cancer Therapy</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/3/16">doi: 10.3390/receptors3030016</a></p>
	<p>Authors:
		Arvee Prajapati
		Shagun Rangra
		Rashmi Patil
		Nimeet Desai
		Vaskuri G. S. Sainaga Jyothi
		Sagar Salave
		Prakash Amate
		Derajram Benival
		Nagavendra Kommineni
		</p>
	<p>Receptor-targeted drug delivery has been extensively explored for active targeting of therapeutic moiety in cancer treatment. In this review, we discuss the receptors that are overexpressed on tumor cells and have the potential to be targeted by nanocarrier systems for cancer treatment. We also highlight the different types of nanocarrier systems and targeting ligands that researchers have explored. Our discussion covers various therapeutic modalities, including small molecules, aptamers, peptides, antibodies, and cell-based targeting strategies, and focuses on clinical developments. Additionally, this article highlights the challenges that arise during the clinical translation of nanocarrier-based targeting strategies. It also provides future directions for improving research in the area of clinically translatable cancer-targeted therapy to improve treatment efficacy while minimizing toxicity.</p>
	]]></content:encoded>

	<dc:title>Receptor-Targeted Nanomedicine for Cancer Therapy</dc:title>
			<dc:creator>Arvee Prajapati</dc:creator>
			<dc:creator>Shagun Rangra</dc:creator>
			<dc:creator>Rashmi Patil</dc:creator>
			<dc:creator>Nimeet Desai</dc:creator>
			<dc:creator>Vaskuri G. S. Sainaga Jyothi</dc:creator>
			<dc:creator>Sagar Salave</dc:creator>
			<dc:creator>Prakash Amate</dc:creator>
			<dc:creator>Derajram Benival</dc:creator>
			<dc:creator>Nagavendra Kommineni</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3030016</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-07-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-07-03</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>323</prism:startingPage>
		<prism:doi>10.3390/receptors3030016</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/3/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/3/15">

	<title>Receptors, Vol. 3, Pages 304-322: Targeting Liver X Receptors in Cancer Drug Discovery</title>
	<link>https://www.mdpi.com/2813-2564/3/3/15</link>
	<description>Liver X receptors (LXRs) are members of the nuclear receptor superfamily of ligand-dependent transcription factors. LXR&amp;amp;alpha; is predominantly expressed in metabolic tissues, whereas LXR&amp;amp;beta; is ubiquitously expressed. Upon ligand binding, they regulate the expression of target genes involved in lipid metabolism, cholesterol homeostasis, and immune responses, including those which function in pathways that are commonly reprogrammed during carcinogenesis. Known LXR ligands include oxysterols and natural and synthetic agonists which upregulate LXR transcriptional activity and target gene expression. Synthetic inverse agonists have also been identified that inhibit LXR activity. While both types of ligands have been shown to inhibit cancer cells and tumor growth either directly or indirectly by modulating the activities of stromal cells within the tumor microenvironment, they appear to target different aspects of cancer metabolism and other cancer hallmarks, including immune evasion. This review summarizes the characterization of LXRs and their ligands and their mechanisms of action in cancer models and discusses the future directions for translating these discoveries into novel cancer therapeutics.</description>
	<pubDate>2024-06-29</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 304-322: Targeting Liver X Receptors in Cancer Drug Discovery</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/3/15">doi: 10.3390/receptors3030015</a></p>
	<p>Authors:
		Asitha Premaratne
		Abhinav Bagchi
		Shinjini Basu
		Jan-Åke Gustafsson
		Chin-Yo Lin
		</p>
	<p>Liver X receptors (LXRs) are members of the nuclear receptor superfamily of ligand-dependent transcription factors. LXR&amp;amp;alpha; is predominantly expressed in metabolic tissues, whereas LXR&amp;amp;beta; is ubiquitously expressed. Upon ligand binding, they regulate the expression of target genes involved in lipid metabolism, cholesterol homeostasis, and immune responses, including those which function in pathways that are commonly reprogrammed during carcinogenesis. Known LXR ligands include oxysterols and natural and synthetic agonists which upregulate LXR transcriptional activity and target gene expression. Synthetic inverse agonists have also been identified that inhibit LXR activity. While both types of ligands have been shown to inhibit cancer cells and tumor growth either directly or indirectly by modulating the activities of stromal cells within the tumor microenvironment, they appear to target different aspects of cancer metabolism and other cancer hallmarks, including immune evasion. This review summarizes the characterization of LXRs and their ligands and their mechanisms of action in cancer models and discusses the future directions for translating these discoveries into novel cancer therapeutics.</p>
	]]></content:encoded>

	<dc:title>Targeting Liver X Receptors in Cancer Drug Discovery</dc:title>
			<dc:creator>Asitha Premaratne</dc:creator>
			<dc:creator>Abhinav Bagchi</dc:creator>
			<dc:creator>Shinjini Basu</dc:creator>
			<dc:creator>Jan-Åke Gustafsson</dc:creator>
			<dc:creator>Chin-Yo Lin</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3030015</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-06-29</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-06-29</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>304</prism:startingPage>
		<prism:doi>10.3390/receptors3030015</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/3/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/14">

	<title>Receptors, Vol. 3, Pages 280-303: Receptors Implicated in Microgravity-Induced Bone Loss</title>
	<link>https://www.mdpi.com/2813-2564/3/2/14</link>
	<description>For humans to explore and colonize the universe, both engineering and physiological obstacles must be successfully addressed. A major physiological problem is that humans lose bone rapidly in microgravity. Understanding the underlying mechanisms for this bone loss is crucial for designing strategies to ameliorate these effects. Because bone physiology is entangled with other organ systems, and bone loss is a component of human adaptation to microgravity, strategies to reduce bone loss must also account for potential effects on other systems. Here, we consider the receptors involved in normal bone remodeling and how this regulation is altered in low-gravity environments. We examine how single cells, tissues and organs, and humans as a whole are affected by low gravity, and the role of receptors that have been implicated in responses leading to bone loss. These include receptors linking cells to the extracellular matrix and to each other, alterations in the extracellular matrix associated with changes in gravity, and changes in fluid distribution and fluid behavior due to lack of gravity that may have effects on receptor-based signaling shared by bone and other regulatory systems. Inflammatory responses associated with the environment in space, which include microgravity and radiation, can also potentially trigger bone loss.</description>
	<pubDate>2024-06-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 280-303: Receptors Implicated in Microgravity-Induced Bone Loss</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/14">doi: 10.3390/receptors3020014</a></p>
	<p>Authors:
		Elizabeth Ferreira Martinez
		André Antonio Pelegrine
		L. Shannon Holliday
		</p>
	<p>For humans to explore and colonize the universe, both engineering and physiological obstacles must be successfully addressed. A major physiological problem is that humans lose bone rapidly in microgravity. Understanding the underlying mechanisms for this bone loss is crucial for designing strategies to ameliorate these effects. Because bone physiology is entangled with other organ systems, and bone loss is a component of human adaptation to microgravity, strategies to reduce bone loss must also account for potential effects on other systems. Here, we consider the receptors involved in normal bone remodeling and how this regulation is altered in low-gravity environments. We examine how single cells, tissues and organs, and humans as a whole are affected by low gravity, and the role of receptors that have been implicated in responses leading to bone loss. These include receptors linking cells to the extracellular matrix and to each other, alterations in the extracellular matrix associated with changes in gravity, and changes in fluid distribution and fluid behavior due to lack of gravity that may have effects on receptor-based signaling shared by bone and other regulatory systems. Inflammatory responses associated with the environment in space, which include microgravity and radiation, can also potentially trigger bone loss.</p>
	]]></content:encoded>

	<dc:title>Receptors Implicated in Microgravity-Induced Bone Loss</dc:title>
			<dc:creator>Elizabeth Ferreira Martinez</dc:creator>
			<dc:creator>André Antonio Pelegrine</dc:creator>
			<dc:creator>L. Shannon Holliday</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020014</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-06-13</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-06-13</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>280</prism:startingPage>
		<prism:doi>10.3390/receptors3020014</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/13">

	<title>Receptors, Vol. 3, Pages 255-279: Deciphering the Role of Virus Receptors in Plant&amp;ndash;Virus&amp;ndash;Vector Interactions</title>
	<link>https://www.mdpi.com/2813-2564/3/2/13</link>
	<description>Insect-transmitted plant viruses are a major threat to global agricultural crop production. Receptors play a prominent role in the interplay between host-pathogen and vector interaction. The virus&amp;amp;ndash;vector relationship involves both viral and vector receptors. Receptors-like kinases (RLKs) and receptor-like proteins play a crucial role in plant immunity, which acts as a basal defense. Pathogens can evade or block host recognition by their effector proteins to inhibit pathogen recognition receptor (PRR)-mediated signaling. Intriguingly, RLKs are also known to interact with viral proteins and impact plant susceptibility against viruses, while the endocytic receptors in vectors assist in the binding of the virus to the vectors. Unlike other receptors of fungi and bacteria which have three different domains located from extracellular or intracellular to perceive a multitude of molecular patterns, the characterization of viral receptors is quite complex and limited since the virus is directly injected into plant cells by insect vectors. Little is known about these receptors. Unraveling the receptors involved in virus entry and transmission within the vector will provide vital information in virus&amp;amp;ndash;vector interactions. This review focuses on efforts undertaken in the identification and characterization of receptors of plant viruses within the host and vector. This will lead to a better understanding of the cellular mechanism of virus transmission and spread, and further suggests new alternative tools for researchers to develop an integrated approach for the management of viral diseases and associated vectors.</description>
	<pubDate>2024-06-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 255-279: Deciphering the Role of Virus Receptors in Plant&amp;ndash;Virus&amp;ndash;Vector Interactions</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/13">doi: 10.3390/receptors3020013</a></p>
	<p>Authors:
		Sumit Jangra
		Senthilraja Chinnaiah
		Sneha Rashtrapal Patil
		Bhavya Shukla
		Ragunathan Devendran
		Manish Kumar
		</p>
	<p>Insect-transmitted plant viruses are a major threat to global agricultural crop production. Receptors play a prominent role in the interplay between host-pathogen and vector interaction. The virus&amp;amp;ndash;vector relationship involves both viral and vector receptors. Receptors-like kinases (RLKs) and receptor-like proteins play a crucial role in plant immunity, which acts as a basal defense. Pathogens can evade or block host recognition by their effector proteins to inhibit pathogen recognition receptor (PRR)-mediated signaling. Intriguingly, RLKs are also known to interact with viral proteins and impact plant susceptibility against viruses, while the endocytic receptors in vectors assist in the binding of the virus to the vectors. Unlike other receptors of fungi and bacteria which have three different domains located from extracellular or intracellular to perceive a multitude of molecular patterns, the characterization of viral receptors is quite complex and limited since the virus is directly injected into plant cells by insect vectors. Little is known about these receptors. Unraveling the receptors involved in virus entry and transmission within the vector will provide vital information in virus&amp;amp;ndash;vector interactions. This review focuses on efforts undertaken in the identification and characterization of receptors of plant viruses within the host and vector. This will lead to a better understanding of the cellular mechanism of virus transmission and spread, and further suggests new alternative tools for researchers to develop an integrated approach for the management of viral diseases and associated vectors.</p>
	]]></content:encoded>

	<dc:title>Deciphering the Role of Virus Receptors in Plant&amp;amp;ndash;Virus&amp;amp;ndash;Vector Interactions</dc:title>
			<dc:creator>Sumit Jangra</dc:creator>
			<dc:creator>Senthilraja Chinnaiah</dc:creator>
			<dc:creator>Sneha Rashtrapal Patil</dc:creator>
			<dc:creator>Bhavya Shukla</dc:creator>
			<dc:creator>Ragunathan Devendran</dc:creator>
			<dc:creator>Manish Kumar</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020013</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-06-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-06-03</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>255</prism:startingPage>
		<prism:doi>10.3390/receptors3020013</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/12">

	<title>Receptors, Vol. 3, Pages 220-254: The G Protein-Coupled Estrogen Receptor GPER in the Development and Progression of Cancer</title>
	<link>https://www.mdpi.com/2813-2564/3/2/12</link>
	<description>The high incidence of cancer and the prevalence of chemoresistance are serious problems worldwide, underscoring the urgency of novel research focused on understanding the underlying mechanisms and finding new therapeutic targets. Recently, the G protein-coupled estrogen receptor (GPER) has received increasing attention, and it has been studied in various models, including physiological and pathological conditions, using appropriate pharmacological and molecular biological strategies. Numerous studies indicate that GPER plays an important role in cancer progression and resistance. This review focuses on the structure of GPER, the diversity of its ligands and GPER-activated signaling pathways, the role of GPER in cancer progression, and mechanisms of chemoresistance, with special emphasis on different cancer types and the tumor microenvironment. GPER was evidenced to exhibit conformational plasticity and different ligand binding modes. Therefore, GPER-mediated effects can be triggered by estrogens or various estrogen mimetics, including synthesized compounds, licensed drugs, or exogenous environmental compounds. We found multiple reports evidencing that GPER is differentially expressed in healthy tissues and tumors and plays a protumor role in breast, ovarian, lung, thyroid, and endometrial cancers. Additionally, there are several studies that indicate that GPER expression in cells of the tumor microenvironment may also contribute to cancer progression. Among the major mechanisms of GPER-mediated chemoresistance are the epithelial-mesenchymal transition, the overexpression of multidrug resistance pumps, and autophagy regulation.</description>
	<pubDate>2024-05-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 220-254: The G Protein-Coupled Estrogen Receptor GPER in the Development and Progression of Cancer</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/12">doi: 10.3390/receptors3020012</a></p>
	<p>Authors:
		Liliana Torres-López
		Miguel Olivas-Aguirre
		Oxana Dobrovinskaya
		</p>
	<p>The high incidence of cancer and the prevalence of chemoresistance are serious problems worldwide, underscoring the urgency of novel research focused on understanding the underlying mechanisms and finding new therapeutic targets. Recently, the G protein-coupled estrogen receptor (GPER) has received increasing attention, and it has been studied in various models, including physiological and pathological conditions, using appropriate pharmacological and molecular biological strategies. Numerous studies indicate that GPER plays an important role in cancer progression and resistance. This review focuses on the structure of GPER, the diversity of its ligands and GPER-activated signaling pathways, the role of GPER in cancer progression, and mechanisms of chemoresistance, with special emphasis on different cancer types and the tumor microenvironment. GPER was evidenced to exhibit conformational plasticity and different ligand binding modes. Therefore, GPER-mediated effects can be triggered by estrogens or various estrogen mimetics, including synthesized compounds, licensed drugs, or exogenous environmental compounds. We found multiple reports evidencing that GPER is differentially expressed in healthy tissues and tumors and plays a protumor role in breast, ovarian, lung, thyroid, and endometrial cancers. Additionally, there are several studies that indicate that GPER expression in cells of the tumor microenvironment may also contribute to cancer progression. Among the major mechanisms of GPER-mediated chemoresistance are the epithelial-mesenchymal transition, the overexpression of multidrug resistance pumps, and autophagy regulation.</p>
	]]></content:encoded>

	<dc:title>The G Protein-Coupled Estrogen Receptor GPER in the Development and Progression of Cancer</dc:title>
			<dc:creator>Liliana Torres-López</dc:creator>
			<dc:creator>Miguel Olivas-Aguirre</dc:creator>
			<dc:creator>Oxana Dobrovinskaya</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020012</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-05-27</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-05-27</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>220</prism:startingPage>
		<prism:doi>10.3390/receptors3020012</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/11">

	<title>Receptors, Vol. 3, Pages 201-219: An Evaluation of the Anxiolytic Potential of Amentoflavone in Adult Zebrafish Undergoing Alcohol Withdrawal: In Vivo and In Silico Studies</title>
	<link>https://www.mdpi.com/2813-2564/3/2/11</link>
	<description>The constant use of alcoholic beverages can deregulate serotonin levels, affecting neurotransmitters and triggering symptoms of anxiety. In this context, the objective of this work was to evaluate the anxiolytic potential and possible action mechanisms of the natural compound amentoflavone against the deleterious effects caused by alcohol withdrawal on the behavior of adult zebrafish (aZF). The experiments showed that amentoflavone did not change locomotion and did not cause toxicity in aZF during up to 96 h of analysis, with a median lethal concentration (LC50) greater than 1.0 mg/mL. The reversal of anxiety by pretreatment with granisetron suggested that the anxiolytic effect of amentoflavone is dependent on serotonergic 5-HT3A/3B receptors. Furthermore, amentoflavone reversed anxiety due to flumazenil pretreatment, suggesting a dependence on the GABAA receptor. The three concentrations of amentoflavone tested were effective in treating anxiety resulting from alcohol withdrawal. In silico analysis validated the in vivo results, supporting the idea that the interaction of amentoflavone with the protein occurs in a more stable manner than reference compounds. Amid growing interest in natural alternatives to treat anxiety disorders, amentoflavone is a potential candidate for a new anxiolytic compound that acts specifically on the 5HT3A/3B and GABAergic serotonergic pathways.</description>
	<pubDate>2024-05-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 201-219: An Evaluation of the Anxiolytic Potential of Amentoflavone in Adult Zebrafish Undergoing Alcohol Withdrawal: In Vivo and In Silico Studies</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/11">doi: 10.3390/receptors3020011</a></p>
	<p>Authors:
		Lucas Soares Frota
		Wildson Max Barbosa da Silva
		Daniela Ribeiro Alves
		Sacha Aubrey Alves Rodrigues Santos
		Gabriela Alves do Nascimento
		Francisco Ernani Alves Magalhães
		Adriana Rolim Campos
		Selene Maia de Morais
		</p>
	<p>The constant use of alcoholic beverages can deregulate serotonin levels, affecting neurotransmitters and triggering symptoms of anxiety. In this context, the objective of this work was to evaluate the anxiolytic potential and possible action mechanisms of the natural compound amentoflavone against the deleterious effects caused by alcohol withdrawal on the behavior of adult zebrafish (aZF). The experiments showed that amentoflavone did not change locomotion and did not cause toxicity in aZF during up to 96 h of analysis, with a median lethal concentration (LC50) greater than 1.0 mg/mL. The reversal of anxiety by pretreatment with granisetron suggested that the anxiolytic effect of amentoflavone is dependent on serotonergic 5-HT3A/3B receptors. Furthermore, amentoflavone reversed anxiety due to flumazenil pretreatment, suggesting a dependence on the GABAA receptor. The three concentrations of amentoflavone tested were effective in treating anxiety resulting from alcohol withdrawal. In silico analysis validated the in vivo results, supporting the idea that the interaction of amentoflavone with the protein occurs in a more stable manner than reference compounds. Amid growing interest in natural alternatives to treat anxiety disorders, amentoflavone is a potential candidate for a new anxiolytic compound that acts specifically on the 5HT3A/3B and GABAergic serotonergic pathways.</p>
	]]></content:encoded>

	<dc:title>An Evaluation of the Anxiolytic Potential of Amentoflavone in Adult Zebrafish Undergoing Alcohol Withdrawal: In Vivo and In Silico Studies</dc:title>
			<dc:creator>Lucas Soares Frota</dc:creator>
			<dc:creator>Wildson Max Barbosa da Silva</dc:creator>
			<dc:creator>Daniela Ribeiro Alves</dc:creator>
			<dc:creator>Sacha Aubrey Alves Rodrigues Santos</dc:creator>
			<dc:creator>Gabriela Alves do Nascimento</dc:creator>
			<dc:creator>Francisco Ernani Alves Magalhães</dc:creator>
			<dc:creator>Adriana Rolim Campos</dc:creator>
			<dc:creator>Selene Maia de Morais</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020011</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-05-10</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-05-10</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>201</prism:startingPage>
		<prism:doi>10.3390/receptors3020011</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/10">

	<title>Receptors, Vol. 3, Pages 182-200: Estrogen Signals through ER&amp;beta; in Breast Cancer; What We Have Learned since the Discovery of the Receptor</title>
	<link>https://www.mdpi.com/2813-2564/3/2/10</link>
	<description>Estrogen receptor (ER) &amp;amp;beta; (ER&amp;amp;beta;) is the second ER subtype that mediates the effects of estrogen in target tissues along with ER&amp;amp;alpha; that represents a validated biomarker and target for endocrine therapy in breast cancer. ER&amp;amp;alpha; was the only known ER subtype until 1996 when the discovery of ER&amp;amp;beta; opened a new chapter in endocrinology and prompted a thorough reevaluation of the estrogen signaling paradigm. Unlike the oncogenic ER&amp;amp;alpha;, ER&amp;amp;beta; has been proposed to function as a tumor suppressor in breast cancer, and extensive research is underway to uncover the full spectrum of ER&amp;amp;beta; activities and elucidate its mechanism of action. Recent studies have relied on new transgenic models to capture effects in normal and malignant breast that were not previously detected. They have also benefited from the development of highly specific synthetic ligands that are used to demonstrate distinct mechanisms of gene regulation in cancer. As a result, significant new information about the biology and clinical importance of ER&amp;amp;beta; is now available, which is the focus of discussion in the present article.</description>
	<pubDate>2024-05-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 182-200: Estrogen Signals through ER&amp;beta; in Breast Cancer; What We Have Learned since the Discovery of the Receptor</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/10">doi: 10.3390/receptors3020010</a></p>
	<p>Authors:
		Harika Nagandla
		Christoforos Thomas
		</p>
	<p>Estrogen receptor (ER) &amp;amp;beta; (ER&amp;amp;beta;) is the second ER subtype that mediates the effects of estrogen in target tissues along with ER&amp;amp;alpha; that represents a validated biomarker and target for endocrine therapy in breast cancer. ER&amp;amp;alpha; was the only known ER subtype until 1996 when the discovery of ER&amp;amp;beta; opened a new chapter in endocrinology and prompted a thorough reevaluation of the estrogen signaling paradigm. Unlike the oncogenic ER&amp;amp;alpha;, ER&amp;amp;beta; has been proposed to function as a tumor suppressor in breast cancer, and extensive research is underway to uncover the full spectrum of ER&amp;amp;beta; activities and elucidate its mechanism of action. Recent studies have relied on new transgenic models to capture effects in normal and malignant breast that were not previously detected. They have also benefited from the development of highly specific synthetic ligands that are used to demonstrate distinct mechanisms of gene regulation in cancer. As a result, significant new information about the biology and clinical importance of ER&amp;amp;beta; is now available, which is the focus of discussion in the present article.</p>
	]]></content:encoded>

	<dc:title>Estrogen Signals through ER&amp;amp;beta; in Breast Cancer; What We Have Learned since the Discovery of the Receptor</dc:title>
			<dc:creator>Harika Nagandla</dc:creator>
			<dc:creator>Christoforos Thomas</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020010</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-05-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-05-03</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>182</prism:startingPage>
		<prism:doi>10.3390/receptors3020010</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/9">

	<title>Receptors, Vol. 3, Pages 155-181: Dopamine D1&amp;ndash;D5 Receptors in Brain Nuclei: Implications for Health and Disease</title>
	<link>https://www.mdpi.com/2813-2564/3/2/9</link>
	<description>Understanding the intricate role of dopamine D1&amp;amp;ndash;D5 receptors is pivotal in addressing the challenges posed by the aging global population, as well as by social stress and advancing therapeutic interventions. Central to diverse brain functions such as movement, cognition, motivation, and reward, dopamine receptors are ubiquitously distributed across various brain nuclei. This comprehensive review explores the nuanced functions of each dopamine receptor, D1, D2, D3, D4, and D5, in distinct brain regions, elucidating the alterations witnessed in several neurological and psychiatric disorders. From the substantia nigra and ventral tegmental area, crucial for motor control and reward processing, to the limbic system influencing emotional responses, motivation, and cognitive functions, each brain nucleus reveals a specific involvement of dopamine receptors. In addition, genetic variations in dopamine receptors affect the risk of developing schizophrenia and parkinsonism. The review further investigates the physiological significance and pathogenic impacts of dopamine receptors in critical areas like the prefrontal cortex, hypothalamus, and striatum. By unraveling the complexities of dopamine receptor biology, especially those focused on different brain nuclei, this review provides a foundation for understanding their varied roles in health and disease, which is essential for the development of targeted therapeutic strategies aimed at mitigating the impact of aging and mental health on neurological well-being.</description>
	<pubDate>2024-04-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 155-181: Dopamine D1&amp;ndash;D5 Receptors in Brain Nuclei: Implications for Health and Disease</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/9">doi: 10.3390/receptors3020009</a></p>
	<p>Authors:
		Ichiro Kawahata
		David I. Finkelstein
		Kohji Fukunaga
		</p>
	<p>Understanding the intricate role of dopamine D1&amp;amp;ndash;D5 receptors is pivotal in addressing the challenges posed by the aging global population, as well as by social stress and advancing therapeutic interventions. Central to diverse brain functions such as movement, cognition, motivation, and reward, dopamine receptors are ubiquitously distributed across various brain nuclei. This comprehensive review explores the nuanced functions of each dopamine receptor, D1, D2, D3, D4, and D5, in distinct brain regions, elucidating the alterations witnessed in several neurological and psychiatric disorders. From the substantia nigra and ventral tegmental area, crucial for motor control and reward processing, to the limbic system influencing emotional responses, motivation, and cognitive functions, each brain nucleus reveals a specific involvement of dopamine receptors. In addition, genetic variations in dopamine receptors affect the risk of developing schizophrenia and parkinsonism. The review further investigates the physiological significance and pathogenic impacts of dopamine receptors in critical areas like the prefrontal cortex, hypothalamus, and striatum. By unraveling the complexities of dopamine receptor biology, especially those focused on different brain nuclei, this review provides a foundation for understanding their varied roles in health and disease, which is essential for the development of targeted therapeutic strategies aimed at mitigating the impact of aging and mental health on neurological well-being.</p>
	]]></content:encoded>

	<dc:title>Dopamine D1&amp;amp;ndash;D5 Receptors in Brain Nuclei: Implications for Health and Disease</dc:title>
			<dc:creator>Ichiro Kawahata</dc:creator>
			<dc:creator>David I. Finkelstein</dc:creator>
			<dc:creator>Kohji Fukunaga</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020009</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-04-12</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-04-12</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>155</prism:startingPage>
		<prism:doi>10.3390/receptors3020009</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/8">

	<title>Receptors, Vol. 3, Pages 145-154: Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases</title>
	<link>https://www.mdpi.com/2813-2564/3/2/8</link>
	<description>Neuroendocrine tumors (NETs) represent a diverse group of neoplasms originating from neuroendocrine cells, presenting varied clinical behaviors and posing significant challenges in management. This review explores the emerging roles of receptor tyrosine kinases (RTKs) in the pathogenesis and progression of NETs, including vascular endothelial growth factor receptors (VEGFRs), insulin-like growth factor receptors (IGF-1R), RET, epidermal growth factor receptor (EGFR), and ALK. The dysregulation of RTK signaling pathways contributes to key cellular processes such as proliferation, survival, and invasion in NETs. We discuss the potential of targeting RTKs as therapeutic strategies in NETs, with a focus on recent developments in RET inhibitors and the therapeutic implications of RTK alterations.</description>
	<pubDate>2024-04-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 145-154: Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/8">doi: 10.3390/receptors3020008</a></p>
	<p>Authors:
		Lara Toffoli
		Angeliki Ditsiou
		Teresa Gagliano
		</p>
	<p>Neuroendocrine tumors (NETs) represent a diverse group of neoplasms originating from neuroendocrine cells, presenting varied clinical behaviors and posing significant challenges in management. This review explores the emerging roles of receptor tyrosine kinases (RTKs) in the pathogenesis and progression of NETs, including vascular endothelial growth factor receptors (VEGFRs), insulin-like growth factor receptors (IGF-1R), RET, epidermal growth factor receptor (EGFR), and ALK. The dysregulation of RTK signaling pathways contributes to key cellular processes such as proliferation, survival, and invasion in NETs. We discuss the potential of targeting RTKs as therapeutic strategies in NETs, with a focus on recent developments in RET inhibitors and the therapeutic implications of RTK alterations.</p>
	]]></content:encoded>

	<dc:title>Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases</dc:title>
			<dc:creator>Lara Toffoli</dc:creator>
			<dc:creator>Angeliki Ditsiou</dc:creator>
			<dc:creator>Teresa Gagliano</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020008</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-04-05</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-04-05</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>145</prism:startingPage>
		<prism:doi>10.3390/receptors3020008</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/2/7">

	<title>Receptors, Vol. 3, Pages 122-144: Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?</title>
	<link>https://www.mdpi.com/2813-2564/3/2/7</link>
	<description>Recent research has emphasized the potential of natural and synthetic cannabinoids as anticancer agents. Yet it remains unclear whether and in which sense cannabinoids affect the anticancer activity of NK cells, an important branch of anticancer immunity. Similar uncertainty exists regarding NK cells-based immunotherapy. Here we presented an overview of multiple cannabinoid targets as canonical (mainly CB2) and non-canonical receptors, ion channels, transporters, and enzymes, expressed in NK cells, along with underlying molecular mechanisms. Through them, cannabinoids can affect viability, proliferation, migration, cytokine production, and the overall anticancer activity of NK cells. Respective holistic studies are limited, and, mostly, are phenomenological, not linking observed effects with certain molecular targets. Another problem of existing studies is the lack of standardisation, so that diverse cannabinoids at variable concentrations and ways of administration are applied, and often, instead of purified NK cells, the whole lymphocyte population is used. Therefore, there is an urgent need for more focused, systemic, and in-depth studies of the impact of the cannabinoid toolkit on NK cell function, to critically address the compatibility and potential synergies between NK activity and cannabinoid utilization in the realm of anticancer interventions.</description>
	<pubDate>2024-03-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 122-144: Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/2/7">doi: 10.3390/receptors3020007</a></p>
	<p>Authors:
		Miguel Olivas-Aguirre
		Cecilia Gutiérrez-Iñiguez
		Igor Pottosin
		Oxana Dobrovinskaya
		</p>
	<p>Recent research has emphasized the potential of natural and synthetic cannabinoids as anticancer agents. Yet it remains unclear whether and in which sense cannabinoids affect the anticancer activity of NK cells, an important branch of anticancer immunity. Similar uncertainty exists regarding NK cells-based immunotherapy. Here we presented an overview of multiple cannabinoid targets as canonical (mainly CB2) and non-canonical receptors, ion channels, transporters, and enzymes, expressed in NK cells, along with underlying molecular mechanisms. Through them, cannabinoids can affect viability, proliferation, migration, cytokine production, and the overall anticancer activity of NK cells. Respective holistic studies are limited, and, mostly, are phenomenological, not linking observed effects with certain molecular targets. Another problem of existing studies is the lack of standardisation, so that diverse cannabinoids at variable concentrations and ways of administration are applied, and often, instead of purified NK cells, the whole lymphocyte population is used. Therefore, there is an urgent need for more focused, systemic, and in-depth studies of the impact of the cannabinoid toolkit on NK cell function, to critically address the compatibility and potential synergies between NK activity and cannabinoid utilization in the realm of anticancer interventions.</p>
	]]></content:encoded>

	<dc:title>Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?</dc:title>
			<dc:creator>Miguel Olivas-Aguirre</dc:creator>
			<dc:creator>Cecilia Gutiérrez-Iñiguez</dc:creator>
			<dc:creator>Igor Pottosin</dc:creator>
			<dc:creator>Oxana Dobrovinskaya</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3020007</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-03-25</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-03-25</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>122</prism:startingPage>
		<prism:doi>10.3390/receptors3020007</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/2/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/1/6">

	<title>Receptors, Vol. 3, Pages 107-121: Fundamental Mechanisms in Membrane Receptology: Old Paradigms, New Concepts and Perspectives</title>
	<link>https://www.mdpi.com/2813-2564/3/1/6</link>
	<description>Receptology, the science of receptors, is a multidimensional field of research which can be dissected into biosynthesis, membrane sorting, ligand binding and signal transduction. Plasma membrane receptors connect the cells with their environment and transmit signals that are translated into biological information. The historical paradigm of ligand&amp;amp;ndash;receptor interactions is the lock-and-key model. This model presupposes that both partners have a precise 3D shape that perfectly fits together to form the ligand&amp;amp;ndash;receptor complex. However, this simple model suffers from severe limitations due to several levels of simplifications: (i) water molecules and membrane lipids are not considered; (ii) not all ligands have a stable 3D structure; (iii) the ligand-binding pocket of the receptor is often flexible and conformationally rearranged after the initial binding step (induced fit mechanism) and/or subjected to conformational selection by the ligand; (iv) there are signal transduction mechanisms which can be either purely mechanical (conformational change of the receptor induced after binding of the ligand), lipid-assisted (e.g., by raft lipids such as cholesterol or gangliosides), or in some instances of quantic nature (detection of odorant molecules). The aim of the present review is to challenge the old paradigms and present new concepts of membrane receptology that consider the impact of critical parameters such as water molecules, membrane lipids, electrostatic surface potential and quantum mechanisms.</description>
	<pubDate>2024-03-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 107-121: Fundamental Mechanisms in Membrane Receptology: Old Paradigms, New Concepts and Perspectives</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/1/6">doi: 10.3390/receptors3010006</a></p>
	<p>Authors:
		Jacques Fantini
		</p>
	<p>Receptology, the science of receptors, is a multidimensional field of research which can be dissected into biosynthesis, membrane sorting, ligand binding and signal transduction. Plasma membrane receptors connect the cells with their environment and transmit signals that are translated into biological information. The historical paradigm of ligand&amp;amp;ndash;receptor interactions is the lock-and-key model. This model presupposes that both partners have a precise 3D shape that perfectly fits together to form the ligand&amp;amp;ndash;receptor complex. However, this simple model suffers from severe limitations due to several levels of simplifications: (i) water molecules and membrane lipids are not considered; (ii) not all ligands have a stable 3D structure; (iii) the ligand-binding pocket of the receptor is often flexible and conformationally rearranged after the initial binding step (induced fit mechanism) and/or subjected to conformational selection by the ligand; (iv) there are signal transduction mechanisms which can be either purely mechanical (conformational change of the receptor induced after binding of the ligand), lipid-assisted (e.g., by raft lipids such as cholesterol or gangliosides), or in some instances of quantic nature (detection of odorant molecules). The aim of the present review is to challenge the old paradigms and present new concepts of membrane receptology that consider the impact of critical parameters such as water molecules, membrane lipids, electrostatic surface potential and quantum mechanisms.</p>
	]]></content:encoded>

	<dc:title>Fundamental Mechanisms in Membrane Receptology: Old Paradigms, New Concepts and Perspectives</dc:title>
			<dc:creator>Jacques Fantini</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3010006</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-03-18</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-03-18</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>107</prism:startingPage>
		<prism:doi>10.3390/receptors3010006</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/1/5">

	<title>Receptors, Vol. 3, Pages 58-106: Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers</title>
	<link>https://www.mdpi.com/2813-2564/3/1/5</link>
	<description>The development of potent BRAF inhibitors has revolutionized the treatment of BRAF mutant cancers, in particular, melanomas. However, BRAF mutant cancers of other entities, e.g., colorectal cancers, display distinctly reduced responses to BRAF inhibitors. In addition, the emergence of cancer resistance to BRAF inhibitor treatment poses a severe problem. The reactivation of MAPK/ERK signaling was identified as an important mode of BRAF inhibitor resistance. Receptor tyrosine kinases (RTKs), which are prominent anticancer drug targets in their own right, play a crucial role in the development of drug resistance to BRAF inhibitors and the reactivation of MAPK/ERK signal transduction, as well as the establishment of bypassing signaling pathways. MAPK reactivation can occur via increased expression of RTKs, altered RTK signaling, and post-translational processes, among others. This review summarizes the influence of pertinent RTKs on BRAF mutant cancers and BRAF inhibitor resistance and outlines possible and proven ways to circumvent BRAF-associated resistance mechanisms.</description>
	<pubDate>2024-03-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 58-106: Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/1/5">doi: 10.3390/receptors3010005</a></p>
	<p>Authors:
		Bernhard Biersack
		Lubna Tahtamouni
		Michael Höpfner
		</p>
	<p>The development of potent BRAF inhibitors has revolutionized the treatment of BRAF mutant cancers, in particular, melanomas. However, BRAF mutant cancers of other entities, e.g., colorectal cancers, display distinctly reduced responses to BRAF inhibitors. In addition, the emergence of cancer resistance to BRAF inhibitor treatment poses a severe problem. The reactivation of MAPK/ERK signaling was identified as an important mode of BRAF inhibitor resistance. Receptor tyrosine kinases (RTKs), which are prominent anticancer drug targets in their own right, play a crucial role in the development of drug resistance to BRAF inhibitors and the reactivation of MAPK/ERK signal transduction, as well as the establishment of bypassing signaling pathways. MAPK reactivation can occur via increased expression of RTKs, altered RTK signaling, and post-translational processes, among others. This review summarizes the influence of pertinent RTKs on BRAF mutant cancers and BRAF inhibitor resistance and outlines possible and proven ways to circumvent BRAF-associated resistance mechanisms.</p>
	]]></content:encoded>

	<dc:title>Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers</dc:title>
			<dc:creator>Bernhard Biersack</dc:creator>
			<dc:creator>Lubna Tahtamouni</dc:creator>
			<dc:creator>Michael Höpfner</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3010005</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-03-04</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-03-04</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>58</prism:startingPage>
		<prism:doi>10.3390/receptors3010005</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/1/4">

	<title>Receptors, Vol. 3, Pages 36-57: D1-Like and D2-Like Dopamine Receptors in the Rat Prefrontal Cortex: Impacts of Genetic Generalized Epilepsies and Social Behavioral Deficits</title>
	<link>https://www.mdpi.com/2813-2564/3/1/4</link>
	<description>The involvement of the prefrontal cortical dopaminergic system in the psychopathology of epilepsies and comorbid conditions such as autism spectrum disorder (ASD) still needs to be explored. We used autoradiography to study the D1-like (D1DR) and D2-like (D2DR) receptor binding density in the prefrontal cortex of normal Wistar rats and Wistar-derived strains with generalized convulsive and/or non-convulsive epilepsy. WAG/Rij rats served as a model for non-convulsive absence epilepsy, WAG/Rij-AGS as a model of mixed convulsive/non-convulsive form, and KM strain was a model for convulsive epilepsy comorbid with an ASD-like behavioral phenotype. The prefrontal cortex of rats with any epileptic pathology studied demonstrated profound decreases in binding densities to both D1DR and D2DR; the effects were localized in the primary and secondary anterior cingulate cortices, and adjacent regions. The local decreased D1DR and D2DR binding densities were independent of (not correlated with) each other. The particular group of epileptic rats with an ASD-like phenotype (KM strain) displayed changes in the lateral prefrontal cortex: D1DR were lowered, whereas D2DR were elevated, in the dysgranular insular cortex and adjacent regions. Thus, epilepsy-related changes in the dopaminergic system of the rat archeocortex were localized in the medial prefrontal regions, whereas ASD-related changes were seen in the lateral prefrontal aspects. The findings point to putative local dopaminergic dysfunctions, associated with generalized epilepsies and/or ASD.</description>
	<pubDate>2024-02-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 36-57: D1-Like and D2-Like Dopamine Receptors in the Rat Prefrontal Cortex: Impacts of Genetic Generalized Epilepsies and Social Behavioral Deficits</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/1/4">doi: 10.3390/receptors3010004</a></p>
	<p>Authors:
		Lidia M. Birioukova
		Gilles van Luijtelaar
		Inna S. Midzyanovskaya
		</p>
	<p>The involvement of the prefrontal cortical dopaminergic system in the psychopathology of epilepsies and comorbid conditions such as autism spectrum disorder (ASD) still needs to be explored. We used autoradiography to study the D1-like (D1DR) and D2-like (D2DR) receptor binding density in the prefrontal cortex of normal Wistar rats and Wistar-derived strains with generalized convulsive and/or non-convulsive epilepsy. WAG/Rij rats served as a model for non-convulsive absence epilepsy, WAG/Rij-AGS as a model of mixed convulsive/non-convulsive form, and KM strain was a model for convulsive epilepsy comorbid with an ASD-like behavioral phenotype. The prefrontal cortex of rats with any epileptic pathology studied demonstrated profound decreases in binding densities to both D1DR and D2DR; the effects were localized in the primary and secondary anterior cingulate cortices, and adjacent regions. The local decreased D1DR and D2DR binding densities were independent of (not correlated with) each other. The particular group of epileptic rats with an ASD-like phenotype (KM strain) displayed changes in the lateral prefrontal cortex: D1DR were lowered, whereas D2DR were elevated, in the dysgranular insular cortex and adjacent regions. Thus, epilepsy-related changes in the dopaminergic system of the rat archeocortex were localized in the medial prefrontal regions, whereas ASD-related changes were seen in the lateral prefrontal aspects. The findings point to putative local dopaminergic dysfunctions, associated with generalized epilepsies and/or ASD.</p>
	]]></content:encoded>

	<dc:title>D1-Like and D2-Like Dopamine Receptors in the Rat Prefrontal Cortex: Impacts of Genetic Generalized Epilepsies and Social Behavioral Deficits</dc:title>
			<dc:creator>Lidia M. Birioukova</dc:creator>
			<dc:creator>Gilles van Luijtelaar</dc:creator>
			<dc:creator>Inna S. Midzyanovskaya</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3010004</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-02-20</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-02-20</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>36</prism:startingPage>
		<prism:doi>10.3390/receptors3010004</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/1/3">

	<title>Receptors, Vol. 3, Pages 27-35: The Glucocorticoid Receptor&amp;rsquo;s tau1c Activation Domain 35 Years on&amp;mdash;Making Order out of Disorder</title>
	<link>https://www.mdpi.com/2813-2564/3/1/3</link>
	<description>Almost exactly 35 years after starting to work with the human glucocorticoid receptor (hGR), it is interesting for me to re-evaluate the data and results obtained in the 1980s&amp;amp;ndash;1990s with the benefit of current knowledge. What was understood then and how can modern perspectives increase that understanding? The hGR&amp;amp;rsquo;s tau1c activation domain that we delineated was an enigmatic protein domain. It was apparently devoid of secondary and tertiary protein structures but nonetheless maintained gene activation activity in the absence of other hGR domains, not only in human cells but also in yeast, which is evolutionarily very divergent from humans and which does not contain hGR or other nuclear receptors. We now know that the basic machinery of cells is much more conserved across evolution than was previously thought, so the hGR&amp;amp;rsquo;s tau1c domain was able to utilise transcription machinery components that were conserved between humans and yeast. Further, we can now see that structure&amp;amp;ndash;function aspects of the tau1c domain conform to a general mechanistic framework, such as the acidic exposure model, that has been proposed for many activation domains. As for many transcription factor activation domains, it is now clear that tau1c activity requires regions of transient secondary structure. We now know that there is a tendency for positive Darwinian selection to target intrinsically disordered protein domains. It will be interesting to study the distribution and nature of the many single nucleotide variants of the hGR in this respect.</description>
	<pubDate>2024-02-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 27-35: The Glucocorticoid Receptor&amp;rsquo;s tau1c Activation Domain 35 Years on&amp;mdash;Making Order out of Disorder</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/1/3">doi: 10.3390/receptors3010003</a></p>
	<p>Authors:
		Anthony P. H. Wright
		</p>
	<p>Almost exactly 35 years after starting to work with the human glucocorticoid receptor (hGR), it is interesting for me to re-evaluate the data and results obtained in the 1980s&amp;amp;ndash;1990s with the benefit of current knowledge. What was understood then and how can modern perspectives increase that understanding? The hGR&amp;amp;rsquo;s tau1c activation domain that we delineated was an enigmatic protein domain. It was apparently devoid of secondary and tertiary protein structures but nonetheless maintained gene activation activity in the absence of other hGR domains, not only in human cells but also in yeast, which is evolutionarily very divergent from humans and which does not contain hGR or other nuclear receptors. We now know that the basic machinery of cells is much more conserved across evolution than was previously thought, so the hGR&amp;amp;rsquo;s tau1c domain was able to utilise transcription machinery components that were conserved between humans and yeast. Further, we can now see that structure&amp;amp;ndash;function aspects of the tau1c domain conform to a general mechanistic framework, such as the acidic exposure model, that has been proposed for many activation domains. As for many transcription factor activation domains, it is now clear that tau1c activity requires regions of transient secondary structure. We now know that there is a tendency for positive Darwinian selection to target intrinsically disordered protein domains. It will be interesting to study the distribution and nature of the many single nucleotide variants of the hGR in this respect.</p>
	]]></content:encoded>

	<dc:title>The Glucocorticoid Receptor&amp;amp;rsquo;s tau1c Activation Domain 35 Years on&amp;amp;mdash;Making Order out of Disorder</dc:title>
			<dc:creator>Anthony P. H. Wright</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3010003</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-02-05</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-02-05</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Perspective</prism:section>
	<prism:startingPage>27</prism:startingPage>
		<prism:doi>10.3390/receptors3010003</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/1/2">

	<title>Receptors, Vol. 3, Pages 13-26: Biased Agonism or &amp;ldquo;Biaism&amp;rdquo; for Dummies: A Commentary</title>
	<link>https://www.mdpi.com/2813-2564/3/1/2</link>
	<description>That signaling bias is a nth level of complexity in the understanding of G protein-coupled receptor (GPCR) activation is a first fact. That its exhaustive description, including the mode d&amp;amp;rsquo;emploi of its quantitative measurement, remains a challenge is a second fact. That the use of this concept is promising for the design of drug candidates is a third fact. That the translation of signaling biases observed into in vivo specific effects is well documented is a fourth fact. However, the road to apply those aspects of receptology to a systematic description of a ligand and, a fortiori, of a drug candidate, still necessitates a huge body of studies. In the present commentary, the merits of the molecular description of receptor bias signaling are highlighted and the ligand induced-fit impact on GPCR structure, as well as on the functional repertoire of GPCRs, is discussed. An emphasis is given to the practical aspects during drug design, and, thus, the practical limitations of the current approaches, particularly in the context of as soon as the data are transferred to more integrated/living systems, might be a major limitation.</description>
	<pubDate>2024-01-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 13-26: Biased Agonism or &amp;ldquo;Biaism&amp;rdquo; for Dummies: A Commentary</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/1/2">doi: 10.3390/receptors3010002</a></p>
	<p>Authors:
		Jean A. Boutin
		Jérôme Leprince
		</p>
	<p>That signaling bias is a nth level of complexity in the understanding of G protein-coupled receptor (GPCR) activation is a first fact. That its exhaustive description, including the mode d&amp;amp;rsquo;emploi of its quantitative measurement, remains a challenge is a second fact. That the use of this concept is promising for the design of drug candidates is a third fact. That the translation of signaling biases observed into in vivo specific effects is well documented is a fourth fact. However, the road to apply those aspects of receptology to a systematic description of a ligand and, a fortiori, of a drug candidate, still necessitates a huge body of studies. In the present commentary, the merits of the molecular description of receptor bias signaling are highlighted and the ligand induced-fit impact on GPCR structure, as well as on the functional repertoire of GPCRs, is discussed. An emphasis is given to the practical aspects during drug design, and, thus, the practical limitations of the current approaches, particularly in the context of as soon as the data are transferred to more integrated/living systems, might be a major limitation.</p>
	]]></content:encoded>

	<dc:title>Biased Agonism or &amp;amp;ldquo;Biaism&amp;amp;rdquo; for Dummies: A Commentary</dc:title>
			<dc:creator>Jean A. Boutin</dc:creator>
			<dc:creator>Jérôme Leprince</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3010002</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-01-25</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-01-25</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/receptors3010002</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/3/1/1">

	<title>Receptors, Vol. 3, Pages 1-12: Regulation of Hippocampal GABAergic Transmission by Fluoxetine and Its Metabolite Norfluoxetine</title>
	<link>https://www.mdpi.com/2813-2564/3/1/1</link>
	<description>Major depression is related to dysfunction of the GABAergic pathway. Interestingly, the antidepressant fluoxetine modifies GABAergic neurotransmission in human and animal models of depression. However, the effects of norfluoxetine (the main metabolite of fluoxetine) on GABAergic neurotransmission have not yet been studied. Therefore, we explored whether fluoxetine and/or norfluoxetine may regulate GABAergic transmission and whether these substances interact with GABAA receptors in hippocampal CA1 stratum radiatum interneurons. For these purposes, we recorded the firing profile, GABAergic spontaneous inhibitory postsynaptic currents (sIPSCs), and currents induced by GABA puffs in stratum radiatum interneurons using both whole-cell current- and voltage-clamp techniques. Interneurons were selected according with their high firing profile. We found that both fluoxetine and norfluoxetine (at 20 &amp;amp;micro;M) significantly decreased the frequency of sIPSCs without modifying their amplitude and decreased the amplitude of GABA-induced currents. These results indicate that fluoxetine and norfluoxetine decrease GABA release from neurons contacting stratum radiatum interneurons and negatively modulate GABAA receptors in these interneurons, resulting in their disinhibition, which in turn may contribute to increasing the inhibition of hippocampal CA1 pyramidal neurons.</description>
	<pubDate>2024-01-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 3, Pages 1-12: Regulation of Hippocampal GABAergic Transmission by Fluoxetine and Its Metabolite Norfluoxetine</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/3/1/1">doi: 10.3390/receptors3010001</a></p>
	<p>Authors:
		Elizabeth Vázquez-Gómez
		Andy Hernández-Abrego
		Jassiel Mejía-Piedras
		Jesús García-Colunga
		</p>
	<p>Major depression is related to dysfunction of the GABAergic pathway. Interestingly, the antidepressant fluoxetine modifies GABAergic neurotransmission in human and animal models of depression. However, the effects of norfluoxetine (the main metabolite of fluoxetine) on GABAergic neurotransmission have not yet been studied. Therefore, we explored whether fluoxetine and/or norfluoxetine may regulate GABAergic transmission and whether these substances interact with GABAA receptors in hippocampal CA1 stratum radiatum interneurons. For these purposes, we recorded the firing profile, GABAergic spontaneous inhibitory postsynaptic currents (sIPSCs), and currents induced by GABA puffs in stratum radiatum interneurons using both whole-cell current- and voltage-clamp techniques. Interneurons were selected according with their high firing profile. We found that both fluoxetine and norfluoxetine (at 20 &amp;amp;micro;M) significantly decreased the frequency of sIPSCs without modifying their amplitude and decreased the amplitude of GABA-induced currents. These results indicate that fluoxetine and norfluoxetine decrease GABA release from neurons contacting stratum radiatum interneurons and negatively modulate GABAA receptors in these interneurons, resulting in their disinhibition, which in turn may contribute to increasing the inhibition of hippocampal CA1 pyramidal neurons.</p>
	]]></content:encoded>

	<dc:title>Regulation of Hippocampal GABAergic Transmission by Fluoxetine and Its Metabolite Norfluoxetine</dc:title>
			<dc:creator>Elizabeth Vázquez-Gómez</dc:creator>
			<dc:creator>Andy Hernández-Abrego</dc:creator>
			<dc:creator>Jassiel Mejía-Piedras</dc:creator>
			<dc:creator>Jesús García-Colunga</dc:creator>
		<dc:identifier>doi: 10.3390/receptors3010001</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2024-01-04</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2024-01-04</prism:publicationDate>
	<prism:volume>3</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/receptors3010001</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/3/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/4/18">

	<title>Receptors, Vol. 2, Pages 264-283: The NR4A Orphan Receptor Modulator C-DIM12 Selectively Alters Inflammatory Mediators in Myeloid Cells</title>
	<link>https://www.mdpi.com/2813-2564/2/4/18</link>
	<description>Orphan nuclear receptor subfamily 4A (NR4A) are key regulators of inflammatory responses, largely by their interactions with NF-&amp;amp;kappa;B. Over the last decade, several NR4A modulators have been developed, and they are showing potential as therapeutics, although their widespread use in laboratory settings is limited. Here, we have examined, using myeloid cell line THP-1, whether the NR4A modulator 3-[(4-Chlorophenyl)-(1H-indol-3-yl)methyl]-1H-indole (C-DIM12) can alter the inflammatory outcome of six inflammatory ligands: lipopolysaccharide (LPS), tumour necrosis factor alpha (TNF&amp;amp;alpha;), interleukin-1 beta (IL-1&amp;amp;beta;), flagellin (FL), lipoteichoic acid (LTA), and zymosan (ZY). We demonstrate that C-DIM12 (10 &amp;amp;micro;M) selectively alters the secretion of inflammatory chemokine MCP-1 following exposure to distinct inflammatory ligands in a concentration-dependent manner. Furthermore, data obtained from THP-1 Lucia cell experiments show that 10 &amp;amp;micro;M C-DIM12, and not 1 &amp;amp;micro;M C-DIM12, can significantly attenuate the increased NF-&amp;amp;kappa;B transcriptional activity observed following the exposure to several inflammatory ligands (LPS, FL, TNF&amp;amp;alpha;, LTA, and ZY). Lastly, experimental analysis confirms that the cellular action(s) of C-DIM12 is independent of changes in metabolic parameters. Thus, these data contribute to the understanding of how the NR4A modulator C-DIM12 alters inflammatory responses in a myeloid cell following exposure to multiple ligands.</description>
	<pubDate>2023-12-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 264-283: The NR4A Orphan Receptor Modulator C-DIM12 Selectively Alters Inflammatory Mediators in Myeloid Cells</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/4/18">doi: 10.3390/receptors2040018</a></p>
	<p>Authors:
		Sarah Aldhafiri
		Mariam Marai
		Mohamed Ismaiel
		Brenda Murphy
		Hugh E. Giffney
		Thomas J. Hall
		Evelyn P. Murphy
		Eoin P. Cummins
		Daniel Crean
		</p>
	<p>Orphan nuclear receptor subfamily 4A (NR4A) are key regulators of inflammatory responses, largely by their interactions with NF-&amp;amp;kappa;B. Over the last decade, several NR4A modulators have been developed, and they are showing potential as therapeutics, although their widespread use in laboratory settings is limited. Here, we have examined, using myeloid cell line THP-1, whether the NR4A modulator 3-[(4-Chlorophenyl)-(1H-indol-3-yl)methyl]-1H-indole (C-DIM12) can alter the inflammatory outcome of six inflammatory ligands: lipopolysaccharide (LPS), tumour necrosis factor alpha (TNF&amp;amp;alpha;), interleukin-1 beta (IL-1&amp;amp;beta;), flagellin (FL), lipoteichoic acid (LTA), and zymosan (ZY). We demonstrate that C-DIM12 (10 &amp;amp;micro;M) selectively alters the secretion of inflammatory chemokine MCP-1 following exposure to distinct inflammatory ligands in a concentration-dependent manner. Furthermore, data obtained from THP-1 Lucia cell experiments show that 10 &amp;amp;micro;M C-DIM12, and not 1 &amp;amp;micro;M C-DIM12, can significantly attenuate the increased NF-&amp;amp;kappa;B transcriptional activity observed following the exposure to several inflammatory ligands (LPS, FL, TNF&amp;amp;alpha;, LTA, and ZY). Lastly, experimental analysis confirms that the cellular action(s) of C-DIM12 is independent of changes in metabolic parameters. Thus, these data contribute to the understanding of how the NR4A modulator C-DIM12 alters inflammatory responses in a myeloid cell following exposure to multiple ligands.</p>
	]]></content:encoded>

	<dc:title>The NR4A Orphan Receptor Modulator C-DIM12 Selectively Alters Inflammatory Mediators in Myeloid Cells</dc:title>
			<dc:creator>Sarah Aldhafiri</dc:creator>
			<dc:creator>Mariam Marai</dc:creator>
			<dc:creator>Mohamed Ismaiel</dc:creator>
			<dc:creator>Brenda Murphy</dc:creator>
			<dc:creator>Hugh E. Giffney</dc:creator>
			<dc:creator>Thomas J. Hall</dc:creator>
			<dc:creator>Evelyn P. Murphy</dc:creator>
			<dc:creator>Eoin P. Cummins</dc:creator>
			<dc:creator>Daniel Crean</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2040018</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-12-18</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-12-18</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>264</prism:startingPage>
		<prism:doi>10.3390/receptors2040018</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/4/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/4/17">

	<title>Receptors, Vol. 2, Pages 251-263: Association of Bitter Taste Receptors with Obesity and Diabetes and Their Role in Related Tissues</title>
	<link>https://www.mdpi.com/2813-2564/2/4/17</link>
	<description>Taste 2 receptors (T2Rs) are G-protein-coupled receptors responsible for sensing bitter tastes. Many studies have shown the expression of T2Rs in extraoral tissues and the unique role of T2Rs in each tissue. Single-nucleotide polymorphisms of T2Rs are associated with the risk of obesity and diabetes, and the organs/tissues associated with the development of these metabolic diseases, including the intestine, adipose, muscle, liver, and pancreas, are reported to express T2R genes. This result suggests that T2Rs in extraoral tissues contribute to the development of obesity and diabetes. In this narrative review, we summarize current knowledge of the associations of T2Rs with obesity and diabetes, provide an overview of extraoral tissues that are associated with the development of obesity and diabetes that express T2R genes, and summarize the current knowledge of T2Rs.</description>
	<pubDate>2023-12-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 251-263: Association of Bitter Taste Receptors with Obesity and Diabetes and Their Role in Related Tissues</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/4/17">doi: 10.3390/receptors2040017</a></p>
	<p>Authors:
		Eisuke Kato
		Shota Oshima
		</p>
	<p>Taste 2 receptors (T2Rs) are G-protein-coupled receptors responsible for sensing bitter tastes. Many studies have shown the expression of T2Rs in extraoral tissues and the unique role of T2Rs in each tissue. Single-nucleotide polymorphisms of T2Rs are associated with the risk of obesity and diabetes, and the organs/tissues associated with the development of these metabolic diseases, including the intestine, adipose, muscle, liver, and pancreas, are reported to express T2R genes. This result suggests that T2Rs in extraoral tissues contribute to the development of obesity and diabetes. In this narrative review, we summarize current knowledge of the associations of T2Rs with obesity and diabetes, provide an overview of extraoral tissues that are associated with the development of obesity and diabetes that express T2R genes, and summarize the current knowledge of T2Rs.</p>
	]]></content:encoded>

	<dc:title>Association of Bitter Taste Receptors with Obesity and Diabetes and Their Role in Related Tissues</dc:title>
			<dc:creator>Eisuke Kato</dc:creator>
			<dc:creator>Shota Oshima</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2040017</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-12-05</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-12-05</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>251</prism:startingPage>
		<prism:doi>10.3390/receptors2040017</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/4/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/4/16">

	<title>Receptors, Vol. 2, Pages 232-250: Evidence for the Involvement of the Tachykinin NK1 Receptor in Acute Inflammation of the Central Nervous System</title>
	<link>https://www.mdpi.com/2813-2564/2/4/16</link>
	<description>Neuroinflammation is considered to be a significant component in a range of neuropathologies. Unfortunately, whilst its role is well recognised, the options for therapeutic intervention are limited. As such, there is a need to identify novel targets in order to increase treatment options. Given its role as both a neurotransmitter and an immune modulator, substance P (SP) and its NK1 receptor (NK1R) have been widely studied as a potential therapeutic target. There is evidence that NK1R antagonists may exert beneficial effects in a range of conditions, including traumatic brain injury and stroke. Blocking the NK1R has been shown to reduce blood&amp;amp;ndash;brain barrier dysfunction, reduce cerebral oedema, and reduce the levels of pro-inflammatory cytokines. These actions are associated with improved survival and functional outcomes. The NK1R has also been shown to be involved in the inflammatory reaction to CNS infection, and hence antagonists may have some benefit in reducing infection-driven inflammation. However, the NK1R may also play a role in the host immune response to infection, and so here, the potential beneficial and detrimental effects need to be carefully balanced. The purpose of this review is to provide a summary of evidence for the involvement of the NK1R in acute CNS inflammation, particularly in the context of traumatic brain injury and stroke.</description>
	<pubDate>2023-11-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 232-250: Evidence for the Involvement of the Tachykinin NK1 Receptor in Acute Inflammation of the Central Nervous System</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/4/16">doi: 10.3390/receptors2040016</a></p>
	<p>Authors:
		Renée J. Turner
		Alan J. Nimmo
		</p>
	<p>Neuroinflammation is considered to be a significant component in a range of neuropathologies. Unfortunately, whilst its role is well recognised, the options for therapeutic intervention are limited. As such, there is a need to identify novel targets in order to increase treatment options. Given its role as both a neurotransmitter and an immune modulator, substance P (SP) and its NK1 receptor (NK1R) have been widely studied as a potential therapeutic target. There is evidence that NK1R antagonists may exert beneficial effects in a range of conditions, including traumatic brain injury and stroke. Blocking the NK1R has been shown to reduce blood&amp;amp;ndash;brain barrier dysfunction, reduce cerebral oedema, and reduce the levels of pro-inflammatory cytokines. These actions are associated with improved survival and functional outcomes. The NK1R has also been shown to be involved in the inflammatory reaction to CNS infection, and hence antagonists may have some benefit in reducing infection-driven inflammation. However, the NK1R may also play a role in the host immune response to infection, and so here, the potential beneficial and detrimental effects need to be carefully balanced. The purpose of this review is to provide a summary of evidence for the involvement of the NK1R in acute CNS inflammation, particularly in the context of traumatic brain injury and stroke.</p>
	]]></content:encoded>

	<dc:title>Evidence for the Involvement of the Tachykinin NK1 Receptor in Acute Inflammation of the Central Nervous System</dc:title>
			<dc:creator>Renée J. Turner</dc:creator>
			<dc:creator>Alan J. Nimmo</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2040016</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-11-15</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-11-15</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>232</prism:startingPage>
		<prism:doi>10.3390/receptors2040016</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/4/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/4/15">

	<title>Receptors, Vol. 2, Pages 220-231: The Role of Substance P and NK1 Receptors in Mild to Severe Traumatic Brain Injury: From CTE to ICP</title>
	<link>https://www.mdpi.com/2813-2564/2/4/15</link>
	<description>Binding of substance P to the tachykinin NK1 receptor is involved in numerous physiological and pathophysiological processes ranging from modulation of sensory and motor function to inflammation, cancer, and brain injury, amongst others. NK1 antagonists therefore have enormous potential as a therapeutic intervention in a wide variety of human disease states, albeit that the clinical potential is yet to be fully realised. In the current review, the role of substance P in the pathophysiology of traumatic brain injury (TBI) will be discussed, summarising both experimental and clinical observations in mild, moderate, and severe TBI. In addition, the potential for NK1 antagonists to be a valuable therapeutic intervention against chronic traumatic encephalopathy (CTE) after repeated concussive brain injury as well as raised intracranial pressure (ICP) following severe TBI will be addressed, highlighting the various pathophysiological processes that are attenuated by the intervention.</description>
	<pubDate>2023-11-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 220-231: The Role of Substance P and NK1 Receptors in Mild to Severe Traumatic Brain Injury: From CTE to ICP</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/4/15">doi: 10.3390/receptors2040015</a></p>
	<p>Authors:
		Robert Vink
		Frances Corrigan
		</p>
	<p>Binding of substance P to the tachykinin NK1 receptor is involved in numerous physiological and pathophysiological processes ranging from modulation of sensory and motor function to inflammation, cancer, and brain injury, amongst others. NK1 antagonists therefore have enormous potential as a therapeutic intervention in a wide variety of human disease states, albeit that the clinical potential is yet to be fully realised. In the current review, the role of substance P in the pathophysiology of traumatic brain injury (TBI) will be discussed, summarising both experimental and clinical observations in mild, moderate, and severe TBI. In addition, the potential for NK1 antagonists to be a valuable therapeutic intervention against chronic traumatic encephalopathy (CTE) after repeated concussive brain injury as well as raised intracranial pressure (ICP) following severe TBI will be addressed, highlighting the various pathophysiological processes that are attenuated by the intervention.</p>
	]]></content:encoded>

	<dc:title>The Role of Substance P and NK1 Receptors in Mild to Severe Traumatic Brain Injury: From CTE to ICP</dc:title>
			<dc:creator>Robert Vink</dc:creator>
			<dc:creator>Frances Corrigan</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2040015</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-11-11</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-11-11</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>220</prism:startingPage>
		<prism:doi>10.3390/receptors2040015</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/4/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/4/14">

	<title>Receptors, Vol. 2, Pages 204-219: Regulation of Cholesterol Transporters by Nuclear Receptors</title>
	<link>https://www.mdpi.com/2813-2564/2/4/14</link>
	<description>Atherosclerosis is a pathological condition characterized by the accumulation of plaques in the arteries, leading to cardiovascular diseases. The deposition of cholesterol in peripheral cells increases the risk of atherosclerosis. Reverse cholesterol transport (RCT) is essential to reduce the risk of atherosclerosis because it removes excessive cholesterol from the peripheral tissues. ATP-binding cassette transporters such as ABCA1, ABCG1, ABCG5, and ABCG8 are involved in the efflux of cholesterol. The upregulation of these ABC transporters enhances RCT, thereby promoting the removal of excess cholesterol from the body. The expression and activity of ABC transporters are regulated by transcriptional and post-transcriptional mechanisms, as well as by post-translational modifications. In this review, the regulation of ABC transporters by nuclear receptors such as farnesoid X receptor, liver X receptor, retinoid X receptor, retinoic acid receptor, and peroxisome proliferator-activated receptors is discussed. Pharmacological and natural compounds serving as agonists for the nuclear receptors have been identified to elevate the mRNA levels of the transporters. Consequently, it is anticipated that these compounds will attenuate the development of atherosclerosis through stimulation of the ABC transporters, thereby enhancing RCT and fecal cholesterol excretion. Understanding these regulatory processes can aid in the development of therapeutic approaches to prevent atherosclerosis.</description>
	<pubDate>2023-10-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 204-219: Regulation of Cholesterol Transporters by Nuclear Receptors</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/4/14">doi: 10.3390/receptors2040014</a></p>
	<p>Authors:
		Michinori Matsuo
		</p>
	<p>Atherosclerosis is a pathological condition characterized by the accumulation of plaques in the arteries, leading to cardiovascular diseases. The deposition of cholesterol in peripheral cells increases the risk of atherosclerosis. Reverse cholesterol transport (RCT) is essential to reduce the risk of atherosclerosis because it removes excessive cholesterol from the peripheral tissues. ATP-binding cassette transporters such as ABCA1, ABCG1, ABCG5, and ABCG8 are involved in the efflux of cholesterol. The upregulation of these ABC transporters enhances RCT, thereby promoting the removal of excess cholesterol from the body. The expression and activity of ABC transporters are regulated by transcriptional and post-transcriptional mechanisms, as well as by post-translational modifications. In this review, the regulation of ABC transporters by nuclear receptors such as farnesoid X receptor, liver X receptor, retinoid X receptor, retinoic acid receptor, and peroxisome proliferator-activated receptors is discussed. Pharmacological and natural compounds serving as agonists for the nuclear receptors have been identified to elevate the mRNA levels of the transporters. Consequently, it is anticipated that these compounds will attenuate the development of atherosclerosis through stimulation of the ABC transporters, thereby enhancing RCT and fecal cholesterol excretion. Understanding these regulatory processes can aid in the development of therapeutic approaches to prevent atherosclerosis.</p>
	]]></content:encoded>

	<dc:title>Regulation of Cholesterol Transporters by Nuclear Receptors</dc:title>
			<dc:creator>Michinori Matsuo</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2040014</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-10-09</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-10-09</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>204</prism:startingPage>
		<prism:doi>10.3390/receptors2040014</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/4/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/3/13">

	<title>Receptors, Vol. 2, Pages 191-203: Expression of the Purinergic P2X7 Receptor in Murine MOPC315.BM Myeloma Cells</title>
	<link>https://www.mdpi.com/2813-2564/2/3/13</link>
	<description>The adenosine-5&amp;amp;rsquo; triphosphate (ATP)-gated, ion channel, P2X receptor superfamily has seven members expressed by many cancer types. Subtype 7 (P2X7 receptor) is expressed consistently at levels higher than in comparatively healthy tissues. Moreover, transcript variant heterogeneity is associated with drug resistance. We have previously described the role of the P2X7 receptor in myeloma, a rare blood disease that uniquely presents with aggressive bone destruction. In this study, we used known agonists of the P2X7 receptor to induce calcium influx and YO-PRO-1 uptake in murine MOPC315.BM myeloma cells as readouts of P2X7 receptor-mediated channel activation and pore formation, respectively. Neither ATP- nor BzATP-induced calcium influx and YO-PRO-1 indicated an absence of the P2X7 receptor function on MOPC315.BM cells. TaqMan revealed low (Ct &amp;amp;gt; 35) P2rx7 but high P2rx4 gene expression in MOPC315.BM; the latter was downregulated with BzATP treatment. The concomitant downregulation of CD39/Entpd1, Icam-1, and Nf-kb1 and the upregulation of Casp-1 genes regulated during purinergic signaling and with established roles in myeloma progression suggest P2RX4-mediated survival adaptation by cancer cells. Further studies are needed to characterize the P2RX4 pharmacology on MOPC315.BM since transcriptional regulation may be utilized by cancer cells to overcome the otherwise toxic effects of high extracellular ATP.</description>
	<pubDate>2023-09-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 191-203: Expression of the Purinergic P2X7 Receptor in Murine MOPC315.BM Myeloma Cells</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/3/13">doi: 10.3390/receptors2030013</a></p>
	<p>Authors:
		Eva Risborg Høyer
		Melisa Demir
		Lasse Kristoffer Bak
		Niklas Rye Jørgensen
		Ankita Agrawal
		</p>
	<p>The adenosine-5&amp;amp;rsquo; triphosphate (ATP)-gated, ion channel, P2X receptor superfamily has seven members expressed by many cancer types. Subtype 7 (P2X7 receptor) is expressed consistently at levels higher than in comparatively healthy tissues. Moreover, transcript variant heterogeneity is associated with drug resistance. We have previously described the role of the P2X7 receptor in myeloma, a rare blood disease that uniquely presents with aggressive bone destruction. In this study, we used known agonists of the P2X7 receptor to induce calcium influx and YO-PRO-1 uptake in murine MOPC315.BM myeloma cells as readouts of P2X7 receptor-mediated channel activation and pore formation, respectively. Neither ATP- nor BzATP-induced calcium influx and YO-PRO-1 indicated an absence of the P2X7 receptor function on MOPC315.BM cells. TaqMan revealed low (Ct &amp;amp;gt; 35) P2rx7 but high P2rx4 gene expression in MOPC315.BM; the latter was downregulated with BzATP treatment. The concomitant downregulation of CD39/Entpd1, Icam-1, and Nf-kb1 and the upregulation of Casp-1 genes regulated during purinergic signaling and with established roles in myeloma progression suggest P2RX4-mediated survival adaptation by cancer cells. Further studies are needed to characterize the P2RX4 pharmacology on MOPC315.BM since transcriptional regulation may be utilized by cancer cells to overcome the otherwise toxic effects of high extracellular ATP.</p>
	]]></content:encoded>

	<dc:title>Expression of the Purinergic P2X7 Receptor in Murine MOPC315.BM Myeloma Cells</dc:title>
			<dc:creator>Eva Risborg Høyer</dc:creator>
			<dc:creator>Melisa Demir</dc:creator>
			<dc:creator>Lasse Kristoffer Bak</dc:creator>
			<dc:creator>Niklas Rye Jørgensen</dc:creator>
			<dc:creator>Ankita Agrawal</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2030013</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-09-07</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-09-07</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>191</prism:startingPage>
		<prism:doi>10.3390/receptors2030013</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/3/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/3/12">

	<title>Receptors, Vol. 2, Pages 176-190: Estrogen Receptor &amp;beta; Isoforms Regulate Chemotherapy Resistance and the Cancer Stem Cell Population in Prostate Cancer Cells</title>
	<link>https://www.mdpi.com/2813-2564/2/3/12</link>
	<description>Estrogen receptor beta 1 (ER&amp;amp;beta;1) is a ligand-activated nuclear receptor, which has been shown to maintain tissue differentiation in the normal prostate, and regulate androgen response and increase expression of tumor suppressors in prostate cancer cell lines. There are three shorter isoforms of ER&amp;amp;beta; expressed in the human prostate, ER&amp;amp;beta;2, ER&amp;amp;beta;4, and ER&amp;amp;beta;5, which have already been implicated in chemotherapy resistance and disease progression, suggesting a possible oncogenic role. Their ligand-binding domain (LBD) is truncated, so they are unable to activate canonical ER&amp;amp;beta;1 signaling pathways; however, they were shown to participate in hypoxic signaling and to induce a gene expression signature associated with stemness and hypoxia. To elucidate the role of the truncated ER&amp;amp;beta; isoforms in prostate cancer, we created a knockout of all isoforms, as well as a truncation of the LBD, to remove the function of ER&amp;amp;beta;1. We showed that the removal of all isoforms leads to a decrease in the expression of cancer stem cell (CSC)-associated genes, decreased chemotherapy resistance, and a decrease in the CSC population, based on sphere formation ability and SORE6 (CSC reporter) activity, while removing the LBD function only had the opposite effect. Our results suggest a more aggressive phenotype in prostate cancer cell lines expressing ER&amp;amp;beta; variants.</description>
	<pubDate>2023-08-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 176-190: Estrogen Receptor &amp;beta; Isoforms Regulate Chemotherapy Resistance and the Cancer Stem Cell Population in Prostate Cancer Cells</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/3/12">doi: 10.3390/receptors2030012</a></p>
	<p>Authors:
		Jessica H. Stevens
		Ayesha Bano
		Lamia Bensaoula
		Anders M. Strom
		Jan-Åke Gustafsson
		</p>
	<p>Estrogen receptor beta 1 (ER&amp;amp;beta;1) is a ligand-activated nuclear receptor, which has been shown to maintain tissue differentiation in the normal prostate, and regulate androgen response and increase expression of tumor suppressors in prostate cancer cell lines. There are three shorter isoforms of ER&amp;amp;beta; expressed in the human prostate, ER&amp;amp;beta;2, ER&amp;amp;beta;4, and ER&amp;amp;beta;5, which have already been implicated in chemotherapy resistance and disease progression, suggesting a possible oncogenic role. Their ligand-binding domain (LBD) is truncated, so they are unable to activate canonical ER&amp;amp;beta;1 signaling pathways; however, they were shown to participate in hypoxic signaling and to induce a gene expression signature associated with stemness and hypoxia. To elucidate the role of the truncated ER&amp;amp;beta; isoforms in prostate cancer, we created a knockout of all isoforms, as well as a truncation of the LBD, to remove the function of ER&amp;amp;beta;1. We showed that the removal of all isoforms leads to a decrease in the expression of cancer stem cell (CSC)-associated genes, decreased chemotherapy resistance, and a decrease in the CSC population, based on sphere formation ability and SORE6 (CSC reporter) activity, while removing the LBD function only had the opposite effect. Our results suggest a more aggressive phenotype in prostate cancer cell lines expressing ER&amp;amp;beta; variants.</p>
	]]></content:encoded>

	<dc:title>Estrogen Receptor &amp;amp;beta; Isoforms Regulate Chemotherapy Resistance and the Cancer Stem Cell Population in Prostate Cancer Cells</dc:title>
			<dc:creator>Jessica H. Stevens</dc:creator>
			<dc:creator>Ayesha Bano</dc:creator>
			<dc:creator>Lamia Bensaoula</dc:creator>
			<dc:creator>Anders M. Strom</dc:creator>
			<dc:creator>Jan-Åke Gustafsson</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2030012</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-08-01</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-08-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>176</prism:startingPage>
		<prism:doi>10.3390/receptors2030012</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/3/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/3/11">

	<title>Receptors, Vol. 2, Pages 166-175: From Antibodies to Crystals: Understanding the Structure of the Glucocorticoid Receptor and Related Proteins</title>
	<link>https://www.mdpi.com/2813-2564/2/3/11</link>
	<description>The steroid/thyroid hormone or nuclear receptor superfamily is quickly approaching its 40th anniversary. During this period, we have seen tremendous progress being made in our understanding of the mechanisms of action of these physiologically important proteins in the field of health and disease. Critical to this has been the insight provided by ever more detailed structural examination of nuclear receptor proteins and the complexes they are responsible for assembling on DNA. In this article, I will focus on the contributions made by Jan-&amp;amp;Aring;ke Gustafsson and colleagues at the Karolinska Institute (Sweden) and, more recently, the University of Houston (USA), to this area of nuclear receptor research.</description>
	<pubDate>2023-07-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 166-175: From Antibodies to Crystals: Understanding the Structure of the Glucocorticoid Receptor and Related Proteins</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/3/11">doi: 10.3390/receptors2030011</a></p>
	<p>Authors:
		Iain J. McEwan
		</p>
	<p>The steroid/thyroid hormone or nuclear receptor superfamily is quickly approaching its 40th anniversary. During this period, we have seen tremendous progress being made in our understanding of the mechanisms of action of these physiologically important proteins in the field of health and disease. Critical to this has been the insight provided by ever more detailed structural examination of nuclear receptor proteins and the complexes they are responsible for assembling on DNA. In this article, I will focus on the contributions made by Jan-&amp;amp;Aring;ke Gustafsson and colleagues at the Karolinska Institute (Sweden) and, more recently, the University of Houston (USA), to this area of nuclear receptor research.</p>
	]]></content:encoded>

	<dc:title>From Antibodies to Crystals: Understanding the Structure of the Glucocorticoid Receptor and Related Proteins</dc:title>
			<dc:creator>Iain J. McEwan</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2030011</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-07-03</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-07-03</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Opinion</prism:section>
	<prism:startingPage>166</prism:startingPage>
		<prism:doi>10.3390/receptors2030011</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/3/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/2/10">

	<title>Receptors, Vol. 2, Pages 160-165: Cycle Numbers of Cell Surface Recycling Receptors</title>
	<link>https://www.mdpi.com/2813-2564/2/2/10</link>
	<description>The cycle number (nc) of a recycling receptor is defined as the average number of round trips (cell surface&amp;amp;ndash;endosome&amp;amp;ndash;cell surface) the receptor can make before it is degraded. This characteristic parameter of recycling receptors can be easily determined from the receptor&amp;amp;rsquo;s half-life (t&amp;amp;frac12;, the time in which 50% of the receptor is degraded) and cycling time (Tc, the time a receptor needs to complete a round trip). Relationship analyses revealed that nc increases linearly with increasing t&amp;amp;frac12; and decreases exponentially with increasing Tc. For commonly observed t&amp;amp;frac12; and Tc values, it was calculated that recycling receptors have nc values of &amp;amp;lt;300. In addition, it was found that recycling receptors in cancer cells have generally smaller nc values (&amp;amp;lt;100), whereas recycling receptors in normal cells have larger nc values (&amp;amp;gt;100). Based on this latter finding, the cycle number nc may be a useful criterion for distinguishing between cancer and normal cells.</description>
	<pubDate>2023-06-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 160-165: Cycle Numbers of Cell Surface Recycling Receptors</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/2/10">doi: 10.3390/receptors2020010</a></p>
	<p>Authors:
		Dietmar Steverding
		</p>
	<p>The cycle number (nc) of a recycling receptor is defined as the average number of round trips (cell surface&amp;amp;ndash;endosome&amp;amp;ndash;cell surface) the receptor can make before it is degraded. This characteristic parameter of recycling receptors can be easily determined from the receptor&amp;amp;rsquo;s half-life (t&amp;amp;frac12;, the time in which 50% of the receptor is degraded) and cycling time (Tc, the time a receptor needs to complete a round trip). Relationship analyses revealed that nc increases linearly with increasing t&amp;amp;frac12; and decreases exponentially with increasing Tc. For commonly observed t&amp;amp;frac12; and Tc values, it was calculated that recycling receptors have nc values of &amp;amp;lt;300. In addition, it was found that recycling receptors in cancer cells have generally smaller nc values (&amp;amp;lt;100), whereas recycling receptors in normal cells have larger nc values (&amp;amp;gt;100). Based on this latter finding, the cycle number nc may be a useful criterion for distinguishing between cancer and normal cells.</p>
	]]></content:encoded>

	<dc:title>Cycle Numbers of Cell Surface Recycling Receptors</dc:title>
			<dc:creator>Dietmar Steverding</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2020010</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-06-06</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-06-06</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>160</prism:startingPage>
		<prism:doi>10.3390/receptors2020010</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/2/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/2/9">

	<title>Receptors, Vol. 2, Pages 148-159: Analysis of Cell&amp;ndash;Cell Communication by Single-Nuclei RNA Sequencing Identifies AHR-Mediated Induction of NRG-ERBB Signaling</title>
	<link>https://www.mdpi.com/2813-2564/2/2/9</link>
	<description>Communication between cells is essential in maintaining homeostasis. The persistent disruption of cell&amp;amp;ndash;cell communication by environmental contaminants contributes to progressive disease and toxicity. In this study, single-nuclei RNA sequencing (snRNAseq) data was used to examine dose-dependent cell-specific changes in cell&amp;amp;ndash;cell communication associated with the development of liver pathologies following the persistent activation of the aryl hydrocarbon receptor (AHR) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Published hepatic snRNAseq data from male mice gavaged with sesame-oil vehicle or TCDD every 4 days for 28 days was used to assess the AHR-mediated disruption of ligand&amp;amp;ndash;receptor interactions. Analysis identified that portal fibroblasts and liver sinusoidal endothelial cells contributed the most ligand&amp;amp;ndash;receptor pairs at doses &amp;amp;lt; 0.3&amp;amp;mu;g/kg TCDD. Doses &amp;amp;ge; 0.3 &amp;amp;mu;g/kg TCDD increased the putative intercellular communication between hepatocytes and hepatic stellate cells. In control livers, interactions primarily consisted of protease-activated receptor (PAR) signaling. TCDD treatment increased the number of active signaling pathways. Within hepatocytes, neuregulin signaling was induced, activating the NRG1&amp;amp;ndash;ERBB4 ligand axis, consistent with AHR genomic enrichment at dioxin response elements in a published chromatin immunoprecipitation sequencing (ChIP-seq) dataset, which suggested a direct regulation. Collectively, the results suggest that the disruption of cell signaling may play a central role in TCDD-elicited liver pathologies.</description>
	<pubDate>2023-05-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 148-159: Analysis of Cell&amp;ndash;Cell Communication by Single-Nuclei RNA Sequencing Identifies AHR-Mediated Induction of NRG-ERBB Signaling</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/2/9">doi: 10.3390/receptors2020009</a></p>
	<p>Authors:
		Rance Nault
		Giovan N. Cholico
		Tim Zacharewski
		</p>
	<p>Communication between cells is essential in maintaining homeostasis. The persistent disruption of cell&amp;amp;ndash;cell communication by environmental contaminants contributes to progressive disease and toxicity. In this study, single-nuclei RNA sequencing (snRNAseq) data was used to examine dose-dependent cell-specific changes in cell&amp;amp;ndash;cell communication associated with the development of liver pathologies following the persistent activation of the aryl hydrocarbon receptor (AHR) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Published hepatic snRNAseq data from male mice gavaged with sesame-oil vehicle or TCDD every 4 days for 28 days was used to assess the AHR-mediated disruption of ligand&amp;amp;ndash;receptor interactions. Analysis identified that portal fibroblasts and liver sinusoidal endothelial cells contributed the most ligand&amp;amp;ndash;receptor pairs at doses &amp;amp;lt; 0.3&amp;amp;mu;g/kg TCDD. Doses &amp;amp;ge; 0.3 &amp;amp;mu;g/kg TCDD increased the putative intercellular communication between hepatocytes and hepatic stellate cells. In control livers, interactions primarily consisted of protease-activated receptor (PAR) signaling. TCDD treatment increased the number of active signaling pathways. Within hepatocytes, neuregulin signaling was induced, activating the NRG1&amp;amp;ndash;ERBB4 ligand axis, consistent with AHR genomic enrichment at dioxin response elements in a published chromatin immunoprecipitation sequencing (ChIP-seq) dataset, which suggested a direct regulation. Collectively, the results suggest that the disruption of cell signaling may play a central role in TCDD-elicited liver pathologies.</p>
	]]></content:encoded>

	<dc:title>Analysis of Cell&amp;amp;ndash;Cell Communication by Single-Nuclei RNA Sequencing Identifies AHR-Mediated Induction of NRG-ERBB Signaling</dc:title>
			<dc:creator>Rance Nault</dc:creator>
			<dc:creator>Giovan N. Cholico</dc:creator>
			<dc:creator>Tim Zacharewski</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2020009</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-05-11</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-05-11</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>148</prism:startingPage>
		<prism:doi>10.3390/receptors2020009</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/2/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/2/8">

	<title>Receptors, Vol. 2, Pages 127-147: Molecular Characterization and Pharmacology of Melatonin Receptors in Animals</title>
	<link>https://www.mdpi.com/2813-2564/2/2/8</link>
	<description>Melatonin, the hormone of darkness, is secreted in minute amounts during the night and is virtually undetectable during the day. Melatonin mainly acts on high-affinity G protein-coupled receptors. The present review will trace the path of the discovery of melatonin receptors from their cloning, expression and purification to the development of recent radioactive and fluorescent tracers. We will then report on the state-of-the-art of melatonin receptor functional properties, including ligand bias and system bias due to receptor-associated proteins and receptor heteromers. Currently available antibodies raised against melatonin receptors will be critically reviewed here for the first time. The review will close with future perspectives in terms of the discovery of allosteric ligands and the in vivo validation of a range of melatonin receptor-associated signaling complexes to improve future drug development.</description>
	<pubDate>2023-04-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 127-147: Molecular Characterization and Pharmacology of Melatonin Receptors in Animals</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/2/8">doi: 10.3390/receptors2020008</a></p>
	<p>Authors:
		Erika Cecon
		Jean A. Boutin
		Ralf Jockers
		</p>
	<p>Melatonin, the hormone of darkness, is secreted in minute amounts during the night and is virtually undetectable during the day. Melatonin mainly acts on high-affinity G protein-coupled receptors. The present review will trace the path of the discovery of melatonin receptors from their cloning, expression and purification to the development of recent radioactive and fluorescent tracers. We will then report on the state-of-the-art of melatonin receptor functional properties, including ligand bias and system bias due to receptor-associated proteins and receptor heteromers. Currently available antibodies raised against melatonin receptors will be critically reviewed here for the first time. The review will close with future perspectives in terms of the discovery of allosteric ligands and the in vivo validation of a range of melatonin receptor-associated signaling complexes to improve future drug development.</p>
	]]></content:encoded>

	<dc:title>Molecular Characterization and Pharmacology of Melatonin Receptors in Animals</dc:title>
			<dc:creator>Erika Cecon</dc:creator>
			<dc:creator>Jean A. Boutin</dc:creator>
			<dc:creator>Ralf Jockers</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2020008</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-04-14</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-04-14</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>127</prism:startingPage>
		<prism:doi>10.3390/receptors2020008</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/2/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/7">

	<title>Receptors, Vol. 2, Pages 116-126: Estrogen Receptor Knockout Mice and Their Effects on Fertility</title>
	<link>https://www.mdpi.com/2813-2564/2/1/7</link>
	<description>Estrogens play a crucial role in sexual development and fertility as well as many other physiological processes, and it is estrogen receptors that mediate the physiological responses. To study the role of the estrogen receptors in these processes, several genetic mouse models have been developed using different strategies, which also in some cases yield different results. Here, we summarize the models that have been made and their impact on fertility in relation to known cases of human estrogen receptor mutations.</description>
	<pubDate>2023-03-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 116-126: Estrogen Receptor Knockout Mice and Their Effects on Fertility</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/7">doi: 10.3390/receptors2010007</a></p>
	<p>Authors:
		Ivan Nalvarte
		Per Antonson
		</p>
	<p>Estrogens play a crucial role in sexual development and fertility as well as many other physiological processes, and it is estrogen receptors that mediate the physiological responses. To study the role of the estrogen receptors in these processes, several genetic mouse models have been developed using different strategies, which also in some cases yield different results. Here, we summarize the models that have been made and their impact on fertility in relation to known cases of human estrogen receptor mutations.</p>
	]]></content:encoded>

	<dc:title>Estrogen Receptor Knockout Mice and Their Effects on Fertility</dc:title>
			<dc:creator>Ivan Nalvarte</dc:creator>
			<dc:creator>Per Antonson</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010007</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-03-07</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-03-07</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>116</prism:startingPage>
		<prism:doi>10.3390/receptors2010007</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/6">

	<title>Receptors, Vol. 2, Pages 100-115: Impact of the Aryl Hydrocarbon Receptor on Aurora A Kinase and the G2/M Phase Pathway in Hematopoietic Stem and Progenitor Cells</title>
	<link>https://www.mdpi.com/2813-2564/2/1/6</link>
	<description>Recent evidence suggests that the environment-sensing transcription factor aryl hydrocarbon receptor (AHR) is an important regulator of hematopoiesis. Yet, the mechanisms and extent of AHR-mediated regulation within the most primitive hematopoietic cells, hematopoietic stem and progenitor cells (HSPCs), are poorly understood. Through a combination of transcriptomic and flow cytometric approaches, this study provides new insight into how the AHR influences hematopoietic stem and progenitor cells. Comparative analysis of intraphenotypic transcriptomes of hematopoietic stem cells (HSCs) and multipotent progenitor (MPP) cells from AHR knockout (AHR KO) and wild type mice revealed significant differences in gene expression patterns. Notable among these were differences in expression of cell cycle regulators, specifically an enrichment of G2/M checkpoint genes when Ahr was absent. This included the regulator Aurora A kinase (Aurka, AurA). Analysis of AurA protein levels in HSPC subsets using flow cytometry, in combination with inducible AHR KO or in vivo AHR antagonism, showed that attenuation of AHR increased levels of AurA in HSCs and lineage-biased MPP cells. Overall, these data highlight a potential novel mechanism by which AHR controls HSC homeostasis and HSPC differentiation. These findings advance the understanding of how AHR influences and regulates primitive hematopoiesis.</description>
	<pubDate>2023-03-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 100-115: Impact of the Aryl Hydrocarbon Receptor on Aurora A Kinase and the G2/M Phase Pathway in Hematopoietic Stem and Progenitor Cells</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/6">doi: 10.3390/receptors2010006</a></p>
	<p>Authors:
		Anthony M. Franchini
		Keegan L. Vaughan
		Soumyaroop Bhattacharya
		Kameshwar P. Singh
		Thomas A. Gasiewicz
		B. Paige Lawrence
		</p>
	<p>Recent evidence suggests that the environment-sensing transcription factor aryl hydrocarbon receptor (AHR) is an important regulator of hematopoiesis. Yet, the mechanisms and extent of AHR-mediated regulation within the most primitive hematopoietic cells, hematopoietic stem and progenitor cells (HSPCs), are poorly understood. Through a combination of transcriptomic and flow cytometric approaches, this study provides new insight into how the AHR influences hematopoietic stem and progenitor cells. Comparative analysis of intraphenotypic transcriptomes of hematopoietic stem cells (HSCs) and multipotent progenitor (MPP) cells from AHR knockout (AHR KO) and wild type mice revealed significant differences in gene expression patterns. Notable among these were differences in expression of cell cycle regulators, specifically an enrichment of G2/M checkpoint genes when Ahr was absent. This included the regulator Aurora A kinase (Aurka, AurA). Analysis of AurA protein levels in HSPC subsets using flow cytometry, in combination with inducible AHR KO or in vivo AHR antagonism, showed that attenuation of AHR increased levels of AurA in HSCs and lineage-biased MPP cells. Overall, these data highlight a potential novel mechanism by which AHR controls HSC homeostasis and HSPC differentiation. These findings advance the understanding of how AHR influences and regulates primitive hematopoiesis.</p>
	]]></content:encoded>

	<dc:title>Impact of the Aryl Hydrocarbon Receptor on Aurora A Kinase and the G2/M Phase Pathway in Hematopoietic Stem and Progenitor Cells</dc:title>
			<dc:creator>Anthony M. Franchini</dc:creator>
			<dc:creator>Keegan L. Vaughan</dc:creator>
			<dc:creator>Soumyaroop Bhattacharya</dc:creator>
			<dc:creator>Kameshwar P. Singh</dc:creator>
			<dc:creator>Thomas A. Gasiewicz</dc:creator>
			<dc:creator>B. Paige Lawrence</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010006</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-03-01</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-03-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>100</prism:startingPage>
		<prism:doi>10.3390/receptors2010006</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/5">

	<title>Receptors, Vol. 2, Pages 93-99: Aryl Hydrocarbon Receptor (AhR) Signaling in Colonic Cells and Tumors</title>
	<link>https://www.mdpi.com/2813-2564/2/1/5</link>
	<description>The aryl hydrocarbon receptor (AhR) is overexpressed in many tumor types and exhibits tumor-specific tumor promoter and tumor suppressor-like activity. In colon cancer, most but not all studies suggest that the AhR exhibits tumor suppressor activity which is enhanced by AhR ligands acting as agonists. Our studies investigated the role of the AhR in colon tumorigenesis using wild-type and AhR-knockout mice, the inflammation model of colon tumorigenesis using mice treated with azoxymethane (AOM)/dextran sodium sulfate (DSS) and APCS580/+; KrasG12D/+ mice all of which form intestinal tumors. The effects of tissue-specific AhR loss in the intestine of the tumor-forming mice on colonic stem cells, organoid-initiating capacity, colon tumor formation and mechanisms of AhR-mediated effects were investigated. Loss of AhR enhanced stem cell and tumor growth and in the AOM/DSS model AhR-dependent suppression of FOXM1 and downstream genes was important for AhR-dependent anticancer activity. Furthermore, the effectiveness of interleukin-22 (IL22) in colonic epithelial cells was also dependent on AhR expression. IL22 induced phosphorylation of STAT3, inhibited colonic organoid growth, promoted colonic cell proliferation in vivo and enhanced DNA repair in AOM/DSS-induced tumors. In this mouse model, the AhR suppressed SOCS3 expression and enhanced IL22-mediated activation of STAT3, whereas the loss of the AhR increased levels of SOCS3 which in turn inhibited IL22-induced STAT3 activation. In the APCS580/+; KrasG12D/+ mouse model, the loss of the AhR enhanced Wnt signaling and colon carcinogenesis. Results in both mouse models of colon carcinogenesis were complemented by single cell transcriptomics on colonic intestinal crypts which also showed that AhR deletion promoted expression of FOXM1-regulated genes in multiple colonic cell subtypes. These results support the role of the AhR as a tumor suppressor-like gene in the colon.</description>
	<pubDate>2023-02-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 93-99: Aryl Hydrocarbon Receptor (AhR) Signaling in Colonic Cells and Tumors</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/5">doi: 10.3390/receptors2010005</a></p>
	<p>Authors:
		Stephen Safe
		Huajun Han
		Arul Jayaraman
		Laurie A. Davidson
		Clinton D. Allred
		Ivan Ivanov
		Yongjian Yang
		James J. Cai
		Robert S. Chapkin
		</p>
	<p>The aryl hydrocarbon receptor (AhR) is overexpressed in many tumor types and exhibits tumor-specific tumor promoter and tumor suppressor-like activity. In colon cancer, most but not all studies suggest that the AhR exhibits tumor suppressor activity which is enhanced by AhR ligands acting as agonists. Our studies investigated the role of the AhR in colon tumorigenesis using wild-type and AhR-knockout mice, the inflammation model of colon tumorigenesis using mice treated with azoxymethane (AOM)/dextran sodium sulfate (DSS) and APCS580/+; KrasG12D/+ mice all of which form intestinal tumors. The effects of tissue-specific AhR loss in the intestine of the tumor-forming mice on colonic stem cells, organoid-initiating capacity, colon tumor formation and mechanisms of AhR-mediated effects were investigated. Loss of AhR enhanced stem cell and tumor growth and in the AOM/DSS model AhR-dependent suppression of FOXM1 and downstream genes was important for AhR-dependent anticancer activity. Furthermore, the effectiveness of interleukin-22 (IL22) in colonic epithelial cells was also dependent on AhR expression. IL22 induced phosphorylation of STAT3, inhibited colonic organoid growth, promoted colonic cell proliferation in vivo and enhanced DNA repair in AOM/DSS-induced tumors. In this mouse model, the AhR suppressed SOCS3 expression and enhanced IL22-mediated activation of STAT3, whereas the loss of the AhR increased levels of SOCS3 which in turn inhibited IL22-induced STAT3 activation. In the APCS580/+; KrasG12D/+ mouse model, the loss of the AhR enhanced Wnt signaling and colon carcinogenesis. Results in both mouse models of colon carcinogenesis were complemented by single cell transcriptomics on colonic intestinal crypts which also showed that AhR deletion promoted expression of FOXM1-regulated genes in multiple colonic cell subtypes. These results support the role of the AhR as a tumor suppressor-like gene in the colon.</p>
	]]></content:encoded>

	<dc:title>Aryl Hydrocarbon Receptor (AhR) Signaling in Colonic Cells and Tumors</dc:title>
			<dc:creator>Stephen Safe</dc:creator>
			<dc:creator>Huajun Han</dc:creator>
			<dc:creator>Arul Jayaraman</dc:creator>
			<dc:creator>Laurie A. Davidson</dc:creator>
			<dc:creator>Clinton D. Allred</dc:creator>
			<dc:creator>Ivan Ivanov</dc:creator>
			<dc:creator>Yongjian Yang</dc:creator>
			<dc:creator>James J. Cai</dc:creator>
			<dc:creator>Robert S. Chapkin</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010005</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-02-08</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-02-08</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>93</prism:startingPage>
		<prism:doi>10.3390/receptors2010005</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/4">

	<title>Receptors, Vol. 2, Pages 47-92: Biophysical Dissection of Isolated GPCRs: The Adenosine A2A Receptor under the Bistouries</title>
	<link>https://www.mdpi.com/2813-2564/2/1/4</link>
	<description>In an effort to provide an overview of the biophysical approaches used to study G-protein-coupled receptors, we chose to consider the adenosine A2A receptor as a model, as it is widely reported in the literature to explore the way GPCRs are studied nowadays. After a brief introduction of the receptor, we gathered descriptions of the various tools used to investigate the pharmacology and structure of the A2A receptor. We began by describing the key developments which have led to successful studies of GPCRs including the cloning, expression and purification of A2A, and the subsequent characterizations including quality control, binding and functional studies that have been necessary for the further understanding of the receptor. Then, we reviewed the reconstitution of A2A into nanodiscs as well as the use of this biological material in structural mass spectrometry, NMR, calorimetry and various other approaches to gain not only information about the structure and function of A2A, but also the dynamics of the receptor and the tools necessary to pursue such investigations. The body of techniques presented herein are applicable to all GPCRs amenable to purification.</description>
	<pubDate>2023-02-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 47-92: Biophysical Dissection of Isolated GPCRs: The Adenosine A2A Receptor under the Bistouries</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/4">doi: 10.3390/receptors2010004</a></p>
	<p>Authors:
		Jean-Louis Banères
		Thomas Botzanowski
		Jean A. Boutin
		Barbara Calamini
		Jérôme Castel
		Laurent J. Catoire
		Sarah Cianférani
		Claire Demesmay
		Gavin Ferguson
		Gilles Ferry
		Julie Kniazeff
		Isabelle Krimm
		Thierry Langer
		Guillaume Lebon
		Marie Ley
		Miklos Nyerges
		Magali Schwob
		Catherine Venien-Bryan
		Renaud Wagner
		Gabrielle Zeder-Lutz
		Claudia Zilian-Stohrer
		</p>
	<p>In an effort to provide an overview of the biophysical approaches used to study G-protein-coupled receptors, we chose to consider the adenosine A2A receptor as a model, as it is widely reported in the literature to explore the way GPCRs are studied nowadays. After a brief introduction of the receptor, we gathered descriptions of the various tools used to investigate the pharmacology and structure of the A2A receptor. We began by describing the key developments which have led to successful studies of GPCRs including the cloning, expression and purification of A2A, and the subsequent characterizations including quality control, binding and functional studies that have been necessary for the further understanding of the receptor. Then, we reviewed the reconstitution of A2A into nanodiscs as well as the use of this biological material in structural mass spectrometry, NMR, calorimetry and various other approaches to gain not only information about the structure and function of A2A, but also the dynamics of the receptor and the tools necessary to pursue such investigations. The body of techniques presented herein are applicable to all GPCRs amenable to purification.</p>
	]]></content:encoded>

	<dc:title>Biophysical Dissection of Isolated GPCRs: The Adenosine A2A Receptor under the Bistouries</dc:title>
			<dc:creator>Jean-Louis Banères</dc:creator>
			<dc:creator>Thomas Botzanowski</dc:creator>
			<dc:creator>Jean A. Boutin</dc:creator>
			<dc:creator>Barbara Calamini</dc:creator>
			<dc:creator>Jérôme Castel</dc:creator>
			<dc:creator>Laurent J. Catoire</dc:creator>
			<dc:creator>Sarah Cianférani</dc:creator>
			<dc:creator>Claire Demesmay</dc:creator>
			<dc:creator>Gavin Ferguson</dc:creator>
			<dc:creator>Gilles Ferry</dc:creator>
			<dc:creator>Julie Kniazeff</dc:creator>
			<dc:creator>Isabelle Krimm</dc:creator>
			<dc:creator>Thierry Langer</dc:creator>
			<dc:creator>Guillaume Lebon</dc:creator>
			<dc:creator>Marie Ley</dc:creator>
			<dc:creator>Miklos Nyerges</dc:creator>
			<dc:creator>Magali Schwob</dc:creator>
			<dc:creator>Catherine Venien-Bryan</dc:creator>
			<dc:creator>Renaud Wagner</dc:creator>
			<dc:creator>Gabrielle Zeder-Lutz</dc:creator>
			<dc:creator>Claudia Zilian-Stohrer</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010004</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-02-04</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-02-04</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>47</prism:startingPage>
		<prism:doi>10.3390/receptors2010004</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/3">

	<title>Receptors, Vol. 2, Pages 34-46: A Novel Liver X Receptor Inverse Agonist Impairs Cholesterol and Phospholipid Metabolism and Induces Apoptosis and Necroptosis in Pancreatic Ductal Adenocarcinoma Cells</title>
	<link>https://www.mdpi.com/2813-2564/2/1/3</link>
	<description>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high mortality rate and few effective treatments. A growing area of cancer therapeutics seeks to exploit the metabolic dysregulation of cancer cells, such as glucose, amino acid, and fatty acid metabolism, to selectively target malignant cells. As ligand-dependent transcription factors and critical regulators of metabolism, liver X receptors (LXRs) are amenable to small-molecule targeting for such purposes. We have profiled the transcriptomic, metabolomic, and cytotoxic effects of a newly discovered small-molecule LXR modulator, GAC0003A4 (3A4), in PDAC cell lines. On the transcriptomic level, marked changes in gene expression were observed, including downregulation of LXR target genes and pathways. Gene set enrichment analysis determined downregulation of several metabolic pathways, such as fatty acid and cholesterol metabolism, while upregulated pathways involved TNF&amp;amp;alpha;/NF-&amp;amp;kappa;B and other stress-induced processes. Metabolomic analyses revealed altered metabolites in several pathways, the most enriched categories being lipids and amino acid metabolites, while phospholipids and sphingolipids, including ceramides, were also found to be significantly altered. Insights from transcriptomic and metabolomic studies helped guide the determination of alterations in cholesterol and ceramides as integral to the antiproliferative mechanisms of 3A4. Additionally, a concurrent programmed cell death mechanism involving apoptosis and necroptosis was shown to be activated. These studies provide novel insights into the effects of LXR modulation on gene expression, metabolism, and cell death induction in PDAC cells. The metabolic and cytotoxic effects of LXR modulation on the PDAC cell lines used in this study could also aid in the design and application of drugs to target other refractory cancers.</description>
	<pubDate>2023-02-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 34-46: A Novel Liver X Receptor Inverse Agonist Impairs Cholesterol and Phospholipid Metabolism and Induces Apoptosis and Necroptosis in Pancreatic Ductal Adenocarcinoma Cells</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/3">doi: 10.3390/receptors2010003</a></p>
	<p>Authors:
		Scott Widmann
		Shivangi Srivastava
		Chin-Yo Lin
		</p>
	<p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high mortality rate and few effective treatments. A growing area of cancer therapeutics seeks to exploit the metabolic dysregulation of cancer cells, such as glucose, amino acid, and fatty acid metabolism, to selectively target malignant cells. As ligand-dependent transcription factors and critical regulators of metabolism, liver X receptors (LXRs) are amenable to small-molecule targeting for such purposes. We have profiled the transcriptomic, metabolomic, and cytotoxic effects of a newly discovered small-molecule LXR modulator, GAC0003A4 (3A4), in PDAC cell lines. On the transcriptomic level, marked changes in gene expression were observed, including downregulation of LXR target genes and pathways. Gene set enrichment analysis determined downregulation of several metabolic pathways, such as fatty acid and cholesterol metabolism, while upregulated pathways involved TNF&amp;amp;alpha;/NF-&amp;amp;kappa;B and other stress-induced processes. Metabolomic analyses revealed altered metabolites in several pathways, the most enriched categories being lipids and amino acid metabolites, while phospholipids and sphingolipids, including ceramides, were also found to be significantly altered. Insights from transcriptomic and metabolomic studies helped guide the determination of alterations in cholesterol and ceramides as integral to the antiproliferative mechanisms of 3A4. Additionally, a concurrent programmed cell death mechanism involving apoptosis and necroptosis was shown to be activated. These studies provide novel insights into the effects of LXR modulation on gene expression, metabolism, and cell death induction in PDAC cells. The metabolic and cytotoxic effects of LXR modulation on the PDAC cell lines used in this study could also aid in the design and application of drugs to target other refractory cancers.</p>
	]]></content:encoded>

	<dc:title>A Novel Liver X Receptor Inverse Agonist Impairs Cholesterol and Phospholipid Metabolism and Induces Apoptosis and Necroptosis in Pancreatic Ductal Adenocarcinoma Cells</dc:title>
			<dc:creator>Scott Widmann</dc:creator>
			<dc:creator>Shivangi Srivastava</dc:creator>
			<dc:creator>Chin-Yo Lin</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010003</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-02-01</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-02-01</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>34</prism:startingPage>
		<prism:doi>10.3390/receptors2010003</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/2">

	<title>Receptors, Vol. 2, Pages 16-33: Why Search for Alternative GPCR Agonists?</title>
	<link>https://www.mdpi.com/2813-2564/2/1/2</link>
	<description>Intuitively, it is easy to understand why we search for G protein-coupled receptor (GPCR) antagonists. It is obviously to block a functionality of a specific receptor potentially linked to some aspects of disease. Whether by focused research or by serendipity, many drugs were discovered in the last century that function as antagonist at a precise receptor. A current idea is that at least half of the drugs on the market are antagonist ligands of GPCRs. Then, why are we searching for alternative receptor agonists while the endogenous activating molecule is known? In the present commentary we try to rationalize these fields of research, since they proved to be very successful over the years, with receptor pharmacology populated with dozens of alternative agonists, particularly to bioaminergic receptors, and to a lesser extent to peptidergic ones. However, the action of such compounds is not well-characterized: are they surrogates to the endogenous agonist, and if yes in which context and for which purpose? The present essay is a reflection on this subject that leads to fundamental interrogations of our understanding of GPCR roles and functions.</description>
	<pubDate>2023-01-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 16-33: Why Search for Alternative GPCR Agonists?</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/2">doi: 10.3390/receptors2010002</a></p>
	<p>Authors:
		Jean A. Boutin
		Jérôme Leprince
		</p>
	<p>Intuitively, it is easy to understand why we search for G protein-coupled receptor (GPCR) antagonists. It is obviously to block a functionality of a specific receptor potentially linked to some aspects of disease. Whether by focused research or by serendipity, many drugs were discovered in the last century that function as antagonist at a precise receptor. A current idea is that at least half of the drugs on the market are antagonist ligands of GPCRs. Then, why are we searching for alternative receptor agonists while the endogenous activating molecule is known? In the present commentary we try to rationalize these fields of research, since they proved to be very successful over the years, with receptor pharmacology populated with dozens of alternative agonists, particularly to bioaminergic receptors, and to a lesser extent to peptidergic ones. However, the action of such compounds is not well-characterized: are they surrogates to the endogenous agonist, and if yes in which context and for which purpose? The present essay is a reflection on this subject that leads to fundamental interrogations of our understanding of GPCR roles and functions.</p>
	]]></content:encoded>

	<dc:title>Why Search for Alternative GPCR Agonists?</dc:title>
			<dc:creator>Jean A. Boutin</dc:creator>
			<dc:creator>Jérôme Leprince</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010002</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-01-04</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-01-04</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/receptors2010002</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/2/1/1">

	<title>Receptors, Vol. 2, Pages 1-15: Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease</title>
	<link>https://www.mdpi.com/2813-2564/2/1/1</link>
	<description>Numerous nuclear receptors including farnesoid X receptor, liver X receptor, peroxisome proliferator-activated receptors, pregnane X receptor, hepatic nuclear factors have been extensively studied within the context of non-alcoholic fatty liver disease (NAFLD). Following the first description of the Aryl hydrocarbon Receptor (AhR) in the 1970s and decades of research which unveiled its role in toxicity and pathophysiological processes, the functional significance of AhR in NAFLD has not been completely decoded. Recently, multiple research groups have utilized a plethora of in vitro and in vivo models that mimic NAFLD pathology to investigate the functional significance of AhR in fatty liver disease. This review provides a comprehensive account of studies describing both the beneficial and possible detrimental role of AhR in NAFLD. A plausible reconciliation for the paradox indicating AhR as a &amp;amp;lsquo;double-edged sword&amp;amp;rsquo; in NAFLD is discussed. Finally, understanding AhR ligands and their signaling in NAFLD will facilitate us to probe AhR as a potential drug target to design innovative therapeutics against NAFLD in the near future.</description>
	<pubDate>2023-01-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 2, Pages 1-15: Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/2/1/1">doi: 10.3390/receptors2010001</a></p>
	<p>Authors:
		Nikhil Y. Patil
		Jacob E. Friedman
		Aditya D. Joshi
		</p>
	<p>Numerous nuclear receptors including farnesoid X receptor, liver X receptor, peroxisome proliferator-activated receptors, pregnane X receptor, hepatic nuclear factors have been extensively studied within the context of non-alcoholic fatty liver disease (NAFLD). Following the first description of the Aryl hydrocarbon Receptor (AhR) in the 1970s and decades of research which unveiled its role in toxicity and pathophysiological processes, the functional significance of AhR in NAFLD has not been completely decoded. Recently, multiple research groups have utilized a plethora of in vitro and in vivo models that mimic NAFLD pathology to investigate the functional significance of AhR in fatty liver disease. This review provides a comprehensive account of studies describing both the beneficial and possible detrimental role of AhR in NAFLD. A plausible reconciliation for the paradox indicating AhR as a &amp;amp;lsquo;double-edged sword&amp;amp;rsquo; in NAFLD is discussed. Finally, understanding AhR ligands and their signaling in NAFLD will facilitate us to probe AhR as a potential drug target to design innovative therapeutics against NAFLD in the near future.</p>
	]]></content:encoded>

	<dc:title>Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease</dc:title>
			<dc:creator>Nikhil Y. Patil</dc:creator>
			<dc:creator>Jacob E. Friedman</dc:creator>
			<dc:creator>Aditya D. Joshi</dc:creator>
		<dc:identifier>doi: 10.3390/receptors2010001</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2023-01-04</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2023-01-04</prism:publicationDate>
	<prism:volume>2</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/receptors2010001</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/2/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/1/1/6">

	<title>Receptors, Vol. 1, Pages 98-111: The NK-1 Receptor Signaling: Distribution and Functional Relevance in the Eye</title>
	<link>https://www.mdpi.com/2813-2564/1/1/6</link>
	<description>Neurokinin-1 receptor (NK1R) signaling pathways play a crucial role in a number of biological processes in the eye. Specifically, in the ocular surface, their activity modulates epithelial integrity, inflammation, and generation of pain, while they have a role in visual processing in the retina. The NK1R is broadly expressed in the eye, in both ocular and non-ocular cells, such as leukocytes and neurons. In this review, we will discuss the roles of neurokinin-1 receptors and substance P (SP) in the physiopathology of eye disorders. Finally, we will review and highlight the therapeutic benefits of NK1R antagonists in the treatment of ocular diseases.</description>
	<pubDate>2022-11-17</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 1, Pages 98-111: The NK-1 Receptor Signaling: Distribution and Functional Relevance in the Eye</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/1/1/6">doi: 10.3390/receptors1010006</a></p>
	<p>Authors:
		Ibrahim Halil Demirsoy
		Giulio Ferrari
		</p>
	<p>Neurokinin-1 receptor (NK1R) signaling pathways play a crucial role in a number of biological processes in the eye. Specifically, in the ocular surface, their activity modulates epithelial integrity, inflammation, and generation of pain, while they have a role in visual processing in the retina. The NK1R is broadly expressed in the eye, in both ocular and non-ocular cells, such as leukocytes and neurons. In this review, we will discuss the roles of neurokinin-1 receptors and substance P (SP) in the physiopathology of eye disorders. Finally, we will review and highlight the therapeutic benefits of NK1R antagonists in the treatment of ocular diseases.</p>
	]]></content:encoded>

	<dc:title>The NK-1 Receptor Signaling: Distribution and Functional Relevance in the Eye</dc:title>
			<dc:creator>Ibrahim Halil Demirsoy</dc:creator>
			<dc:creator>Giulio Ferrari</dc:creator>
		<dc:identifier>doi: 10.3390/receptors1010006</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2022-11-17</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2022-11-17</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>98</prism:startingPage>
		<prism:doi>10.3390/receptors1010006</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/1/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/1/1/5">

	<title>Receptors, Vol. 1, Pages 72-97: The Neurokinin-1 Receptor: A Promising Antitumor Target</title>
	<link>https://www.mdpi.com/2813-2564/1/1/5</link>
	<description>The important role played by the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancer is reviewed: this includes tumor cell proliferation and migration, anti-apoptotic mechanisms, and angiogenesis. SP, through the NK-1R, behaves as a universal mitogen in cancer cells. The NK-1R is overexpressed in tumor cells and, in addition, affects the viability of cancer cells. NK-1R antagonists counteract all the previous actions mediated by SP through NK-1R. In a concentration-dependent manner, these antagonists promote tumor cell death by apoptosis. Therefore, NK-1R is a potential and promising therapeutic target for cancer treatment by using NK-1R antagonists (e.g., aprepitant) alone or in combination therapy with chemotherapy or radiotherapy.</description>
	<pubDate>2022-11-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 1, Pages 72-97: The Neurokinin-1 Receptor: A Promising Antitumor Target</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/1/1/5">doi: 10.3390/receptors1010005</a></p>
	<p>Authors:
		Rafael Coveñas
		Francisco D. Rodríguez
		Miguel Muñoz
		</p>
	<p>The important role played by the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancer is reviewed: this includes tumor cell proliferation and migration, anti-apoptotic mechanisms, and angiogenesis. SP, through the NK-1R, behaves as a universal mitogen in cancer cells. The NK-1R is overexpressed in tumor cells and, in addition, affects the viability of cancer cells. NK-1R antagonists counteract all the previous actions mediated by SP through NK-1R. In a concentration-dependent manner, these antagonists promote tumor cell death by apoptosis. Therefore, NK-1R is a potential and promising therapeutic target for cancer treatment by using NK-1R antagonists (e.g., aprepitant) alone or in combination therapy with chemotherapy or radiotherapy.</p>
	]]></content:encoded>

	<dc:title>The Neurokinin-1 Receptor: A Promising Antitumor Target</dc:title>
			<dc:creator>Rafael Coveñas</dc:creator>
			<dc:creator>Francisco D. Rodríguez</dc:creator>
			<dc:creator>Miguel Muñoz</dc:creator>
		<dc:identifier>doi: 10.3390/receptors1010005</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2022-11-07</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2022-11-07</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>72</prism:startingPage>
		<prism:doi>10.3390/receptors1010005</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/1/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/1/1/4">

	<title>Receptors, Vol. 1, Pages 54-71: The Neurokinin-1 Receptor: Structure Dynamics and Signaling</title>
	<link>https://www.mdpi.com/2813-2564/1/1/4</link>
	<description>Substance P (SP), the first isolated neuropeptide, belongs to the family of tachykinin peptides and is the natural ligand of neurokinin-1 receptors (NK-1R), also named SP receptors. The undecapeptide activates the receptor after specifically binding to the protein and triggers intracellular signals leading to different biochemical events and subsequent physiological responses. This study reviews the main architectural features of this receptor, its interaction with natural and synthetic ligands, and the functional conformational states adopted after interacting with ligands and effector G proteins. The analysis of the main intracellular signaling pathways turned on by the activation of NK-1 receptors reveals the participation of different proteins supporting metabolic changes and genetic and epigenetic regulations. Furthermore, the analysis of receptor occupancy and receptor downregulation and internalization represents a complex and estimable field for basic and clinical research focused on the role of SP in physiopathology. Profound knowledge of the structural dynamics of NK-1R may help develop and assay new selective synthetic non-peptide antagonists as potential therapeutic agents applied to various pathologies and symptoms.</description>
	<pubDate>2022-10-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 1, Pages 54-71: The Neurokinin-1 Receptor: Structure Dynamics and Signaling</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/1/1/4">doi: 10.3390/receptors1010004</a></p>
	<p>Authors:
		Francisco Rodríguez
		Rafael Coveñas
		</p>
	<p>Substance P (SP), the first isolated neuropeptide, belongs to the family of tachykinin peptides and is the natural ligand of neurokinin-1 receptors (NK-1R), also named SP receptors. The undecapeptide activates the receptor after specifically binding to the protein and triggers intracellular signals leading to different biochemical events and subsequent physiological responses. This study reviews the main architectural features of this receptor, its interaction with natural and synthetic ligands, and the functional conformational states adopted after interacting with ligands and effector G proteins. The analysis of the main intracellular signaling pathways turned on by the activation of NK-1 receptors reveals the participation of different proteins supporting metabolic changes and genetic and epigenetic regulations. Furthermore, the analysis of receptor occupancy and receptor downregulation and internalization represents a complex and estimable field for basic and clinical research focused on the role of SP in physiopathology. Profound knowledge of the structural dynamics of NK-1R may help develop and assay new selective synthetic non-peptide antagonists as potential therapeutic agents applied to various pathologies and symptoms.</p>
	]]></content:encoded>

	<dc:title>The Neurokinin-1 Receptor: Structure Dynamics and Signaling</dc:title>
			<dc:creator>Francisco Rodríguez</dc:creator>
			<dc:creator>Rafael Coveñas</dc:creator>
		<dc:identifier>doi: 10.3390/receptors1010004</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2022-10-08</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2022-10-08</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>54</prism:startingPage>
		<prism:doi>10.3390/receptors1010004</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/1/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/1/1/3">

	<title>Receptors, Vol. 1, Pages 13-53: Novel Cell Receptor System of Eukaryotes Formed by Previously Unknown Nucleic Acid-Based Receptors</title>
	<link>https://www.mdpi.com/2813-2564/1/1/3</link>
	<description>Here, our data provide the first evidence for the existence of a previously unknown receptive system formed by novel DNA- and RNA-based receptors in eukaryotes. This system, named the TR-system, is capable of recognizing and generating a response to different environmental factors and has been shown to orchestrate major vital functions of fungi, mammalian cells, and plants. Recently, we discovered the existence of a similar regulatory system in prokaryotes. These DNA- and RNA-based receptors are localized outside of the membrane forming a type of a network around cells that responds to a variety of chemical, biological, and physical factors and enabled the TR-system to regulate major aspects of eukaryotic cell life as follows: growth, including reproduction and development of multicellular structures; sensitivity to temperature, geomagnetic field, UV, light, and hormones; interaction with viruses; gene expression, recognition and utilization of nutrients. The TR-system was also implicated in cell-memory formation and was determined to be responsible for its maintenance and the forgetting of preceding events. This system is the most distant receptive and regulatory system of the cell that regulates interactions with the outer environment and governs the functions of other receptor-mediated signaling pathways.</description>
	<pubDate>2022-08-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 1, Pages 13-53: Novel Cell Receptor System of Eukaryotes Formed by Previously Unknown Nucleic Acid-Based Receptors</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/1/1/3">doi: 10.3390/receptors1010003</a></p>
	<p>Authors:
		Victor Tetz
		George Tetz
		</p>
	<p>Here, our data provide the first evidence for the existence of a previously unknown receptive system formed by novel DNA- and RNA-based receptors in eukaryotes. This system, named the TR-system, is capable of recognizing and generating a response to different environmental factors and has been shown to orchestrate major vital functions of fungi, mammalian cells, and plants. Recently, we discovered the existence of a similar regulatory system in prokaryotes. These DNA- and RNA-based receptors are localized outside of the membrane forming a type of a network around cells that responds to a variety of chemical, biological, and physical factors and enabled the TR-system to regulate major aspects of eukaryotic cell life as follows: growth, including reproduction and development of multicellular structures; sensitivity to temperature, geomagnetic field, UV, light, and hormones; interaction with viruses; gene expression, recognition and utilization of nutrients. The TR-system was also implicated in cell-memory formation and was determined to be responsible for its maintenance and the forgetting of preceding events. This system is the most distant receptive and regulatory system of the cell that regulates interactions with the outer environment and governs the functions of other receptor-mediated signaling pathways.</p>
	]]></content:encoded>

	<dc:title>Novel Cell Receptor System of Eukaryotes Formed by Previously Unknown Nucleic Acid-Based Receptors</dc:title>
			<dc:creator>Victor Tetz</dc:creator>
			<dc:creator>George Tetz</dc:creator>
		<dc:identifier>doi: 10.3390/receptors1010003</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2022-08-09</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2022-08-09</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/receptors1010003</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/1/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/1/1/2">

	<title>Receptors, Vol. 1, Pages 3-12: Pharmacology of Minor Cannabinoids at the Cannabinoid CB1 Receptor: Isomer- and Ligand-Dependent Antagonism by Tetrahydrocannabivarin</title>
	<link>https://www.mdpi.com/2813-2564/1/1/2</link>
	<description>(1) Background: In addition to the major phytocannabinoids, trans-&amp;amp;Delta;9-tetrahydrocannabinol (&amp;amp;Delta;9-THC) and cannabidiol (CBD), the cannabis plant (Cannabis sativa L.) synthesizes over 120 additional cannabinoids that are known as minor cannabinoids. These minor cannabinoids have been proposed to act as agonists and antagonists at numerous targets including cannabinoid type 1 (CB1) and type 2 (CB2) receptors, transient receptor potential (TRP) channels and others. The goal of the present study was to determine the agonist effects of the minor cannabinoids: cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabitriol (CBT) and cannabidivarin (CBDV) at the CB1 receptor. In addition, the CB1 receptor antagonist effects of &amp;amp;Delta;9-tetrahydrocannabivarin (&amp;amp;Delta;9-THCV) were compared with its isomer &amp;amp;Delta;8-tetrahydrocannabivarin (&amp;amp;Delta;8-THCV). (2) Methods: CB1 receptor activity was monitored by measuring cannabinoid activation of G protein-gated inward rectifier K+ (GIRK) channels in AtT20 pituitary cells using a membrane potential-sensitive fluorescent dye assay. (3) Results: When compared to the CB1 receptor full agonist WIN 55,212-2 and the partial agonist &amp;amp;Delta;9-THC, none of the minor cannabinoids caused a significant activation of Gi/GIRK channel signaling. However, &amp;amp;Delta;9-THCV and &amp;amp;Delta;8-THCV antagonized the effect of WIN 55,212-2 with half-maximal inhibitory concentrations (IC50s) of 434 nM and 757 nM, respectively. &amp;amp;Delta;9-THCV antagonism of the CB1 receptor was &amp;amp;ldquo;ligand-dependent&amp;amp;rdquo;; &amp;amp;Delta;9-THCV was more potent in inhibiting WIN 55,212-2 and 2-arachidonoylglycerol (2-AG) than &amp;amp;Delta;9-THC. (4) Conclusions: While none of the minor cannabinoids caused Gi/GIRK channel activation, &amp;amp;Delta;9-THCV antagonized the CB1 receptor in an isomer- and ligand-dependent manner.</description>
	<pubDate>2022-08-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 1, Pages 3-12: Pharmacology of Minor Cannabinoids at the Cannabinoid CB1 Receptor: Isomer- and Ligand-Dependent Antagonism by Tetrahydrocannabivarin</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/1/1/2">doi: 10.3390/receptors1010002</a></p>
	<p>Authors:
		Kenneth B. Walsh
		Andrea E. Holmes
		</p>
	<p>(1) Background: In addition to the major phytocannabinoids, trans-&amp;amp;Delta;9-tetrahydrocannabinol (&amp;amp;Delta;9-THC) and cannabidiol (CBD), the cannabis plant (Cannabis sativa L.) synthesizes over 120 additional cannabinoids that are known as minor cannabinoids. These minor cannabinoids have been proposed to act as agonists and antagonists at numerous targets including cannabinoid type 1 (CB1) and type 2 (CB2) receptors, transient receptor potential (TRP) channels and others. The goal of the present study was to determine the agonist effects of the minor cannabinoids: cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabitriol (CBT) and cannabidivarin (CBDV) at the CB1 receptor. In addition, the CB1 receptor antagonist effects of &amp;amp;Delta;9-tetrahydrocannabivarin (&amp;amp;Delta;9-THCV) were compared with its isomer &amp;amp;Delta;8-tetrahydrocannabivarin (&amp;amp;Delta;8-THCV). (2) Methods: CB1 receptor activity was monitored by measuring cannabinoid activation of G protein-gated inward rectifier K+ (GIRK) channels in AtT20 pituitary cells using a membrane potential-sensitive fluorescent dye assay. (3) Results: When compared to the CB1 receptor full agonist WIN 55,212-2 and the partial agonist &amp;amp;Delta;9-THC, none of the minor cannabinoids caused a significant activation of Gi/GIRK channel signaling. However, &amp;amp;Delta;9-THCV and &amp;amp;Delta;8-THCV antagonized the effect of WIN 55,212-2 with half-maximal inhibitory concentrations (IC50s) of 434 nM and 757 nM, respectively. &amp;amp;Delta;9-THCV antagonism of the CB1 receptor was &amp;amp;ldquo;ligand-dependent&amp;amp;rdquo;; &amp;amp;Delta;9-THCV was more potent in inhibiting WIN 55,212-2 and 2-arachidonoylglycerol (2-AG) than &amp;amp;Delta;9-THC. (4) Conclusions: While none of the minor cannabinoids caused Gi/GIRK channel activation, &amp;amp;Delta;9-THCV antagonized the CB1 receptor in an isomer- and ligand-dependent manner.</p>
	]]></content:encoded>

	<dc:title>Pharmacology of Minor Cannabinoids at the Cannabinoid CB1 Receptor: Isomer- and Ligand-Dependent Antagonism by Tetrahydrocannabivarin</dc:title>
			<dc:creator>Kenneth B. Walsh</dc:creator>
			<dc:creator>Andrea E. Holmes</dc:creator>
		<dc:identifier>doi: 10.3390/receptors1010002</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2022-08-02</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2022-08-02</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/receptors1010002</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/1/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2813-2564/1/1/1">

	<title>Receptors, Vol. 1, Pages 1-2: Excited about Receptors</title>
	<link>https://www.mdpi.com/2813-2564/1/1/1</link>
	<description>Receptors are widely expressed in human tissues and play a key role in maintaining cellular homeostasis and in pathophysiology, and they are important drug targets for the treatment of human diseases [...]</description>
	<pubDate>2022-05-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Receptors, Vol. 1, Pages 1-2: Excited about Receptors</b></p>
	<p>Receptors <a href="https://www.mdpi.com/2813-2564/1/1/1">doi: 10.3390/receptors1010001</a></p>
	<p>Authors:
		Stephen Safe
		</p>
	<p>Receptors are widely expressed in human tissues and play a key role in maintaining cellular homeostasis and in pathophysiology, and they are important drug targets for the treatment of human diseases [...]</p>
	]]></content:encoded>

	<dc:title>Excited about Receptors</dc:title>
			<dc:creator>Stephen Safe</dc:creator>
		<dc:identifier>doi: 10.3390/receptors1010001</dc:identifier>
	<dc:source>Receptors</dc:source>
	<dc:date>2022-05-13</dc:date>

	<prism:publicationName>Receptors</prism:publicationName>
	<prism:publicationDate>2022-05-13</prism:publicationDate>
	<prism:volume>1</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/receptors1010001</prism:doi>
	<prism:url>https://www.mdpi.com/2813-2564/1/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
